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1ABSTRACT
My dissertation focuses on the endosperm-specific production of three different HIV-
neutralizing proteins in transgenic rice plants, alone and in combination, followed by tests to
determine their yield, integrity and ability to bind and inactivate HIV. The three components
were the monoclonal antibody 2G12 and the lectins griffithsin (GRFT) and cyanovirin-N (CV-
N). The overall aim was to evaluate rice as a production platform and determine the best overall
production strategies for the preparation of an efficacious microbicide cocktail in planta. Initially
I tested the expression of 2G12 not only to determine whether rice endosperm was viable as a
production platform but also to gain insight into factors that affect the production and functional
efficacy of neutralizing antibodies in plants and the impact they have has on endogenous gene
expression. The antibody was expressed successfully in rice endosperm, but unlike all previous
reports of antibodies expressed in plants, the most prevalent form was the aglycosylated version
with the remaining forms featuring oligomannose-type glycans, complex vacuolar-type glycans
or single GlcNAc residues. These results suggest that a large proportion of the heavy chain is co-
translationally imported into a region of the endoplasmic reticulum (ER) that lacks
glycosyltransferases and accumulates in protein bodies without further modification. The
remaining proportion appears to follow the canonical pathway, undergoing initial glycosylation
in the ER lumen followed by either complex modification in the Golgi body and/or trimming
back to a single GlcNAc residue. The aglycosylated form of the antibody produced in rice
showed greater HIV-neutralizing activity than the glycosylated version produced in tobacco
seeds, although neither was as potent as the original antibody produced in CHO cells. Proteomic
analysis suggested that yields of recombinant proteins could be improved in seed endosperm by
regulating protein/carbohydrate metabolism and by protecting the endosperm from abiotic stress.
Having established that rice is suitable for the expression of 2G12, I expressed GRFT in the
endosperm to determine whether rice is also a suitable platform for the expression of HIV-
neutralizing lectins. GRFT was expressed successfully in rice, with yields comparable to or even
higher than other antibodies expressed in rice and GRFT produced by transient expression in
tobacco leaves. GRFT produced in rice showed similar potency in HIV-inhibition assays to the
control GRFT produced in Escherichia coli. CV-N was also expressed successfully in rice
endosperm but the yield was low and the potency in HIV-inhibition assays was lower than CV-N
produced in other platforms, suggesting rice is not the ideal expression system for this protein.
2Having shown that all three proteins could be produced individually in rice endosperm, I tested
them in all possible pairwise combinations. The aim of these experiments was to determine
whether the proteins could be coexpressed in rice endosperm and whether the extracts containing
multiple proteins were more potent against HIV. The CV-N/GRFT combination was tested using
a whole-cell assay against HIV and showed good activity. In addition, all the combinations
showed enhanced activity against HIV in an infectivity assay. The 2G12 crude extract showed
concentration-dependent activity. This is the first time that more than one HIV-neutralizing
protein has been stably expressed in rice endosperm, opening the way for more combinatorial
experiments to determine the best microbicide cocktails for the prevention of HIV.
3RESUMEN
Mi tesis doctoral está enfocada en la producción en el endospermo de arroz, de tres proteínas
diferentes con capacidad para neutralizar el virus del SIDA, solas o en combinación y en la
detección de su producción, integridad y capacidad para unirse e inactivar al HIV. Las tres
proteínas son el anticuerpo monoclonal 2G12, la lecitina grifithsin (GRFT) y la lecitina
cianovirina (CV-N).  El objetivo general era evaluar si se podía utilizar arroz como una
plataforma de producción y determinar la mejor estrategia de producción en planta de un coctel
microbicida eficaz. En la primera parte de mi tesis investigué si podía producir 2G12 en el
endospermo de arroz y cuáles eran los factores que afectaban a su producción y su eficacia
funcional. Exprese con éxito el anticuerpo monoclonal Ab2G12 humano en el endospermo de
arroz, el cual se acumuló en una forma aglicosilada, además de con alguna forma con glicanos
del tipo oligomanosa y otros del tipo de complejos vacuolares o residuos de GlcNAc sencillos.
Estos resultados sugieren que una proporción muy elevada de la cadena pesada del anticuerpo
era importada, al mismo tiempo que transcrita, a una región del retículo endoplasmatico que
carece de glucosiltransferasa y acumulándose en los cuerpos proteicos sin modificaciones
posteriores. La proporción restante parece que sigue la ruta canónica, produciéndose una
glucosilacion inicial en el lumen del retículo endoplasmatico seguida de complejas
modificaciones en el cuerpo de Golgui y/o recortando a residuos de GlcNAc sencillos. La forma
aglicosilada del anticuerpo producida en arroz demostró un mayor actividad neutralizante del
virus HIV que la forma glicosilada, producida con anterioridad en semillas de tabaco; pero
ninguna de las dos era tan potente como la molécula producida en células CHO. Los análisis del
proteoma sugirieron que los rendimientos obtenidos de proteínas recombinantes podrían ser
mejorados en el endospermo de la semilla mediante la regulación del metabolismo de las
proteínas/carbohidratos y también protegiendo al endospermo de estreses abióticos. Una vez
establecido que en arroz se puede expresar 2G12, pase a introducir la lectina GRFT en el
endospermo de arroz para determinar si este podía ser una plataforma de expresión de esta
lectina neutralizante del HIV. GRFT se acumuló en arroz, con una producción comparable o
incluso más alta que otros anticuerpos producidos en arroz y a GRFT producida de forma
transitoria en tabaco. GRFT producida en arroz tuvo una potencia inhibitoria en ensayos de
inhibición del virus HIV semejante a la control GRFT producida en E. coli. También exprese la
proteína CV-N en endospermo de arroz, pero tanto la concentración como la actividad
4neutralizante fueron bajas, y la potencia de inhibición del virus HIV fue más baja que en ensayos
donde CV-N fue producida utilizando otras plataformas, indicando que arroz no es el sistema
ideal para la acumulación de esta proteína. Una vez demostré que las tres proteínas podían
producirse individualmente en el endospermo del arroz, probé si era posible producirlas en
combinaciones. El objetivo de estos experimentos era ver si las proteínas podían ser co-
expresada en el endospermo de arroz y si los extractos conteniendo múltiples proteínas eran más
potentes contra HIV. La combinación CV-N/GRFT  fue testada contra el virus HIV y demostró
muy buena actividad neutralizante. Además todas las combinaciones mostraron actividad
mejorada contra HIV en ensayos de infecciones. El extracto crudo 2G12 demostró que su
actividad dependía de la concentración. Esta es la primera vez que más de una proteína que
neutraliza el virus HIV es producida de forma estable en el endospermo de un cereal, abriendo
un nuevo camino hacia la producción de un cóctel microbicida para evitar la transmisión del
virus del sida.
5RESUM
La meva tesis doctoral està enfocada en la producció a endosperma d’arròs, de tres proteïnes
diferents amb capacitat per a neutralitzar l’HIV, soles o en combinació i en la detecció de la seva
producció, integritat i capacitat par a unir-se e inactivar a l’HIV. Les tres proteïnes son l’anticòs
monoclonal 2G12, la lecitina griffithsin (GRFT) i la lecitina cianovirina (CV-N). L’objectiu
general era avaluar si es podia utilitzar arròs com a una plataforma de producció i determinar la
millor estratègia de producció en planta d’un còctel microbicida eficaç. En la primera part de la
meva tesis he investigat si es podia produir 2G12 a l’endosperma d’arròs i quins eren els factors
que afectaven la seva producció i la seva eficàcia funcional. Vaig expressar amb èxit l’anticòs
monoclonal 2G12 humà a l’endosperma d’arròs, el qual es va acumular en una forma
aglicosilada, a mes amb alguna forma amb glicans del tipus oligomanosa i altres del tipus de
complexes vacuolars o residus de GlcNAc senzills. Aquest resultats suggereixen que una
proporció molt elevada de la cadena pesada de l’anticòs era importada, al mateix temps que
transcrita, a una regió del reticle endoplasmàtic que no te la glucosiltransferasa i s’acumula als
cossos proteics sense modificacions posteriors. La proporció romanent sembla que segueix la
ruta canònica, produint-se una glucosilació inicial al lumen del reticle endoplasmàtic seguida de
modificacions complexes als cossos de Golgui i/o retallan a residuos de GlcNAc senzills. La
forma aglicosilada de l’anticòs produïda en arròs va demostrar tenir una major activitat
neutralitzant del virus HIV que la forma glicosilada, produïda amb anterioritat en llavors de
tabac; però cap d’elles va ser tant potent como la molècula produïda en cèl•lules CHO. Els
anàlisis del proteoma van suggerir que els rendiments obtinguts de proteïnes recombinants
podrien esser millorats a l’endosperma de la llavor mitjançant la regulació del metabolisme de
les proteïnes/carbohidrats i també protegint l’endosperma d’estressos abiòtics. Un cop establert
que a l’arròs es pot expressar 2G12, vaig passar a introduir la lectina GRFT a l’endosperma
d’arròs per a determinar si aquest podria ser una plataforma d’expressió d’aquest lectina
neutralitzant de l’HIV. GRFT s’acumula en arròs, amb una producció semblant i inclús mes alta
que altres anticossos produïts en el mateix sistema i a GRFT produïda de forma transitòria en
tabac. GRFT produïda a l’arròs va tenir una potencia inhibitòria en assajos de inhibició del virus
HIV semblant a la control GRFT produïda en E. coli. També vaig expressar la proteïna CV-N a
l’endosperma d’arròs, però tant la concentració com l’activitat neutralitzant van esser baixes, i la
potencia d’inhibició del virus HIV va esser inclús mes baixa que als assajos on CV-N va esser
6produïda utilitzant altres plataformes, indicant que l’arròs no es el sistema ideal per a
l’acumulació d’aquesta proteïna. Un cop demostrat que les tres proteïnes es podien produir
individualment a l’endosperma de l’arros, vaig provar si era possible produir-les en
combinacions. L’objectiu d’aquest experiments era veure si les proteïnes podien esser co-
expresades a l’endosperma d’arròs i si els extractes contenint múltiples proteïnes eren mes
potents contra HIV. La combinació CV-N/GRFT va esser provada contra el HIV i va demostrar
molt bona activitat neutralitzant. Ames, totes les combinacions van mostrar activitat millorada
contra HIV en assajos d’infeccions. El extracto cru 2G12 va demostrar que la seva activitat
depenia de la concentració. Aquest es el primer cop que mes d’una proteïna que neutralitza el
virus HIV es produïda de forma estable en l’endosperma d’un cereal, obrint un camí nou cap a la
producció d’un còctel microbicida per a evitar la transmissió del virus de la sida.
7ABBREVIATIONS
ADCC Antibody-Dependent Cell-mediated Cytotoxicity
AIDS Acquired Immunodeficiency Syndrome
ART Antiretroviral Therapy
ARV Antiretroviral
bp Base Pairs
BiP Binding Immunoglobulin Protein
BSA Bovine Serum Albumin
CaMV 35S Cauliflower Mosaic Virus 35S
CAP Cellulose Acetate Phthalate
CBAs Carbohydrate-binding Agents
CCR5 C-C chemokine Receptor type 5
CD4 Cluster of Differentiation 4
CDC Complement-Dependent Cytotoxicity
CDC Centers for Disease Control and Prevention
CHO Chinese Hamster Ovary
CS Cellulose Sulfate
CV-N Cyanovirin-N
CXCR4 C-X-C chemokine receptor type 4
DARPA Defense Advanced Research Projects Agency
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin
DNA Deoxyribonucleic Acid
DS Dextrin Sulfate
EC The half maximal Effective Concentration
EDTA Ethylenediaminetetraacetic Acid
ELISA Enzyme-Linked ImmunoSorbent Assay
ELP Elastin Like Peptide
EMRT Exact Mass Retention Time
ENGase Endoglycosidase
Env Envelope
ER Endoplasmic Reticulum
EU European Union
Fab Fragment Antigen-binding
FDA US Food and Drug Administration
GlcNAc N-Acetyl-glucosamine
GLGB Glycogen Branching Enzyme
GLGS Glycogen Synthesis Protein
GN Gene Name
gp120 Glycoprotein 120KDa
gp41 Glycoprotein 41KDa
GRAS Generally Regarded As Safe
GRFT Griffithsin
GRXC8 Glutaredoxin-C8
HAART Highly Active Antiretroviral Therapy
HC Heavy Chain
HCV Hepatitis C Virus
HIV Human Immunodeficiency Virus
hpt Hygromycin
HPV Human Papilloma Virus
HRP Horseradish Peroxidase
HSV Herpes Simplex Virus
H1N1 Influenza A
IC The half maximal Inhibitory Concentration
Ig Immunoglobulin
8kDa Kilo Dalton
LC Light Chain
MAb Monoclonal Antibody
MnP Manganese peroxidase
MS Mass Spectrometry
MPER Membrane Proximal Region
MPDS MassPREP Digestion Standards
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
MWCO Molecular Weight Cut-off
NCI National Cancer Institute
ngram AVG nanogram Average
NMR Nuclear Magnetic Resonance
NNRTIs Non- Nucleoside Reverse Transcriptase Inhibitors
Nos Nopaline Synthase gene
NRTIs Nucleoside Reverse Transcriptase Inhibitors
N-9 Nonoxynol-9
OD Optical Density at 540 nm
OS Oryza Sativa
PB-I Protein body type one
PB-II Protein body type two
PBMCs Peripherial Blood Mononuclear Cells
PBS Phosphate Buffered Saline
PBs Protein Bodies
PCR Polymerase Chain Reaction
PDI Protein Disulfide Isomerase
PE Protein Existence
PIC Pre-integration complex
PrEP Pre-Exposure Prophylaxis
PRO7 Prolamin
PSVs Protein Storage Vacuoles
RAmyD3 rice α-amylase signal sequence
RNA Ribonucleic Acid
RT-PCR Real Time- Polymerase Chain Reaction
SARS Severe Acute Respiratory Syndrome
SARS-CoV Severe Acute Respiratory Syndrome-associated coronavirus
SD Standard Deviation
SE Standard Error
SDS Sodium Dodecyl Sulfate
SDS-PAGE Sodium Dodecyl Sulfate-Poly-Acrylamide Gel Electrophoresis
SHIV Simian-Human Immunodeficiency Virus
SIV Simian Immunodeficiency Virus
SLS Sodium lauryl sulfate
SV SequenceVersion
TBS Tris-Buffered Saline
TEM Transmission Electron Microscopy
TMB 3,3',5,5'-Tetramethylbenzidine substrate
TMV 5' 5'-leader sequence of Tobacco Mosaic Virus
TSP Total Soluble Protein
US United States
USA United States of America
USDA United States Department of Agriculture
VMO-1 Vitelline Membrane Outer layer protein 1
WHO World Health Organisation
XTT 2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt
tetrazolium
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I.1 MOLECULAR PHARMING
Molecular pharming describes the use of plants as factories to produce recombinant
pharmaceutical proteins such as antibodies, vaccines, blood components, and other therapeutic
and diagnostic macromolecules (Ramessar et al., 2008a; Twyman et al., 2003). Plants can be
scaled up rapidly and inexpensively, allowing the economical production of pharmaceutical
proteins that are required in amounts exceeding 100 kg per year. In addition, plants have many
advantages compared with conventional systems such as mammalian cells, Escherichia coli and
yeast (Table I.1). Plants fold and assemble complex proteins, carry out essential posttranslational
modifications and do not contain the endotoxins and pathogens (e.g. prions) that are found in
other production platforms (Ma et al., 2003; Stöger et al., 2005).
Table I.1: Production systems for recombinant human pharmaceutical proteins (adapted from Ma et al., 2003).
*Compared to production in conventional systems such as mammalian cells, E. coli and yeast.
Molecular pharming has been used to produce many commercial products, including avidin and
trypsin (Twyman et al., 2014), collagen, aprotinin, growth hormone and human serum albumin
(Ma et al., 2003). Antibodies have also been successfully produced in plants, including single-
chain variable fragments (scFv) and full-size IgGs targeting Herpes simplex virus (HSV),
Respiratory syncytial virus, Rabies virus, colon cancer antigens and Hepatitis B virus (Ko and
Koprowski, 2005; Ramessar et al., 2008a; Stöger et al., 2005) as well as IgMs targeting a
System Overall cost Productiontimescale
Scale-up
capacity Product quality Glycosylation Contamination risk Storage cost
Bacteria Low Short High Low None Endotoxins Moderate
Yeast Medium Medium High Medium Incorrect Low risk Moderate
Mammalian
cell culture High Long Very low Very high Correct
Viruses, prions and
oncogenic DNA Expensive
Transgenic
animals High Very long Low Very high Correct
Viruses, prions and
oncogenic DNA Expensive
Plant cell
culture Medium Medium Medium High
Minor
differences* Low risk Moderate
Transgenic
plants Very low Long Very high High
Minor
differences* Low risk Inexpensive
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neuropeptide hapten (Ma et al., 2003). Antibodies for the prevention of sexually transmitted
diseases have been produced in plants, including an IgG against HSV which prevented
transmission in mice (Zeitlin et al., 1998) and a diagnostic antibody for Human
immunodeficiency virus (HIV) produced in barley (Schünmann et al., 2002). Tobacco and maize
have been used to produce the full size anti-HIV antibodies 2G12 and 2F5 (Rademacher et al.,
2008; Ramessar et al., 2008b; Sack et al., 2007). Cyanovirin-N has been produced transiently in
tobacco (Nicotiana tabacum) and griffithsin in N. benthamiana (O’Keefe et al., 2009; Sexton et
al., 2009).
The US Department of Defense Advanced Research Projects Agency (DARPA) has recently
challenged plant biotechnology companies to develop new strategies for the large-scale
manufacture of influenza vaccines. This resulted in a successful phase I clinical trial of the H1N1
HAC1 subunit, showing that the product was safe and well tolerated at all dose levels (iBio Inc,
2012). Pharma-Planta was an EU Sixth Framework Program integrated project that secured
approval for the HIV-neutralizing antibody 2G12 produced in transgenic tobacco (Pharma-
Planta, 2011), which completed a first-in-human phase I clinical trial to confirm its safety and
tolerability (Fischer et al., 2012).
The pharmaceutical company Synthon (Nijmegen, NL) acquired a molecular pharming platform
based on aquatic plants from Biolex Therapeutics (Pittsboro, NC, USA) and is now developing
clinical candidates such as Locteron (interferon-α2b) and a human CD30-specific antibody
(McCarthy, 2005; Synthon, 2014). Protalix Biotherapeutics recently gained FDA approval for
the commercialization of a recombinant form of the enzyme glucocerebrosidase
(prGCD/ELELYSOTM) produced in carrot cells. This enzyme is also produced in mammalian
cells by Genzyme (Cerezyme™) and Shire (VpriV®), but it requires in vitro modification before
formulation to remove sialic acid groups from the glycans thus exposing terminal mannose
residues (Shaaltiel et al., 2007). Protalix targeted this enzyme to the vacuole, producing the
oiligomannose version directly, thus avoiding the need for in vitro processing (Aviezer et al.,
2009). Protalix Biotherapeuics was the first company to gain approval for the marketing of a
plant-derived pharmaceutical protein intended for use in humans (Paul et al., 2013).
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I.2 SEEDS AS A PRODUCTION PLATFORM FOR
MOLECULAR PHARMING
Many different plant-based systems have been described for the  production of pharmaceutical
proteins, often using leaf biomass, fruits, tubers, or specialized aquatic plants or cultured plant
cells (Fischer et al., 2004; Ma et al., 2003; Twyman et al., 2003). Seeds provide further
advantages over these systems because they accumulate large amounts of protein in a relatively
small volume and provide a stable environment that promotes protein accumulation and inhibits
degradation, thus facilitating long-term storage (Ma et al., 2003; Stöger et al., 2005). For
example, antibodies accumulate at high levels in seeds and remain stable for several years with
no loss of activity when stored at ambient temperatures (Stöger et al., 2000). In practical terms,
this means that cereal seeds containing pharmaceutical proteins can be stored and distributed in
countries lacking a reliable cold chain.
A relatively high protein concentration is achieved because most seeds are small and compact
with a simple proteome, which also reduces the number of competing proteins released during
processing. Seeds also tend to lack the metabolites present in leaves that interfere with
downstream processing by fouling membranes and chromatography media, e.g. polyphenolic
compounds (Moloney et al., 1999). The specialized organelles in seeds provide further
advantages such as increased stability and capacity for accumulation, bioencapsulation and
containment, and enhanced processing strategies such as the extraction of oil bodies found in
oilseeds such as safflower and rapeseed (Moloney et al., 1999).
Seed-based production systems can be scaled up and down rapidly in response to market demand
simply by adjusting the amount of land used for a specific pharmaceutical crop. Field plants can
be scaled up between 100-fold and 1000-fold in a single season depending on the species
(Schillberg et al., 2002) and plant lines can be stored indefinitely and in an easily accessible form
simply by storing seeds (Twyman et al., 2003). In addition, edible seeds have GRAS status
(generally regarded as safe for human consumption) making them particularly suitable for the
development of oral vaccines that can be administered as flakes or flour with minimal
purification (Peters and Stöger, 2011).
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Cereal seeds naturally accumulate large amounts of protein in the endosperm, which has evolved
to store proteins and other macromolecules for consumption during germination. By subverting
the natural protein storage mechanisms, cereal endosperm tissue therefore provides an ideal
biochemical environment for the accumulation of recombinant proteins, and this is generally
achieved by the formation of specialized storage compartments such as protein bodies and
protein storage vacuoles, which are derived from the secretory pathway (Ramessar et al., 2008a).
Recombinant proteins expressed in seeds have remained stable and active after storage at room
temperature for more than six years (Ma et al., 2003; Stöger et al., 2000; Twyman et al., 2003).
Commercial development has focused on three staple cereal crops, i.e. maize, rice and barley,
with maize as a clear market leader (Ma et al., 2003; Ramessar et al., 2008b; Sabalza et al., 2013;
Stöger et al., 2005).
I.3 RICE AS A PRODUCTION PLATFORM FOR MOLECULAR
PHARMING
Rice has many advantages, such as the high grain yield, the existence of straightforward in vitro
cultivation and transformation procedures, and the ability to scale up production rapidly. In
addition, rice is a self-pollinating species so in theory there should be a lower risk of gene flow
from pharmaceutical to non-pharmaceutical rice crops and wild relatives. However, the protein
content of rice seeds is lower than maize, wheat and barley and the cost of growing rice is also
much higher than the other cereals (Stöger et al., 2005). The US company Ventria Bioscience
Inc. has developed rice as a commercial platform and has produced USDA-approved lines that
express high levels of lactoferrin and lysozyme for non-pharmaceutical use (Hennegan et al.,
2005; Lau and Sun, 2009; Nandi et al., 2002; Ramessar et al., 2008a; Yang et al., 2003, 2001).
An interesting and apparently unique property of rice endosperm is the diversity of storage
compartments. The endosperm cells of most cereals contain specialized storage compartments
known as protein bodies, which have evolved specifically for the storage or proteins, and these
bud from the endoplasmic reticulum (ER) when sufficient protein has accumulated (Takaiwa et
al., 2009). These compartments can also be used to accumulate recombinant proteins expressed
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using the appropriate promoters and targeting sequences, increasing protein yields by providing
an ideal stable environment (Muntz, 1998; Yamagata and Tanaka, 1986).
Most cereals form a single type of protein body but two distinct compartments are found in the
rice endosperm, known as PB-I and PB-II (Takaiwa et al., 2009). Protein bodies are insoluble in
low-salt aqueous buffers, so they can be purified by centrifugation (Sabalza et al., 2013). The
presence of two different protein bodies in rice potentially allows different proteins to be
expressed and targeted to different compartments simultaneously, and then recovered by first
separating the compartments by density centrifugation.
I.4 HIV PREVALENCE
In 2012 there were 35.3 million people living with HIV, up from 29.4 million in 2001. This
increase reflected general population growth, the appearance of new infections (UNAIDS, 2013)
and also the increased longevity of HIV patients because antiretroviral therapy is becoming more
effective (Abdool Karim and Baxter, 2012; Lynch et al., 2012).
Although HIV is now a pandemic, some geographical regions are more affected than others.
More than 95% of people with HIV live in developing countries, where most new infections
occur (UNAIDS, 2013). The global prevalence among people aged 15–49 was 0.8% in 2012
(Figure I.1). Sub-Saharan Africa, which is home to only 11% of the world’s population,
accounted for 4.7% of all HIV infections in 2013 (Figure I.2) (UNAIDS, 2013).
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Figure I.1: A global view of HIV infection. HIV prevalence in adults (aged 15–49) in 2012 was ~0.8% although the
prevalence differs significantly by region (www.globalhealthfacts.org, based on UNAIDS, 2013).
Figure I.2: Adult HIV prevalence by region in 2012 (UNAIDS, 2013).
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Currently there is no cure for HIV. Nevertheless, the disease can be managed with antiretroviral
drugs that reduce the rate of HIV replication and hence the mortality and morbidity associated
with acquired immunodeficiency syndrome (AIDS). The best current treatment is highly active
antiretroviral therapy (HAART), which comprises a cocktail of antiretroviral drugs that combat
HIV proliferation by inhibiting different components of the virus. However, resistance to
HAART is a growing problem and despite measures to increase the distribution of anti-retroviral
drugs, the number of new HIV infections is outstripping the number of recipients of HAART by
2:1 (MTN, 2014). For this reason, new strategies are required to prevent the spread of HIV.
I.5 MECHANISMS OF HIV-1 SEXUAL TRANSMISSION
HIV-1 is transmitted by males more often than females, and requires the virus to pass through
the mucosal epithelium of the vagina or rectum (Shattock and Moore, 2003; McGowan, 2006).
The exact transmission mechanism remains unknown, and several different pathways may be
involved (McGowan, 2006; Shattock and Moore, 2003) (Figure I.3). The virus must penetrate
multiple layers of stratified squamous epithelium in the vagina and ectocervix of females or the
inner foreskin, penile glans and fossa navicularis in males. The effectiveness of this barrier was
demonstrated when the epithelial layer of rhesus macaques was thinned by hormonal treatment,
substantially reducing ‘physical resistance’ to the virus (Marx et al., 1996; Smith et al., 2000).
It is broadly accepted that HIV infection requires some breakdown of the epithelial stroma and
this happens frequently during intercourse. In addition, the positive effects of male circumcision
against HIV might be explained by the fact that the circumcision reduces the possibility of
microtrauma to the large surface area of foreskin (Auvert et al., 2005; AVAC, 2014).
Rectal infection is more difficult to prevent because the rectum features a single layer of
columnar epithelium instead of stratified epithelial cells. Anal intercourse combined with some
kind of injury increases the possibility of HIV-1 infection (McGowan, 2006). Anything that may
cause mild epithelial disruption, such as trauma, ulceration or inflammation, makes the
epithelium more susceptible to HIV (Mostad et al., 1997; Strathdee et al., 1996).
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Figure I.3: Potential mechanisms for HIV-1 transmission across mucosal epithelium. a) Direct infection of
epithelial cells. b) Transcytosis through epithelial cells and/or specialized microfold (M) cells. c) Epithelial
transmigration of infected donor cells. d) Uptake by intra-epithelial Langerhans cells. e) Circumvention of the
epithelial barrier through physical breaches. Successful transfer of virus across epithelial barriers would result in
HIV-1 uptake by migratory dendritic cells (DC-SIGN or another mannose C-type lectin receptor) and subsequent
dissemination to draining lymph nodes, and/or localized mucosal HIV-1 infection leading to recruitment of
additional susceptible cells (Shattock and Moore, 2003).
I.6 CONVENTIONAL APPROACHES FOR THE TREATMENT
OF HIV
In 2012, 1.6 million people died of AIDS, which was a 30% reduction since 2005. Deaths have
declined in part due to antiretroviral therapy. Antiretroviral drugs block or inhibit the replication
of retroviruses such as HIV, and HAART in particular has been highly beneficial to many HIV
patients since its introduction in 1996, when the protease inhibitor-based HAART initially
became available (Palella et al., 1998). Currently, there are 30 antiretroviral drugs approved by
the FDA for the treatment of HIV carriers. These drugs are usually combinations or cocktails and
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they fall into five major classes: reverse transcriptase (RT) inhibitors, protease inhibitors, entry
and fusion inhibitors, integrase inhibitors and multidrug combination products (NAID, 2014).
However, HAART neither cures HIV nor eliminates all symptoms, and high virus titers, often
HAART-resistant, return if treatment is stopped (Dybul et al., 2002; Martinez-Picado et al.,
2000). HAART can suppress the virus, even to undetectable levels, as long as the patient remains
under treatment (Blankson et al., 2002). This means that the drugs must be taken for life, and
although the number of HAART recipients has increased, universal access remains limited.
Almost 26 million people are eligible for HAART based on WHO 2013 guidelines but the
treatment gap was 16.2 million in 2012 indicating a requirement for new therapeutic strategies
(WHO, 2013).
The prevention of sexual transmission is necessary to curtail the HIV pandemic. Heterosexual
sex accounts for approximately two thirds of new infections (AVERT, 2014). In the past, simple
preventative methods have been advocated such as abstinence, monogamy, a reduction in the
number of sexual partners, and the use of barrier methods such as male and female condoms.
However, these methods are inadequate because they depend on compliance from both partners
to work effectively. These challenges have encouraged research into HIV prophylaxis and
therapeutic vaccines, but there has been little progress and early efficacy trials were
disappointing (Dolgin, 2010; Walker and Burton, 2010). Researchers have also focused on
prevention strategies, such as pre-exposure prophylaxis, microbicides and voluntary male
circumcision (AVAC, 2014). Microbicides are self-administered agents that can be applied to the
vaginal or rectal mucosal surfaces with the goal of preventing or reducing the transmission of
sexually transmitted infections (Singh et al., 2014).
Truvada (Gilead Sciences, Inc., Foster City, CA) is the first product indicated for pre-exposure
prophylaxis (PrEP) in uninfected people who have a high risk of infection, e.g. those engaging in
sexual activity with a known HIV-infected partner (FDA, 2012). The FDA originally approved
Truvada for use in combination with other antiretroviral agents for the treatment (not prevention)
of HIV-infected adults and children 12 years or older (FDA, 2012) but also approved it for PrEP
in July 2012. Truvada comprises two antiretroviral drugs, the RT inhibitor emtricitabine and
tenofovir disoproxil fumarate. In order to reduce the risk of HIV infection, Truvada must be
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taken daily by the at-risk group and individuals must be tested to confirm their HIV– status at
least every 3 months (FDA, 2012).
I.7 THE DEVELOPMENT OF MUCOSAL MICROBICIDES AND
POTENTIAL MECHANISMS OF ACTION
Based on recent epidemiological data, women are 2–4 times more susceptible than men to new
HIV infections (Wang et al., 2013). In addition, women carry a greater burden of HIV risk
because of the greater exposed area of mucosal membrane, the biology of the virus, and
unknown or high-risk behavior among partners and the inability to enforce compliance with the
use of barrier methods. In developing countries these risks are exacerbated by low
socioeconomic status, the high prevalence of non-consensual sex, unprotected sexual intercourse
and other socio-economic and cultural factors (Ibrahim et al., 2013).
For this reason new technologies must be designed in order to empower women. Topical self-
administered microbicides are being developed as a subset of PrEP strategies. These could
significantly reduce the rate of HIV infection especially in women and also reduce the risks of
HIV infection in women with multiple sexual partners.
Microbicides need to be designed for different uses (vaginal or anal intercourse) in order to meet
the needs of every individual. For this reason they are formulated as gels, creams, films, or
suppositories. In addition, a contraceptive effect (with or without spermicidal activity) might be
useful serving a dual purpose by reducing the risk of pregnancy (Lopez et al., 2013).
Women in Brazil, India, South Africa, Thailand, the USA and Zimbabwe have expressed a
positive attitude towards the use of microbicides with or without contraceptives (Coggins et al.,
1998; Darroch and Frost, 1999; Han et al., 2009). In South Africa, in a study among HIV+ men
and women, neither sex objected to using the candidate microbicide (Ramjee et al., 2007).
Until recently, the incomplete understanding of the mechanism of HIV transmission hindered the
development of microbicides. Most of the initial agents (including surfactants and acidifying
agents) acted non-specifically, either by disrupting viral and cellular membranes or creating a
more hostile environment for the virus (Nutan and Gupta, 2011). Progress in understanding how
21
HIV gains entry into the host and establishes lasting infection has allowed the development of
compounds that target specific viral–host cell interactions and has facilitated a more tailored
approach to microbicide development. Topical microbicides can therefore be classified
according to their mechanism of action and their target during HIV transmission (Figure I.4)
(McGowan, 2006).
Figure I.4: Potential mechanisms of action of microbicide compounds (McGowan, 2006).
Microbicides that kill the pathogen (surfactants):
Some microbicides are surfactants that break down the membrane or envelope of the target
pathogen non­specifically, preventing interactions with vaginal epithelial cells. Three surfactants
have been evaluated as topical microbicides: Nonoxynol-9 (nonylphenoxypolyethoxyethanol or
N-9), C31G (SavvyTM, Cellegy Pharmaceuticals Inc., Huntingdon Valley, PA, USA) and sodium
lauryl sulfate (Invisible Condom, Universite Laval, Quebec, Canada). N-9 was developed as a
spermicide in the 1960s but was later tested for its ability to act as a vaginal microbicide against
HIV (Bourinbaiar and Fruhstorfer, 1996). The antiviral activity of N-9 was demonstrated in vitro
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(Hicks et al., 1985) but it was not effective against HIV in phase 2/3 trials, and it was also
associated with local vaginal toxicity (Van Damme et al., 2002). C31G (SavvyTM, Cellegy
Pharmaceuticals Inc., Huntingdon Valley, PA, USA) is a spermicidal and antimicrobial agent
consisting of two surface-active amphoteric agents (cetylbetaine and myristamine oxide). C31G
was shown to be non-toxic to human cells in vitro along with broad-spectrum activity against
Chlamydia trachomatis, HSV and HIV(Krebs et al., 2000; Wyrick et al., 1997). However, phase
III clinical studies in three countries failed to show any protection against HIV-1, resulting in the
termination of C31G as a potential microbicide (Peterson et al., 2007; Feldblum et al., 2008).
Sodium lauryl sulfate (SLS, Invisible condom) is a potent surfactant that inhibits both non-
enveloped viruses (e.g. papillomavirus, rotavirus and poliovirus) and enveloped viruses such as
HSV and HIV (Piret et al., 2002). A randomized, double blind, placebo-controlled Phase II study
in Cameroonian women demonstrated that the Invisible condom was well tolerated and
acceptable, and further clinical evaluation is underway (Mbopi-Keou et al., 2010).
Microbicides that prevent virus replication (replication inhibitors):
Other microbicides are not designed to prevent infection but to block virus replication soon after
initial infection, thus slowing the progression of AIDS before the disease starts to take hold
(Balzarini, 2007). These are the same class of antiretroviral drugs used in HAART and are
particularly useful for the prevention of mother-to-child HIV transmission during birth. For this
reason, interest has grown in the use of RT inhibitors for HIV prevention and there is already a
long list of products that have demonstrated efficacy, inexpensive production and the benefits of
oral administration. However, there are concerns that the use of such microbicides will result in
the emergence in antiretroviral resistance (McGowan, 2006). Tenofovir (Gilead Sciences Inc.,
Foster City, CA, USA), UC-781 and TMC-120 belong to this group of microbicides. Tenofovir
is a nucleoside reverse transcriptase inhibitor (NRTI) and both UC-781 and TMC-120 are non-
nucleoside reverse transcriptase inhibitors (NNRTI) (McGowan, 2006; Nutan and Gupta, 2011).
Tenofovir has shown both in vitro and in vivo efficacy and was therefore the first antiretroviral
drug to be assessed as a vaginal microbicide in clinical trials (Herrera et al., 2009). Even though
NNRTIs have a high therapeutic index and act directly against virus, their low solubility in water
makes their formulation as microbicides challenging (Nutan and Gupta, 2011).
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Microbicides that enhance the vaginal milieu of protectors (buffers):
The acidity of the vaginal canal inhibits several bacteria and viruses (Croughan and Behbehani,
1988; Sturm and Zanen, 1984; Yasin et al., 2002). Various microbicidal compounds have been
developed that protect the acidic vaginal milieu, either by buffering the neutralizing effect of
semen or maintaining sufficient lactobacilli in the vaginal canal (Ramessar et al., 2010).
Acidform (Amphora, Instead Inc., Dallas, TX, USA) is an acidic gel containing gelling agents,
buffer salts, humectants, preservatives and water in a proprietary mixture. A phase I study
revealed that this product was safe, but it caused vaginal irritation in combination with N-9
(Amaral et al., 1999). Carbopol 974P (BufferGel ReProtect, Baltmore, MD, USA) is a buffering
carbopol polymer with spermicidal activity. Preclinical tests showed that it can prevent
pregnancy and the transmission of HIV, HSV, human papilloma virus (HPV) and chlamydia
(Zeitlin et al., 2001). Lactobacilli protect the vaginal milieu from pathogens, and the introduction
of exogenous lactobacilli such as Lactobacillus crispatus achieved a reduction in HIV
proliferation (Klebanoff and Coombs, 1991; Martin et al., 1999). Bioengineered lactobacilli (live
microbicides) are therefore being tested as an alternative microbicidal approach.
Microbicides that block virus entry into host cells (entry/fusion inhibitors):
Entry inhibitors form another broad class of microbicide agents that block the attachment, fusion
or uptake of HIV into host cells. Such agents work either by binding to HIV and disrupting the
interaction with its receptors on the host cell membrane, or by saturating available binding sites.
Entry inhibitors are divided into three groups: anionic polymers or polyanions, CCR5 inhibitors
and fusion inhibitors that bind glycans or their receptors (Ramessar et al., 2010). The anionic
polymers include cellulose sulfate (CS), PRO-2000 (Indevus Pharmaceuticals, Lexington, MA,
USA), dextrin sulfate (DS), SPL7013, Carraguard, mandelic acid condensation polymer
SAMMA (Topical Prevention for Conception and Disease, Rush University, Chicago, IL), and
cellulose acetate phthalate (CAP). All have been evaluated in the clinic and have been shown to
be safe and well tolerated (El-Sadr et al., 2006; Joshi et al., 2006; McCormack et al., 2005;
Patton et al., 2006). The CCR5 inhibitors include PSC-RANTES, which demonstrates
picomolar-range IC50 values against all HIV-1 clades (Kawamura et al., 2003). Finally, the
24
fusion inhibitors include cyanovirin-N, an 11 kDa protein extracted from the cyanobacterium
Nostoc ellipsosporum (Mori and Boyd, 2001). Although CV-N shows efficient neutralization
activity in vitro, the dose has to be increased to 105 times greater than the in vitro ED100to
achieve efficient neutralization in vivo, thus making the production of this protein expensive
(McGowan, 2006). This protein has been produced in transgenic plants (Sexton et al., 2006) and
lactobacilli (Pusch et al., 2005) to reduce production costs accordingly. Microbicides that are
currently undergoing preclinical and clinical development are discussed on the AVAC Global
Advocacy for HIV Prevention website (AVAC, 2014).
a. Potential viral targets for microbicide components
Once HIV enters its target cells, the infection is irreversible (Shattock and Rosenberg, 2012).
Therefore, there is a short window of opportunity between exposure and infection during which
PrEP methods must block the uptake of the virus, and experiments in non-human primates
suggest that this window is 30–60 minutes in duration (Shattock and Rosenberg, 2012). When
the virus interacts with the mucosal tissue, an infection is established in 16–72 hours, forming an
initial focus of infection (Haase, 2011). One strategy to prevent transmission is to block the HIV
proteins that interact with cellular receptors, i.e. gp41 and/or gp120, or the receptors themselves,
i.e. CD4 and/or CCR5. Another is to prevent the production of provirus DNA by using reverse
transcriptase inhibitors and/or to prevent the integration of the provirus using integrase
inhibitors. The final opportunity is to block virus maturation with protease inhibitors thus
preventing the release of progeny viruses with the ability to infect other cells (Figure I.5).
25
Figure I.5: Drugs targeting different stages of the HIV life cycle. Entry into target cells represents the first point at
which microbicides could interrupt initial transmission events either by binding to the viral envelope or blocking the
cellular receptor CD4 or its coreceptor. Reverse transcription represents the second point at which a microbicide
could potentially intervene through the activity of nucleoside reverse transcriptase inhibitors (NRTIs) or non-
nucleoside reverse transcriptase inhibitors (NNRTIs). Integration, a third intervention point, can be prevented by
integrase inhibitors. Finally, protease inhibitors can block viral maturation thus preventing the release of defective
non-infectious virions (Shattock and Rosenberg, 2012).
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b. Recombinant microbicides including combination strategies
HIV treatment is challenging because the incoming virus may already contain mutations
rendering it resistant to certain antiretroviral drugs. Although HIV mutates almost every time a
new copy is made, not every mutation causes resistance (The Body, 2006).
HIV has been able to evolve in vitro escape mutants that circumvent the effects of polyanionic
compounds, which are some of the most promising microbicide candidates (Bobardt et al., 2004;
Este et al., 1997). In order to avoid the development of resistant isolates, combinations of two or
more compounds that target separate viral structures or functions are used in microbicide
formulations. Therefore, the development of effective microbicides will probably require a
combination of several components to prevent the rapid evolution of resistance and to provide
sufficient cross-clade protection (Sexton et al., 2009).
Combination microbicides are advantageous because they have a wider antiviral spectrum, a
higher genetic barrier to resistance, greater potency, and broader cell/tissue coverage than most
individual microbicides, and they often provide simultaneous protection against other sexually
transmitted infections. Examples include combinations of NNRTIs such as efavirenz (EFV,
Sustiva, Stocrin, Efavir) and nevirapine (NVP, Viramune, Boehringer Ingelheim) which are also
used in combination antiretroviral therapy, or the lipophilic molecules UC781 and TMC120,
which have been formulated as vaginal gels for phase III trials (Herrera et al., 2009). Rather than
mixing different components, the microbicidal activities of different polypeptides can be
combined by expressing them as fusion proteins, as shown for the antibody b12 and
cyanovirin-N expressed in tobacco leaves (Sexton et al., 2009). This protein binds gp120 at two
sites: the antibody binds to a conformational amino acid epitope and cyanovirin-N binds to the
high-mannose residues on the surface of the protein. Microbicide combinations may also be used
to target two diseases simultaneously, not only because some HIV microbicides are active
against other viruses but also because diseases caused by one virus may facilitate transmission
and pathogenesis of another. For example epidemiological studies show that HSV infection
increases the risk of HIV (Freeman et al., 2006). Another example is the HIV–malaria link in
which both diseases increase the severity of each other’s symptoms and can make both diagnosis
and therapy more complex (Vamvaka et al., 2014).
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Although microbicides may help to prevent HIV, their success depends on the ability to produce
sufficiently large quantities at a low cost. Estimations based on a 5-mg dose administered twice a
week suggest that a production capacity of 5000 kg/y is required to supply 10 million women
(Shattock and Moore, 2003). Therefore only plants provide the economy of scale required to
ensure the availability of these products in the HIV-endemic regions of Africa and Asia (Fischer
et al., 2004; Ma et al., 2003; Stöger et al., 2005, 2002).
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II. AIMS AND OBJECTIVES
My research project focused on the expression of multi-component third-generation microbicides
in rice endosperm. My specific objectives were to express individually and in combination one
human monoclonal antibody (2G12), and two anti-HIV proteins (cyanovirin-N and griffithsin) in
order to explore whether rice seeds can be used as a production platform for individual and
combination HIV microbicides. I analyzed the expression of these components to identify a lead
event for further characterization, and investigated factors affecting the expression and
accumulation of the 2G12 heavy and light chains so that their expression and accumulation can
be modulated. My ultimate aim was to produce a multicomponent microbicide in rice endosperm
tissue and to investigate how this performs against HIV.
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CHAPTER 1
A recombinant HIV-neutralizing antibody produced in rice
endosperm accumulates predominantly as an aglycosylated
derivative with enhanced neutralizing activity
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1.1 INTRODUCTION
HIV/AIDS is typically a sexually-transmitted disease, although the virus can also be transmitted
via contaminated needles or blood stocks and by mother-to-child transfer during pregnancy,
childbirth or lactation (UNAIDS, 2013). The virus is taken up by T-cells, macrophages and
dendritic cells expressing the surface receptor CD4, which is recognized by envelope
glycoprotein 120 (gp120). Subsequent conformational changes in gp120 initiate virus binding to
the co-receptor (CCR5 or CXCR4) and fusion between the cell membrane and the virus,
mediated by envelope glycoprotein 41 (gp41) (Clapham and McKnight, 2001). HIV carries two
copies of a single-stranded RNA genome, which are reverse transcribed after uncoating to
generate a double-stranded DNA provirus that integrates into the host genome. The integrated
provirus is transcribed by cellular RNA polymerases to generate full-length progeny genomic
RNAs and spliced mRNAs encoding viral proteins (Shors, 2011). After export from the nucleus,
the mRNAs are translated and the resulting proteins are processed by a viral protease before
combining with the genomic RNAs to form new virions. These bud from the membrane,
acquiring lipid envelopes in the process, and become infectious particles (Figure 1.1) (Greene et
al., 2008).
Focusing in the clinical course of HIV-1 infection, the initial step is recognized by the high peak
of plasma viremia. This occurs within 2 weeks of transmission and declines as CD4+ T
lymphocytes accumulate, representing a specific immune response to HIV-1 (Figure 1.2) (Simon
and Ho, 2003). During the chronic stage of HIV infection, infected individuals have different
viral set-points due to variations in genetics, strain specificity and the cytotoxicity of host and
viral factors (Figure 1.2) (Connick et al., 2001). The gradual increase in plasma viremia and loss
of CD4+ cells marks the onset of AIDS (Figure 1.2). Two weeks after infection, the virus begins
to multiply efficiently. This is followed a week later by the production of anti-HIV antibodies,
which inhibit further HIV replication causing the plasma viremia to decline once more (Figure
1.2). The presence of anti-HIV antibodies indicates the end of the first (acute) stage of HIV
infection and the beginning of the second, chronic stage (Morrison et al., 2010; Pilcher et al.,
2004; Schacker et al., 1998).
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Figure 1.1: Schematic overview of the main steps in the HIV replication cycle: binding to CD4 and co-receptors;
fusion with the host cell membrane; uncoating of the viral genome; release of the RNA and proteins into the
cytoplasm; reverse transcription of RNA to DNA; formation of the pre-integration complex (PIC); and translocation
into the nucleus. Once in the nucleus, the proviral DNA is integrated into the host DNA and subsequently
transcribed and translated to form new viral RNA and viral proteins that translocate to the cell surface and assemble
into new immature particles. The virions bud off and are released. Finally, during maturation, the protease cleaves
the structural polyprotein to form mature Gag proteins, resulting in the production of new infectious virions (Barré-
Sinoussi et al., 2013).
Figure 1.2: The natural course of HIV-1 infection based on the longitudinal evolution of the two key surrogate
markers — plasma viremia and CD4+ T-lymphocyte count. The primary infection phase is associated with clinical
symptoms of acute retroviral syndrome. After the first months of infection, plasma viremia stabilizes at an
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individual-specific level and the CD4+ T-lymphocyte number normalizes. The protracted chronic phase of infection
is clinically silent despite the fact that HIV-1 replicates continuously at high levels. AIDS is defined by the
occurrence of opportunistic infections or HIV-1-associated malignancies as defined by the Centers for Disease
Control and Prevention (CDC) classification of 1993. The risk of opportunistic infections increases significantly
when the number of CD4+ T lymphocytes falls to below 200 per mm3. Viral diversity increases over the course of
infection in accordance with the continuously high level of viral replication and the error-prone nature of HIV-1
reverse transcription (Simon and Ho, 2003).
Neutralizing antibodies play a major role in the defense against HIV (Albert et al., 1990;
Montefiori et al., 2001). However, their precise impact is unclear because this early antibody
response specifically targets the autologous circulating virus and is ineffective against
heterologous viruses (Wei et al., 2003). Studies of asymptomatic HIV+ individuals, who have
been infected for at least 1 year without clinical signs of AIDS and who have not received
antiretroviral drug therapy, revealed that 10–30% of such individuals develop broadly
neutralizing antibodies and these tend to accumulate three or more years after infection
(Stamatatos et al., 2009). However, only 1% of HIV+ individuals develop antibodies with
outstanding breadth and potency (Simek et al., 2009).
Early studies led to the isolation of only four broadly neutralizing monoclonal antibodies: b12,
2G12, 2F5 and 4E10 (Cardoso et al., 2005). These are not highly potent, but they nevertheless
helped to define some HIV vulnerable sites and are also efficacious against SHIV infection in
macaques (Baba et al., 2000; Hessell et al., 2010; Mascola et al., 2000). All four antibodies are
atypical and are not found in nature: b12 is a phage-derived antibody (Klein et al., 2013), 2G12
has three rather than the normal two combining sites (Calarese et al., 2003; Trkola et al., 1996),
and 4E10 and 2F5 are self-reactive (Haynes et al., 2005; Yang et al., 2013). The unsuccessful
attempts to stimulate antibody production by vaccination and the large quantities required for
transmission blocking in macaques resulted in limited enthusiasm for the development of these
antibodies (Mascola and Nabel, 2001).
Two recent developments, i.e. single-cell antibody cloning techniques (Scheid et al., 2009) and
the reduced risk of infection achieved by the RV144 human vaccine, have refocused attention on
these antibodies and facilitated the discovery of additional and more suitable candidates (Haynes
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et al., 2012). New antibodies have been discovered that target two or more different sites on the
HIV envelope spike (Bonsignori et al., 2012; Georgiev et al., 2013; Klein et al., 2012; Scheid et
al., 2011, 2009). This second generation of broadly neutralizing antibodies target four major
vulnerable sites on the HIV envelope spike, i.e. the CD4-binding site, the N160 glycan-
dependent site associated with the V1/V2 loops, the N332 glycan-dependent site at the base of
V3 loop and the membrane proximal external region (MPER) on gp41 (Figure 1.3).
Figure 1.3: Epitopes of broadly neutralizing antibodies on HIV-1 Env. Structure of the Env trimer as determined by
electron microscopy (Liu et al., 2008) showing the approximate locations of epitopes on the surface (each epitope is
shown once per trimer): CD4-binding site epitope (red), V3 loop/Asn332 epitope (glycan attached to Asn332 as a
space-ﬁlling model) (blue), V1/V2 loop/Asn160 epitope (glycan attached to Asn160 as a space-ﬁlling model)
(green), MPER epitope (yellow). N-linked glycans are shown as gray sticks and were added to all potential acceptor
sites present in the coordinates for BG505 SOSIP Env (PDB 4NCO) using the GlyProt server (West et al., 2014).
Even though the CD4 binding site is protected, i.e. surrounded by glycans and variable regions
(Zhou et al., 2007), this functionally-conserved site remains accessible to CD4 and the
corresponding antibodies. Two of the most potent antibodies, NIH45-46 AND 3BNC117, share a
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common mode of antigen recognition even though they were isolated from different individuals
(Scheid et al., 2011).
PG9, PG16, CH01–CH04 and PGT141–PGT145 target the N160 glycan-V1/V2 site by
penetrating the glycan shield with a long anionic third heavy chain complementary-determining
region (Julien et al., 2013a; McLellan et al., 2011). The PGT121-like and PGT128-like
antibodies target the N332 glycan-V3 loop site. PGT121-like antibodies contact gp120 at the
base of the V3 loop and a high-mannose or complex-type N-glycan at N332 (Julien et al., 2013b;
Mouquet et al., 2012). In addition, PGT128-like antibodies contact the C-terminus of the V3
loop, mannose Man8/9 glycans and a synthetic Man5 glycan lacking the core N-
acetylglucosamine (Man5GlcNAc2) at positions N332 and N301, respectively (Pejchal et al.,
2011). Finally, 10E8 targets the MPER in gp41 by recognizing an α-helix near the 2F5 and 4E10
recognition site. However, 10E8 is a more potent antibody, which is neither autoreactive nor
phospholipid-reactive (Huang et al., 2012).
A panel of broadly-neutralizing anti-HIV antibodies has been described which differ in terms of
the number of HIV strains and clades neutralized and the potency of in vitro neutralization
(reviewed by McCoy and Weiss, 2013). However, only a few of these have been tested in
preclinical studies for their ability to prevent the transmission of HIV or SHIV (Ramessar et al.,
2010). Importantly, most HIV-neutralizing antibodies are highly mutated and can also carry
insertions and deletions that are uncommon in other antibodies. In addition, these antibodies lose
their neutralizing activity and even fail to bind to most HIV-1 envelope proteins when reverted to
their germ line sequences (Scheid et al., 2011).
The first-generation antibody 2G12 recognizes a cluster of high-mannose glycans attached to
Asn332, Asn295 and Asn339, using a unique domain-swapped architecture that combines both
Fab arms into a single, large antigen-binding (Fab)2 unit (Calarese et al., 2003). Domain-
swapped 2G12 dimers show higher neutralization potency and breadth (West et al., 2009)
through the binding of two (Fab)2 units that are flexibly linked to two Fc regions in the 2G12
dimer (Wu et al., 2013). HIV-neutralizing antibodies 2G12, 2F5 and 4E10 have been produced in
Chinese hamster ovary (CHO) cells for prophylactic and therapeutic use (Hofmann-Lehmann et
al., 2001; Stiegler et al., 2002).
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Several HIV-neutralizing antibodies have been produced in plants. The first was b12, which was
expressed in tobacco as an IgG (Sexton et al., 2009) and also as a fusion with the anti-HIV lectin
cyanovirin-N (Boyd et al., 1997; Dey et al., 2000). Then 4E10 was produced by secretion from
hydroponic tobacco and was shown to assemble and function correctly although the overall
yields were low (Drake et al., 2009). Most work has been carried out with 2G12, which has been
expressed successfully in tobacco and was the first plant-derived antibody to complete a phase I
clinical study in Europe (Fischer et al., 2012). This antibody has also been produced in maize in
two separate studies, in one case by secretion to the apoplast and in the other by retention in the
endoplasmic reticulum (ER) (Rademacher et al., 2008; Ramessar et al., 2008b). In both cases the
yields were high (40–100 mg/kg dry seed weight) and the purified antibody had a neutralization
activity that was similar to or greater than the same antibody produced in CHO cells.
Furthermore, 2G12 has also been expressed transiently in Nicotiana benthamiana with yields of
up to 50 mg/kg fresh biomass (Sainsbury and Lomonossoff, 2008; Strasser et al., 2008). Finally,
2F5 has been produced in tobacco plants as a fusion protein with an elastin like peptide (ELP)
(Floss et al., 2008). Free 2F5 has also been expressed in tobacco suspension cells, with similar
antigen-binding affinity to its CHO counterpart but less potent HIV-1 neutralization activity
(Sack et al., 2007).
Broadly-neutralizing human monoclonal antibodies against HIV can be used as microbicides to
prevent virus transmission. HIV-1 entry into susceptible cells requires the envelope (Env) protein
and a trimer of gp120/gp41 heterodimers, with gp120 acting as the external surface subunit that
engages cellular receptors, and gp41 as the transmembrane subunit that mediates membrane
fusion (Poignard et al., 2001). The gp120 protein interacts with the T-cell surface glycoprotein
CD4 and the co-receptors CCR5 or CXCR4, so antibodies against these proteins can be used to
prevent the uptake of HIV into target cells. The high cost and limited capacity of cell culture
platforms make it unfeasible to meet the demand for these proteins in developing countries
because 100–1000 kg of each antibody would be required annually and each microbicide would
require 2–3 antibodies targeting different epitopes to prevent the emergence of escapes
(Ramessar et al., 2010).
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1.2 AIMS
The aims of the work described in this chapter were to test whether rice endosperm can function
as a platform for the production of 2G12 and to gain insight into the factors that affect the
production and functional efficacy of neutralizing antibodies in plants and the impact this has on
endogenous gene expression.
1.3 MATERIALS AND METHODS
1.3.1 Cloning and construct design
All transformation constructs were based on the binary vector pTRA, a derivative of pPAM
(GenBank accession no. AY027531). The vector contains two tobacco RB7 scaffold attachment
regions flanking the expression cassette. The coding regions of the 2G12 heavy and light chains
(obtained from Polymun, Vienna, Austria) included N-terminal signal sequences targeting each
polypeptide to the secretory pathway (Figure 1.4). The expression cassette comprised the
endosperm-specific rice glutelin-1 promoter, the maize ubiquitin-1 first intron, the Tobacco etch
virus 5' leader, which acts as a translational enhancer, the coding region, and the Cauliflower
mosaic virus 35S terminator, resulting in final constructs pTRAgtiGH and pTRAgtiGL.
Figure 1.4: Transformation constructs for stable expression in rice endosperm. A) pTRAgti-GH containing the
2G12 heavy chain (HC) gene. B) pTRAgti-GLF containing the 2G12 light chain (LC) gene. In both constructs the
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expression cassette comprised the endosperm-specific rice glutelin-1 promoter, the Tobacco etch virus 5' leader, the
coding region and the CaMV 35S terminator (Ramessar et al., 2008b).
1.3.2 Transformation and regeneration of transgenic plants
Seven-day-old mature rice zygotic embryos (Oryza sativa cv. Nipponbarre) were transferred to
osmotic medium (4.4 g/l MS powder supplemented with 0.3 g/l casein hydrolysate, 0.5 g/l
proline, 72.8 g/l mannitol and 30 g/l sucrose) 4 h before bombardment with 10 mg gold particles
coated with the 2G12 heavy and light chain constructs and the selectable marker hpt at a 3:3:1
ratio (Sudhakar et al., 1998; Valdez, 1998). The embryos were returned to osmotic  medium for
12 h before selection on MS medium (4.4 g/l MS powder, 0.3 g/l casein, 0.5 g/l proline and 30
g/l sucrose) supplemented with 50 mg/l hygromycin and 2.5 mg/l 2,4-dichlorophenoxyacetic
acid (2,4-D) in the dark for 2–3 weeks. Transgenic plantlets were regenerated and hardened off
in soil. Plants were grown in the greenhouse and growth chamber at 28/20°C day/night
temperature with a 10-h photoperiod and 60-90% relative humidity for the first 50 days,
followed by maintenance at 21/18°C day/night temperature with a 16-h photoperiod thereafter in
a growth chamber.
1.3.3 Characterization of rice plants and transgene expression
Genomic DNA was isolated from rice leaves by phenol extraction (Edwards et al., 1991) and 50-
ng aliquots were used for PCR with three primers designed to generate overlapping products to
confirm transgene integrity (Figure 1.5). GoTaq DNA polymerase was used with the program
recommended by the manufacturer (Promega). The primers are listed in Table 1.1. The positive
lines were then screened for transgene expression by dot blot. The total soluble protein (TSP)
was extracted in three volumes (v/w) of phosphate buffered saline (PBS). The samples were
centrifuged twice (15 min, 4°C, 13,000 x g) and 4 μl of supernatant was spotted onto a
nitrocellulose membrane (Amersham, GE Healthcare, Buckinghamshire, UK). The membrane
was blocked for 1 h with 5% blocking buffer and probed overnight, shaking at room temperature
with alkaline phosphatase-labeled antibodies against the heavy and light chains (goat anti-human
IgG Fc chain, Sigma (St. Louis, MO, USA) A9544, and goat anti-human kappa light chain,
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Sigma A3813). The blots were washed three times with PBS supplemented with 0.2% Tween-20
(PBST) and the antibody was detected using Sigma FASTTM BCIP/NBT in distilled water.
Figure 1.5: Three primers for the PCR-based detection of intact expression cassettes in transgenic plants.
Table 1.1: Primers used to screen putative transgenic plants by PCR.
Gt1 promoter 2G12 HC gene CaMV 35S terminator
Gt1 promoter 2G12 LC gene CaMV 35S terminator
Set 1 Set 3
Set 2
Set 1 Set 3
Set 2
Set of primers Gene Primer Name Primer sequence
Gt1-F 5’- CAC CTT TCG TGT ACC ACA CTT C -3’
Set 1 Gene-R 5’-CAC GGT GAG CTT GCT GTA GA -3’
2G12 Gt1-F 5’- CAC CTT TCG TGT ACC ACA CTT C -3’
Gene-R 5’- TCC CCT GTT GAA GCT CTT TG -3’
HC-F 5’- GGC TAT TTT AAA AGG TGT CCA GTG TG-3’
Set 2 Gene-R 5’-CAC GGT GAG CTT GCT GTA GA -3’
2G12 Gene-F 5’- TCA GTC TCC TTC CAC CCT GT-3’
Gene-R 5’- TCC CCT GTT GAA GCT CTT TG -3’
Gene-F 5’- AAA GGT GTC CAG TGT GAG GTG-3’
Set 3 EV-Camv-R 5’- GGT TTC TTA TAT GCT CAA CA-3’
2G12 LC-F 5’- TAC TCT GGC TCC CAG GTG CCA AAT-3’
EV-Camv-R 5’- GGT TTC TTA TAT GCT CAA CA-3’LC
HC
LC
HC
LC
HC
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1.3.4 Confirmation of antibody assembly and accumulation (ELISA)
Three seeds representing each event were analyzed by ELISA to quantify 2G12 expression,
using goat anti-human kappa light chain (Sigma K3502) or goat anti-human IgG Fc chain (Sigma
K2136) as capture antibodies. These were diluted 1:200 and coated directly onto 96-well Nunc-
Immuno Maxisorp surface plates (Nalge Nunc) and incubated overnight at 4°C. The plates were
blocked with 5% nonfat milk for 2 h and then washed with PBST. Serial dilutions of the samples
were added to the wells and incubated for 2–3 h at room temperature. After washing, a
horseradish peroxidase (HRP)-conjugated sheep anti-human kappa-chain antiserum (The
Binding Site, Birmingham, UK) was added to the plates at a 1:1000 dilution and incubated at
room temperature for 2 h before the signal was detected with 3,3',5,5'-tetramethylbenzidine
(TMB) substrate (Sigma). After 4–5 min, the signal was quantified by measuring the absorbance
at 450 nm.
1.3.5 Fluorescence microscopy
Fluorescence microscopy was carried out by E Arcalis, Department of Genetics and Cell
Biology, BOKU, Vienna. Sections of immature rice endosperm (20 days after pollination) were
mounted on glass slides and pre-incubated in 5% (w/v) bovine serum albumin (BSA Fraction V)
in phosphate buffer (0.1 M, pH 7.4) and then incubated with polyclonal rabbit anti-HC or anti-
LC antiserum diluted 1:100. Sections were then treated with the secondary antibody diluted in
phosphate buffer (0.1 M, pH 7.4). An AlexaFluor 594-conjugated goat anti-rabbit IgG (red
fluorophore) was used to detect 2G12 and an anti-glutelin antibody (green fluorophore) was used
to detect endogenous glutelins.
1.3.6 Transmission electron microscopy
Transmission electron microscopy (TEM) was carried out by E Arcalis, Department of Genetics
and Cell Biology, BOKU, Vienna. Developing rice seeds (20 days after pollination) were fixed
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and processed as described by Arcalis et al. (2004). Immature seeds from wild-type and
transgenic rice plants were cut into small pieces with a razor blade under PBS (pH 7.4) and fixed
in 4% (w/v) paraformaldehyde with 0.5% (v/v) glutaraldehyde in PBS overnight at 4°C. After
several washes in PBS, the samples were dehydrated through an ethanol series (50%, 70%, 90%,
100%) at 4°C and progressively embedded in LR White resin (25% in ethanol, 50%, 75% and
pure resin for 3 h each) followed by an additional step with fresh 100% resin. Blocks were
mounted in Beem capsules and polymerized overnight at 60°C. Sections showing silver
interference colors were collected on gold grids, pre-incubated in 5% (w/v) BSA in PBS for 15
min at room temperature and then incubated with either polyclonal goat anti-HC or anti-LC
(1:100 in PBS) for 2 h at room temperature. The primary LC antibody is not specific and also
binds HC, whereas the primary HC antibody is specific. After three washes for 10 min in PBST,
sections were incubated with the secondary antibody (donkey anti-goat IgG coupled to 15-nm
colloidal gold particles) diluted 1:30 in PBS and incubated for 1 h at room temperature. After
two washes for 10 min in PBS and two in distilled water, samples were air dried and the sections
were observed using a FEI Tecnai G2 transmission electron microscope.
1.3.7 Protein A affinity chromatography and SDS/PAGE
Rice seeds were ground to a fine powder and extracted overnight at 4°C in five volumes of
buffer (1× PBS, 5 mM EDTA, 1 mM 2-mercaptoethanol, pH 7.4). Insoluble material was
removed by centrifuging twice at 8000 × g for 30 min at 4°C. The supernatant was filtered and
the antibody concentration in the crude extract determined by ELISA. The sample was loaded
onto a protein A affinity column (ceramic HyperDF) at a flow rate of 2 ml/min. The column was
washed with PBST and PBS, and the antibody was eluted in 100 mM glycine (pH 3.6)
containing 100 mM fructose, and buffered with 0.1 volumes of 1 M sodium acetate (pH 4.75).
Antibody-containing fractions were identified by the droplet Bradford method (Bradford, 1976),
and 2G12 concentrations were determined by ELISA. Fractions containing >50 μg/ml were
pooled and dialyzed for 2 days against 10 mM sodium acetate (pH 4.75) containing 1 mM EDTA
and 0.1 mM 2-mercaptoethanol (omitted in the final dialysis step). The dialyzed antibody was
concentrated by ultrafiltration using spin-columns with a 30-kDa molecular weight cut-off
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(MWCO). Antibody heavy and light chains were separated by SDS-PAGE (12%
polyacrylamide) as previously described (Laemmli, 1970).
1.3.8 Glycan analysis
Glycan analysis was carried out by F Altmann, Department of Chemistry, BOKU, Vienna.
Antibody bands from Coomassie-stained polyacrylamide gels were destained,
carbamidomethylated, digested with trypsin, and extracted from gel pieces as described (Shukla
et al., 2007). The peptides were separated by capillary reversed phase chromatography with a Q-
TOF Ultima Global mass spectrometer (Waters) for detection (Van Droogenbroeck et al., 2007).
The MS data from the tryptic peptides were analyzed as previously described (Van
Droogenbroeck et al., 2007) and compared with datasets generated by in silico tryptic digestion
of the 2G12 coding region, using the PeptideMass program (www.expasy.org/tools/peptide-
mass.html). Based on the tryptic peptide datasets, tryptic glycopeptide datasets were generated
by adding glycan mass increments to the masses of the two identified glycopeptides.
1.3.9 In vitro binding to gp120 (ELISA)
The specific antigen-binding activity of 2G12 was determined by coating ELISA wells with 100
ng recombinant gp120 from HIV strain IIIB, provided by the MRC Centralized Facility for
AIDS reagents, Potters Bar, UK. After washing with PBST and blocking with BSA, serial
dilutions of 2G12 were added and the amount of bound antibody determined using a mix of
HRP-conjugated anti gamma-chain and HRP-conjugated anti-kappa chain (The Binding Site)
diluted 1:1000. The wells were washed with PBS and the signal was developed with TMB
substrate followed by reading the absorbance at 450 nm.
1.3.10 Syncytium-inhibition assay for HIV neutralization
The HIV-neutralization assays were carried out by AYH Teh, Molecular Immunology Unit,
Division of Clinical Sciences, St. George’s Hospital Medical School, University of London.
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HIV-1 neutralization was assessed using a syncytium-inhibition assay. Ten two-fold serial
dilutions (starting concentration 100 μg/ml) of OS2G12, CHO2G12, NT2G12 and a non-neutralizing
control were pre-incubated with HIV-1 Bal at 10 half-maximum tissue culture infectious doses
(Terman and Bertram, 1985) per ml for 1 h at 37°C. CD4+ human AA-2 cells were added at a
density of 4 × 105 cells/ml and incubated for a further 5 days. We analyzed eight replicates per
antibody dilution step. The presence of one or more syncytia per well after 5 days was scored as
positive for infection. The half maximal inhibitory concentrations (IC50) were calculated using
the concentrations present during the antibody-virus pre-incubation step (Montefiori, 2005; Wei
et al., 2003).
1.3.11 Comparative proteomic analysis
Comparative proteomic analysis was carried out by A Murad, Embrapa Genetic Resources and
Biotechnology, Laboratory of Synthetic Biology, Parque Estacao Biologica, Distrito Federal,
Brasil. Approximately 100 mg of rice seed powder was vortexed with 500 μl buffer (20 mM
Tris-HCl, pH 8.3, 1.5 mM KCl, 10 mM DTT, 1 mM PMSF and 0.1% (v/v) SDS) at room
temperature for 10 min and centrifuged for 5 min at 10,000 x g. The protein content of the
supernatant was measured using a NanoDrop (Thermo Fisher Scientific, USA) and 100 μg of
TSP was precipitated using 1:4 cold acetone. After centrifugation as above, the pellet was dried
at room temperature for 10 min and dissolved in 50 μl 50 mM NH4HCO3 to a final concentration
of 2 μg/μl, then mixed with 10 μl 50 mM ammonium bicarbonate and 25 µl 0.2% (v/v)
RapiGEST™ at 80°C for 15 min before adding 2.5 μl 100 mM DTT and incubating at 60°C for a
further 30 min. After centrifuging as above, samples were mixed with 2.5 μl 300 mM
iodoacetamide in the dark at room temperature for 30 min and then with 10 µl 300 mM
iodoacetamide at 37°C overnight. RapiGEST was precipitated with 10 μl 5% TFA for 90 min at
37°C and the samples were centrifuged at 10,000 x g at 6°C for 30 min. The supernatants were
transferred to Waters Total Recovery vials (Milford, USA), freeze dried and resuspended in 100
μl 200 mM ammonium formate containing 50 fmol/µl Waters protein standards digested with
rabbit phosphorylase B. The final protein concentration was 1 µg/μl.
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The tryptic peptides were fractionated using a nanoACQUITY™ system (Waters). First-
dimension separation was carried out using an XBridge™ reversed phase column (300 μm x 50
mm, 5-μm C18 resin) with 20 mM ammonium formate as mobile phase A and acetonitrile as
mobile phase B. Second-dimension separation was carried out using a Symmetry pre-column
(300 μm x 50 mm, 5-μm C18 resin) and a HSST3 reversed phase column (75 μm x 150 mm, 1.8-
μm C18 resin) with 0.1% formic acid in water as mobile phase A and 0.1% formic acid in
acetonitrile as mobile phase B.
The samples were injected into the first column at a flow rate of 2 μl/min in 0.1% mobile phase
B and were eluted in 10.8 % mobile phase B for 2 min at the same flow rate. After dilution with
aqueous 0.1% formic acid in the pre-column at a flow rate of 10 μl/min for 8.5 min, the peptides
were separated on the second column using a gradient of 7–35 % mobile phase B for 37 min at a
flow rate of 500 μl/min followed by a 5-min rinse with 85 % mobile phase B. The column
temperature was maintained at 35 °C. After re-equilibration, peptides for the second, third, fourth
and fifth fractions were eluted using 14, 16.7, 20.4 and 50 % of mobile phase B, respectively.
The tryptic peptides were analyzed using a Synapt G2 HDMS™ mass spectrometer (Waters,
Manchester, UK) with a hybrid quadrupole/ion mobility/orthogonal acceleration time-of-flight
(oa-TOF) geometry in positive nanoelectrospray ion mode. Exact mass retention time (EMRT)
nanoLC-MSE data (Silva et al., 2006) were collected in alternating low and elevated energy
mode at 3 eV and 12–45 eV respectively with a continuum spectra acquisition time of 1.5 s and a
0.1-s interscan delay.
MS data were processed and searched using ProteinLynx Global Server (PLGS) v2.5 (Waters,
Manchester, UK). Proteins were identified using the ion accounting algorithm and a search of the
UniProt Oryza spp database with MassPREP digestion standards (MPDS). Identifications and
quantitative data packaging were generated using dedicated algorithms (Li et al., 2009; Silva et
al., 2006) and a search against a species-specific UniProt database. The fixed modification of
carbamidomethyl-C was specified, and the variable modifications included were amidation C-
terminus, deamidation N, deamidation Q, methyl N-terminus, methyl C-terminus, glycation N-
terminus, O-GlcNac ST and oxidation M. Components were typically clustered with a 10 ppm
mass precision and a 0.25-min time tolerance against the database-generated theoretical peptide
ion masses with a minimum of one matched peptide. One missed cleavage site was allowed. The
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protein identification criteria also included the detection of at least three fragment ions per
peptide, six fragments per protein, the determination of at least one peptide per protein, and the
identification of the protein was allowed with a maximum 4% false positive discovery rate in at
least three technical repeatability injections. The intensity measurements were normalized to
those representing peptides of the digested internal standard (Murad and Rech, 2012).
1.3.12 Quantitative real-time PCR
RNA was isolated from rice endosperm 25 days after pollination as described by Li and Trick
(2005) with corrections and modifications. Extraction buffer I was 100 mM Tris (pH 8.0), 150
mM LiCl, 50 mM EDTA, 1.5% SDS, 1.5% 2-mercaptoethanol and extraction buffer II was 4.2
M guanidine thiocyanate, 1 M sodium acetate, (pH 4.0), 0.5% lauryl sarcosine, 25 mM sodium
citrate (pH 7.0). The samples were processed on a Bio-Rad CFX96 system using the Quantitect
reverse transcription kit (Qiagen) in 25 μl reactions comprising 10 ng cDNA, 1x iQ SYBR Green
Supermix (Bio-Rad) and 0.2 μM forward and reverse primers. To calculate relative expression
levels, serial dilutions (60–0.096 ng) were used to produce standard curves for each gene. PCRs
were carried out in triplicate using 96-well optical reaction plates, initially heating for 3 min at
95 °C followed by 40 cycles of 95 °C for 15 s, 50 °C for GLGB, 50.7°C for GRXC8 and PRO7
and 58.3 °C for GLGS for 1 min, and 72 °C for 20 s. Amplification specificity was confirmed by
melt curve analysis on the final PCR products in the temperature range 50–90 °C with
fluorescence acquired after each 0.5 °C increment. The fluorescence threshold value and gene
expression data were calculated using CFX96 system software. Values represent the mean of
three replicates ± SD. The forward and reverse primers for each gene are shown in Table1.2.
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Table 1.2: Oligonucleotide sequences of primers used for quantitative real-time RT-PCR analysis
Transgenes Primer sequence
OsACTIN-F Forward 5'-GACTCTGGTGATGGTGTCAGC-3'
OsACTIN-R Forward 5'-TCATGTCCCTCACAATTT-3'
OsGRXC8-F Forward 5'-TCCGTATGTGGTGGAACTGG-3'
OsGRXC8-R Forward 5'-TTCCACGGTATCATCGCTGCC-3'
OsPRO7-F Forward 5'-GCAGCAGAGCCATTATCAGGAT-3'
OsPRO7-R Forward 5'-CCGAGCACCATTACCACCCT-3'
OsGLGS-F Forward 5'-TAGCGTGATTGGCGAAGGC-3'
OsGLGS-R Forward 5'-GCAGTTTTTTATCCGCTTCG-3'
OsGLGB-F Forward 5'-CGAAGGCAACAACTGGAGC-3'
OsGLGB-R Forward 5'-AATCTGTTTGCTGCTGCTCA-3'
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1.4 RESULTS
1.4.1 Generation of transgenic rice plants expressing 2G12
Rice embryos were transformed by particle bombardment with constructs containing the coding
sequences of the 2G12 heavy and light chains, under the control of the rice glutelin-1 promoter
(Ramessar et al., 2008b) plus a third construct containing the selectable marker hpt. Embryo-
derived callus was selected on hygromycin-supplemented medium and 20 independent
transformants were regenerated and transferred to the greenhouse. Leaves and seeds from these
primary transformants were analyzed by PCR to confirm the presence of the transgene (Figure
1.6) and by dot blot to confirm transgene expression (Figure 1.7). For the heavy chain, the
amplified products for primer sets 1–3 were 1878, 1279 and 1514 bp, respectively. For the light
chain, the amplified products for primer sets 1–3 were 1269, 622 and 808 bp, respectively. The
positive control was used to ensure that the amplification reactions proceeded correctly (Figure
1.6). Six independent lines expressing 2G12 at high levels based on ELISA results were self-
pollinated to produce T1 and T2 seeds for more detailed analysis.
Figure 1.6: PCR amplification of heavy and light chain genes in independent transgenic events. (L) 1-kb DNA
ladder from Promega, (+) positive control plasmids pTRAGti-GH and pTRAGti-G, (–) negative control wild-type
rice to rule out sample contamination.
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Figure 1.7: Dot blot analysis of proteins extracted from T2 transgenic seeds expressing the 2G12 heavy chain (HC)
and light chain (LC), using 4 μl of total soluble protein extract per spot, probed with anti-human K antibody
followed by detection with an alkaline phosphatase-conjugated anti-human IgG antibody.
1.4.2 Confirmation of antibody chain expression and assembly in T1
transgenic endosperm
The presence of correctly-assembled 2G12 in T1 endosperm was confirmed using an
immunoglobulin-speciﬁc sandwich ELISA. The antibody content of the endosperm was
determined by calculating the concentrations from titration curves based on positive controls
spiked with known concentrations of the same antibody produced in maize (Figure 1.8). We used
non-transformed rice endosperm as a negative control to rule out cross reaction with endogenous
plant proteins. Among the six independent lines expressing both antibody chains, we selected the
two lines (4 and 14) producing the highest levels of assembled 2G12 for more detailed
investigation. The yield of 2G12 in lines 4 and 14 was 2.323 and 3.789 μg/ml, respectively.
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Figure 1.8: The expression of 2G12 in mature rice endosperm. An immunoglobulin-speciﬁc sandwich ELISA was
used to screen endosperm extracts from independent transgenic lines for 2G12. The plates were coated with an anti-
human κ-chain antibody and captured 2G12 was detected with an anti-human IgG antibody labeled with horseradish
peroxidase. Four serial dilutions were loaded per sample (neat, 1/2, 1/4 and 1/8). WT = wild type extracts; C– =
negative control (PBS); C+ = 2G12 purified from maize (500 ng/ml) as positive control. OD = optical density at 450
nm.
1.4.3 Accumulation of 2G12 in the rice endosperm induces the formation of
novel protein bodies
The localization of 2G12 in the endosperm of lines 4 and 14 was investigated by fluorescence
microscopy and transmission electron microscopy (TEM). Colocalization with glutelin indicated
that most of the antibody had accumulated in the protein storage vacuoles (glutelin bodies, PB-
II) but additional labeling was detected outside these organelles (Figure 1.9). Consistent with this
result, TEM showed that most of the antibody had accumulated in glutelin bodies and only a
small amount in the ER-derived prolamin bodies (also known as type-I protein bodies PB-I). In
the transgenic endosperm we also observed novel protein bodies that were studded with
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ribosomes but did not contain 2G12 (Figure 1.10). There was no evidence of 2G12 labeling in
the untransformed control plants (data not shown).
Figure 1.9: Localization of 2G12 and the seed storage protein glutelin in rice endosperm. Immunofluorescence
microscopy confirmed that 2G12 accumulated in the PSV. (a) Red fluorescence shows the localization of 2G12; (b)
Green fluorescence shows the localization of glutelin; (c) Yellow fluorescence shows the colocalization of 2G12 and
glutelin.
Figure 1.10: Localization of 2G12 in the rice endosperm by electron microscopy. Ultrathin sections of immature
rice seeds (line 14) revealed (a) the accumulation of 2G12 mostly in PB-II structures and more sparsely in PB-I
structures, as well as (b) novel bodies surrounded by ribosomes (white arrows). Bar = 500 nm, PB-I = protein body
I, prolamins; PB-II = protein body II, glutelins and globulins
61
1.4.4 Glycan analysis reveals that 2G12 produced in rice endosperm is
predominantly aglycosylated
Antibody 2G12 was purified from rice endosperm extracts by protein A affinity chromatography.
Neither the flow-through nor the wash fractions contained measurable amounts of the 2G12
heavy and light chains indicating that the antibody was folded correctly in planta and retained
efficiently on the resin. The final concentration of pure antibody from the T1 generation was 34
μg/g dry seed weight, but after protocol optimization and two rounds of self-pollination to
produce the T3 generation of seeds, the antibody concentration increased to 42 μg/g dry seed
weight. The presence of the heavy and light chains was demonstrated by reducing SDS-PAGE
(50 and 25 kDa bands). No degradation products were present, suggesting the antibody remained
stable in the seeds (Figure 1.11).
The purified antibody heavy chain was digested with trypsin and analyzed by MALDI-TOF mass
spectrometry. Remarkably, we found that 50% of the EEQYNSTYR peptide, which contains the
specific NSx glycan acceptor sequence responsible for heavy chain glycosylation, was
completely aglycosylated. Among the remainder, 19% and 14% contained vacuolar-type
N-glycans (MUXF and MMXF, respectively), 13% carried a single N-acetylglucosamine
(GlcNAc) attached to the asparagine residue, suggesting the presence of ENGase activity in the
early part of the secretory pathway, and the remaining 4% carried high-mannose glycans of the
Man7 configuration (Figure 1.12).
Figure 1.11: SDS-PAGE analysis of 2G12 purified from rice endosperm.
Fractions eluting from the protein A column were separated by SDS-
PAGE (12% polyacrylamide) under reducing conditions and the gels were
stained with Coomassie Brilliant Blue. The heavy (H) and light (L) chains
were identified and no degradation products were observed. M =
molecular weight markers. Lanes 1 and 2 were loaded with 2 and 5 µg of
2G12, respectively.
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Figure 1.12: Glycosylation profile of 2G12 purified from rice endosperm. De-convoluted mass spectrum (m/z =
1100–3100) of the tryptic glycopeptide derived from the 2G12 heavy chain (band H shown in Fig. 4). MMXF =
paucimannosidic structures, Man 7 = mannose 7.
1.4.5 The aglycosylated 2G12 shows enhanced in vitro binding and HIV-
neutralization activity
The ability of the endosperm-derived 2G12 to bind gp120 was tested in vitro using an antigen-
speciﬁc ELISA with both the purified antibody and the crude rice extract. The capture reagent
was gp120IIIB and the bound 2G12 was detected using a mixture of anti-human gamma and
anti-human kappa antibodies which bind the heavy and light chains, respectively. The transgenic
endosperm extracts showed higher gp120IIIB-binding activity than wild-type endosperm extracts
as expected, which confirmed that the assembled 2G12 produced in the transgenic endosperm
was also functional and did not cross-react with endogenous plant proteins. The crude extracts
showed a higher gp120-binding activity than the purified 2G12 produced in rice endosperm and
the purified 2G12 with glycans produced in maize endosperm (Figure 1.13).
The HIV-neutralizing activity of rice endosperm-derived 2G12 (OS2G12) was compared to the
same antibodies produced in CHO cells (CHO2G12) and tobacco (NT2G12) and to an unrelated
antibody recognizing a different antigen (anti-rabies antibody E559). The potency of HIV
neutralization was determined using a syncytium inhibition assay with HIV-1 BaL. The IC50 was
1.197 μg/ml for OS2G12, 0.083 μg/ml for CHO2G12 and 7.889 μg/ml for NT2G12, demonstrating
that CHO2G12 was 14 times more potent than OS2G12 but OS2G12 was approximately seven times
more potent than NT2G12, which was a significant difference at p < 0.05 (Figure 1.14).
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Figure 1.13: Antigen-binding activity of crude extracts from rice endosperm and purified 2G12. ELISA was used to
determine binding activity of purified 2G12 and serially-diluted crude extracts of rice endosperm expressing the
same protein. Plates were coated with the HIV gp120 protein and bound 2G12 was detected with a mixture of anti-
human κ-chain and anti-human IgG antibodies labeled with horseradish peroxidase. Values represent the average of
two experiments and bars indicate standard deviations. The binding kinetics showed a concentration-dependent
relationship. All the crude extracts showed higher binding kinetics compared to wild-type extracts (negative control)
and purified 2G12 (positive control). WT = wild type extracts; C– = negative control (PBS); C+ = 2G12 purified
from maize (500 ng/ml) as positive control. OD = optical density at 450 nm.
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Figure 1.14: In vitro virus neutralization efficacy of 2G12 from different sources. HIV neutralization was measured
using a syncytium inhibition assay (Wei et al., 2003; Montefiori, 2005) with HIV-1 strain BaL. An unrelated plant-
derived anti-rabies antibody E559 was used as a negative control.
1.4.6 Proteomic analysis in rice seeds
Proteomic analysis in rice seeds also helped to determine the 2G12 heavy and light chain protein
and peptide levels, covering almost 80.1% of the heavy chain and 64.4% of the light chain
(Figure 1.15). The different colors represent matches to intact peptides (e.g.
LSDNDPFDAWGPGTVVTVSPASTK = LSDNDPFDAWGPGTVVTVSPASTK), partial
peptides (e.g. SVFIFPPSDEQLK = TVAAPSVFIFPPSDEQLK), modified peptides (e.g.
HKVYACEVTHQGLSSPVTK = HKVYACEVTHQGLSSPVTK, showing carbamidomethyl
cysteine modification) or partial modified peptides (e.g. ASVVCLLNNFYPR =
SGTASVVCLLNNFYPR, also showing carbamidomethyl cysteine modification).
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Figure 1.15: Coverage of the 2G12 antibody by tryptic peptides. The coverage map was A) 80.1% for the 2G12
heavy chain and B) 64.4% for the 2G12 light chain. Different colors represent intact and partial peptides with and
without modifications.
Because 2G12 is a human monoclonal antibody that does not exist naturally in rice seeds, it was
necessary to manually add the sequences for both the heavy and light chains to the rice database
downloaded from UniProt in order to test the distribution of peptides and proteins in the rice
database, and in the seed proteome by NanoUPLC-MSE.
The 2G12 heavy and light chains were detected at both the protein and peptide levels as expected
(Figure 1.16). The data represented by blue squares match entries in the rice database, whereas
those shown as red squares correspond to rice seed proteins. We also tested the distribution of
seed proteins identified within the rice database in terms of their isoelectric points (Figure 1.17).
The data represented by blue squares correspond to the rice peptide database whereas those
shown as red squares correspond to rice seed peptides and those shown as green squares
represent the peptides of the 2G12 antibody.
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In addition, the rice proteins from a transgenic plant (line 15) were identified by mass
spectrometry. Table 1.3 shows the proteins that were identified in the rice endosperm and their
abundance in terms of %TSP. Among the 69 proteins that were identified, the most abundant
were the seed allergenic protein, the 1,4-glycan branching enzyme, glutelin type A1 and the 19
kDa globulin protein. The least abundant proteins were the ubiquitin 60S ribosomal protein, the
ubiquitin NEDD8-like protein, a 14-3-3-like protein, a calmodium-like protein and a superoxide
dismutase (Table 1.3).
Figure 1.16: Distribution of peptides and proteins in (A) the rice database and (B) the seed proteome as determined
by NanoUPLC-MSE.
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Figure 1.17: Distribution of A) seed proteins identified in the rice database sorted by isoelectric point, and B) the
isoelectric points of the identified peptides. Data represented by blue squares correspond to the rice database,
whereas red squares correspond to rice seed proteins and green squares represent the 2G12 heavy and light chains.
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Table 1.3: Protein identification, including the entry number and description of each protein, the molecular weight
(MW) in kDa, ngram average value (ngram AVG) and percent of total soluble protein (% of TSP) in rice seeds.
Entry Description MW(kDa) ngramAVG %TSP
P2G12HC 2G12HC HEAVY CHAIN 52,376.0438 7.7440667 1.395327333
P2G12LC 2G12LC LC CHAIN 26,088.3006 8.030434 1.446925045
P00489
GLYCOGEN PHOSPHORYLASE MUSCLE
FORM EC 97,671.6378 24.4179 4.399621622
Q7XTE8
14 3 3 like protein GF14 B OS Oryza sativa subsp
japonica GN GF14B PE 1 SV 2 29,977.7418 1.0308 0.18572973
Q6ZKC0
14 3 3 like protein GF14 C OS Oryza sativa subsp
japonica GN GF14C PE 1 SV 1 28,997.6467 1.2241666 0.220570559
Q2R2W2
14 3 3 like protein GF14 D OS Oryza sativa subsp
japonica GN GF14D PE 2 SV 1 29,375.7807 0.1882 0.03390991
Q6EUP4
14 3 3 like protein GF14 E OS Oryza sativa subsp
japonica GN GF14E PE 2 SV 1 29,863.585 1.5033 0.270864865
P37833
Aspartate aminotransferase cytoplasmic OS Oryza
sativa subsp japonica GN Os01g0760600 PE 2 SV
1 44,678.2525 4.1755333 0.752348342
Q10DV7
Actin 1 OS Oryza sativa subsp japonica GN ACT1
PE 2 SV 1 42,041.0675 1.2513666 0.225471459
A3C6D7
Actin 2 OS Oryza sativa subsp japonica GN ACT2
PE 2 SV 1 41,907.9403 0 0
Q10AZ4
Actin 3 OS Oryza sativa subsp japonica GN ACT3
PE 2 SV 1 41,991 0 0
P0C540
Actin 7 OS Oryza sativa subsp japonica GN ACT7
PE 3 SV 1 41,899.8943 0.43563333 0.078492492
Q2R8Z5
Alcohol dehydrogenase 1 OS Oryza sativa subsp
japonica GN ADH1 PE 2 SV 2 41,725.7371 4.5635333 0.822258252
P17784
Fructose bisphosphate aldolase cytoplasmic
isozyme OS Oryza sativa subsp japonica GN FBA
PE 1 SV 2 39,262.656 7.0143666 1.263849838
Q01859
ATP synthase subunit beta mitochondrial OS
Oryza sativa subsp japonica GN ATPB PE 1 SV 2 59,048.3303 2.6957 0.485711712
Q0IQB6
Calmodulin like protein 3 OS Oryza sativa subsp
japonica GN CML3 PE 2 SV 1 20,365.487 0.27015 0.048675676
P30287
Dehydrin Rab25 OS Oryza sativa subsp japonica
GN RAB25 PE 2 SV 2 23,236.4077 2.1459668 0.386660685
O64937
Elongation factor 1 alpha OS Oryza sativa subsp
japonica GN REFA1 PE 2 SV 2 49,635.2552 2.8262665 0.509237207
P29545
Elongation factor 1 beta OS Oryza sativa subsp
japonica GN Os07g0662500 PE 1 SV 3 23,856.7601 0.85525 0.154099099
P46520
Embryonic abundant protein 1 OS Oryza sativa
subsp japonica GN EMP1 PE 2 SV 1 10,165.0399 1.1598667 0.208984991
Q42971
Enolase OS Oryza sativa subsp japonica GN
ENO1 PE 1 SV 2 48,314.7712 16.1253 2.905459459
Q0J8A4
Glyceraldehyde 3 phosphate dehydrogenase
cytosolic OS Oryza sativa subsp japonica GN
GAPC PE 1 SV 36,583.788 8.391999 1.512071892
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P49027
Guanine nucleotide binding protein subunit beta
like protein A OS Oryza sativa subsp japonica GN
RA 36,687.9658 1.8069 0.325567568
P29835
19 kDa globulin OS Oryza sativa subsp japonica
GN Os05g0499100 PE 1 SV 2 21,511.0285 39.572765 7.130227928
Q01401
1 4 alpha glucan branching enzyme chloroplastic
amyloplastic OS Oryza sativa subsp japonica GN
SBE 93,806.8118 51.25363 9.234888288
Q01401-2
Isoform 2 of 1 4 alpha glucan branching enzyme
chloroplastic amyloplastic OS Oryza sativa subsp
ja 87,148.1652 1.6293334 0.293573586
P15280
Glucose 1 phosphate adenylyltransferase small
subunit chloroplastic amyloplastic OS Oryza
sativa su 56,503.3604 0 0
P15280-2
Isoform 2 of Glucose 1 phosphate
adenylyltransferase small subunit chloroplastic
amyloplastic OS Or 53,235.6669 10.042966 1.809543423
P07728
Glutelin type A 1 OS Oryza sativa subsp japonica
GN GLUA1 PE 1 SV 2 56,817.2816 39.866932 7.183230991
P07730
Glutelin type A 2 OS Oryza sativa subsp japonica
GN GLUA2 PE 1 SV 1 56,876.4798 21.544767 3.88194
Q09151
Glutelin type A 3 OS Oryza sativa subsp japonica
GN GLUA3 PE 2 SV 2 56,585.3839 17.446333 3.143483423
P14323
Glutelin type B 1 OS Oryza sativa subsp japonica
GN GluB1 A PE 2 SV 3 56,949.8358 24.3509 4.38754955
Q02897
Glutelin type B 2 OS Oryza sativa subsp japonica
GN GLUB2 PE 2 SV 2 56,446.1378 8.123934 1.463771892
P14614
Glutelin type B 4 OS Oryza sativa subsp japonica
GN GLUB4 PE 1 SV 1 57,274.3697 9.673766 1.743020901
Q6ERU3
Glutelin type B 5 OS Oryza sativa subsp japonica
GN GLUB5 PE 2 SV 1 57,264.3312 6.4039664 1.15386782
Q75KH3
Glucose and ribitol dehydrogenase homolog OS
Oryza sativa subsp japonica GN Os05g0140800
PE 2 SV 2 32,495.7058 3.3847666 0.609867856
P55142
Glutaredoxin C6 OS Oryza sativa subsp japonica
GN GRXC6 PE 1 SV 2 11,945.5888 1.7503667 0.315381387
P27777
16 9 kDa class I heat shock protein 1 OS Oryza
sativa subsp japonica GN HSP16 9A PE 1 SV 1 16,939.1789 0.65900004 0.118738746
Q07078
Heat shock protein 81 3 OS Oryza sativa subsp
japonica GN HSP81 3 PE 2 SV 2 80,469.2625 1.531 0.275855856
P29421
Alpha amylase subtilisin inhibitor OS Oryza sativa
subsp japonica GN RASI PE 1 SV 2 21,702.6362 6.105133 1.100023964
Q0JR25
Bowman Birk type bran trypsin inhibitor OS
Oryza sativa subsp japonica GN RBBI3 3 PE 1
SV 2 29,272.5046 5.238933 0.943951892
Q65XK0
Ketol acid reductoisomerase chloroplastic OS
Oryza sativa subsp japonica GN Os05g0573700
PE 1 SV 1 62,719.4694 1.7585499 0.316855838
A3AHG5
Late embryogenesis abundant protein 1 OS Oryza
sativa subsp japonica GN LEA1 PE 2 SV 1 37,019.3515 3.9307334 0.708240252
P0C5A4
Late embryogenesis abundant protein group 3 OS
Oryza sativa subsp japonica GN LEA3 PE 2 SV 1 20,514.1501 2.754 0.496216216
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Q948T6
Lactoylglutathione lyase OS Oryza sativa subsp
japonica GN GLX I PE 1 SV 2 32,895.6179 5.0275664 0.90586782
Q7XDC8
Malate dehydrogenase cytoplasmic OS Oryza
sativa subsp japonica GN Os10g0478200 PE 1 SV
3 35,911.1204 7.535567 1.35775982
Q07661
Nucleoside diphosphate kinase 1 OS Oryza sativa
subsp japonica GN NDKR PE 1 SV 1 16,861.3596 2.5668333 0.462492486
Q0IQK9
Non specific lipid transfer protein 1 OS Oryza
sativa subsp japonica GN LTP PE 1 SV 1 11,801.4456 1.4014667 0.252516523
Q42980
Oleosin 16 kDa OS Oryza sativa subsp japonica
GN OLE16 PE 2 SV 2 15,258.7809 2.08985 0.37654955
Q10EK7
Oleosin 18 kDa OS Oryza sativa subsp japonica
GN OLE18 PE 2 SV 1 17,221.7455 6.2076335 1.118492523
Q10MW3
Pyruvate decarboxylase isozyme 2 OS Oryza
sativa subsp japonica GN PDC2 PE 2 SV 1 65,802.4291 3.52205 0.634603604
Q53LQ0
Protein disulfide isomerase like 1 1 OS Oryza
sativa subsp japonica GN PDIL1 1 PE 2 SV 1 57,082.7688 11.8336 2.13218018
Q6AVA8
Pyruvate phosphate dikinase 1 chloroplastic OS
Oryza sativa subsp japonica GN PPDK1 PE 1 SV
1 103,643.5481 7.225567 1.301903964
Q6AVA8-
2
Isoform 2 of Pyruvate phosphate dikinase 1
chloroplastic OS Oryza sativa subsp japonica GN
PPDK1 96,971.0503 12.148467 2.188912973
Q42465
Prolamin PPROL 14P OS Oryza sativa subsp
japonica GN PROLM20 PE 2 SV 1 17,052.4845 1.9576501 0.352729748
Q0DJ45
Prolamin PPROL 14E OS Oryza sativa subsp
japonica GN PROLM7 PE 2 SV 1 16,926.3287 2.0298667 0.365741748
Q9ARZ9
Ubiquitin 40S ribosomal protein S27a 1 OS Oryza
sativa subsp japonica GN RPS27AA PE 2 SV 1 17,896.6488 0 0
P51431
Ubiquitin 40S ribosomal protein S27a 2 OS Oryza
sativa subsp japonica GN RPS27AB PE 2 SV 3 17,910.7191 0 0
Q01881
Seed allergenic protein RA5 OS Oryza sativa
subsp japonica GN RA5 PE 1 SV 2 17,863.329 7.5655 1.363153153
Q01883
Seed allergenic protein RAG1 OS Oryza sativa
subsp japonica GN RAG1 PE 1 SV 2 18,138.4391 23.414398 4.21881045
Q01882
Seed allergenic protein RAG2 OS Oryza sativa
subsp japonica GN RAG2 PE 1 SV 2 18,434.8769 63.272434 11.40043856
P0C5C9
1 Cys peroxiredoxin A OS Oryza sativa subsp
japonica GN Os07g0638300 PE 2 SV 1 24,213.5309 15.704501 2.82963982
P0CH34
Ubiquitin 60S ribosomal protein L40 1 OS Oryza
sativa subsp japonica GN Ub CEP52 1 PE 2 SV 1 15,012.4505 0.005666667 0.001021021
P0CH35
Ubiquitin 60S ribosomal protein L40 2 OS Oryza
sativa subsp japonica GN Ub CEP52 2 PE 3 SV 1 15,012.4505 0 0
P41095
60S acidic ribosomal protein P0 OS Oryza sativa
subsp japonica GN Os08g0130500 PE 1 SV 3 34,491.7325 1.3687 0.246612613
Q8LJU5
40S ribosomal protein S7 OS Oryza sativa subsp
japonica GN RPS7 PE 2 SV 2 22,364.0004 1.7593999 0.317008991
P0C030
Ubiquitin NEDD8 like protein RUB1 OS Oryza
sativa subsp japonica GN RUB1 PE 2 SV 2 17,129.7071 0.030333333 0.005465465
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P0C031
Ubiquitin NEDD8 like protein RUB2 OS Oryza
sativa subsp japonica GN RUB2 PE 2 SV 2 17,094.6619 0 0
P0C032
Ubiquitin like protein NEDD8 like protein RUB3
OS Oryza sativa subsp japonica GN RUB3 PE 3
SV 2 17,292.8519 0 0
Q0DRV6
Superoxide dismutase Cu Zn 1 OS Oryza sativa
subsp japonica GN SODCC1 PE 1 SV 1 15,365.0518 0.35345 0.063684685
P28757
Superoxide dismutase Cu Zn 2 OS Oryza sativa
subsp japonica GN SODCC2 PE 1 SV 2 15,194.7565 0.5611667 0.101111117
Q43008
Superoxide dismutase Mn mitochondrial OS
Oryza sativa subsp japonica GN SODA PE 2 SV 2 24,997.5114 1.2993335 0.234114144
P30298
Sucrose synthase 2 OS Oryza sativa subsp
japonica GN SUS2 PE 1 SV 2 92,642.9095 5.718 1.03027027
P48494
Triosephosphate isomerase cytosolic OS Oryza
sativa subsp japonica GN TPI PE 1 SV 3 27,291.0846 4.7694 0.859351351
Q58G87
Polyubiquitin 3 OS Oryza sativa subsp japonica
GN UBQ3 PE 2 SV 2 42,725.1482 3.1382 0.565441441
Q53NL5
Xylanase inhibitor protein 2 OS Oryza sativa
subsp japonica GN Chib3H h PE 1 SV 1 31,881.8156 7.733667 1.393453514
We also clustered the identified proteins by functionality into groups such as storage, starch
biosynthesis, type I hypersensitivity and other functions (Figure 1.18). We found that 32% of the
identified proteins were seed storage proteins, 12% were related to starch biosynthesis and other
functions and 18% were related to type I hypersensitivity. Other proteins were clustered in
smaller groups, such as those corresponding to stress responses (7%), glycolysis (5%),
photosynthesis (4%), oxidoreductase activity (3%), plant defense (2%), lipid droplet formation
(2%) and late embryogenesis abundant proteins (1%). The 2G12 heavy and light chains each
accounted for 1% of the total protein content.
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Figure 1.18: Functional clustering of the seed proteome of transgenic rice plants expressing 2G12.
1.4.7 Proteomic analysis and transcript profiling reveal genes modulated by
2G12 expression in rice endosperm
The comparative proteomic analysis of wild-type and transgenic rice endosperm using a
threshold value of 1 (Figure 1.19) revealed two major upregulated proteins and two major
downregulated proteins in the transgenic plants (Table 1.4). One of the upregulated proteins was
the storage protein prolamin and the other was the enzyme glutaredoxin-C8. Both the
downregulated proteins were related to glycogen synthesis and storage.
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Figure 1.19: Pivot chart representing the proteomic analysis of transgenic rice endosperm. Proteins showing a fold
difference (increase or decrease) greater than 1 were chosen for RT-PCR analysis.
Table 1.4: The two most strongly upregulated and downregulated proteins (fold increase/decrease) in transgenic
plants compared to wild-type rice plants.
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We also measured the abundance of the corresponding transcripts by quantitative real-time RT-
PCR in order to correlate the mRNA and protein levels of the modulated genes. Four lines (7, 10,
12 and 14) that express 2G12 at the highest levels were chosen for quantitative RT-PCR analysis.
Accordingly, we found that the transcript levels of endogenous glycogen branching enzyme
(GLGB _ORYSJ) and glycogen synthesis protein (GLGS _ORYSJ) were downregulated in all
the transgenic lines compared to wild-type plants (Figure 1.20 a-b) and that the expression levels
of endogenous glutaredoxin-C8 (GRXC8 _ORYSJ) and prolamin PPROL 14E (PRO7_ORYSJ)
were upregulated in all the transgenic lines compared to wild-type plants (Figure 1.20 c-d).
Figure 1.20: Quantitative real-time RT-PCR analysis of modulated genes. Gene expression was monitored in lines
7, 10, 12, 14 and wild-type plants. The relative expression level of each gene was determined by normalizing against
the housekeeping gene actin. (a) The downregulated gene GLGB; (b) The downregulated gene GLGS; (c) The
upregulated gene GRXC8; (d) The upregulated gene PRO7. Total RNA was extracted from mature T4 seeds from
each line (n = 3). Bars represent means ± SE for three independent experiments.
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1.5 DISCUSSION
Protein microbicides against HIV can prevent infection, as demonstrated in a number of
preclinical and clinical studies (De Clercq, 2007). However, the production and distribution of
therapeutic proteins in key HIV-endemic areas is challenging and expensive because there is
neither sufficient production infrastructure nor a reliable cold chain, meaning that the people
most likely to benefit from the microbicides are effectively excluded on economic grounds.
Many therapeutic proteins have been expressed in plants, including a large number of vaccine
candidates and recombinant antibodies, so the principle of pharmaceutical molecular farming is
well established (Ramessar et al., 2008a; Twyman et al., 2005). Plants have many advantages
over fermenter-based systems (Ma et al., 2003; Paul et al., 2013; Ramessar et al., 2008a) but rice
seeds are particularly suitable in the context of developing countries because they maintain the
stability of recombinant proteins accumulating in the endosperm so that a cold chain is not
necessary for product distribution, and the economy of large-scale production makes the product
affordable without detracting from its safety or performance (Fischer et al., 2012; Sabalza et al.,
2013).
We expressed the HIV-neutralizing antibody 2G12 in transgenic rice endosperm to evaluate the
potential of rice seeds as a vehicle for inexpensive microbicide production. We also investigated
the biochemical and cellular processes that are influenced by the accumulation of a heterologous
recombinant protein such as 2G12 in the endosperm to gain a better understanding of factors that
might control the accumulation of recombinant proteins in plants. We regenerated transgenic rice
plants and confirmed the presence and strong expression of the transgenes in six independent
lines, ultimately choosing two lines with the highest antibody yields for more detailed analysis.
The yields of 2G12 in rice were similar to those reported for 2G12 in other cereal seeds and
better than those reported for other antibodies. We achieved a maximum yield of 42 μg/g dry
seed weight in T3 seeds, which compares well with the 30 μg/g initially achieved for 2G12 in
maize (Rademacher et al., 2008) although this was subsequently improved to 75 μg/g by the
selective breeding of high-performance lines and then to 100 μg/g by passing the best-
performing line through a dedifferentiation–regeneration cycle (Ramessar et al., 2008b). Our
results for 2G12 were far better than those reported for HIV-neutralizing antibody 2F5 in maize
seeds, where the maximum accumulation was 0.80 μg/ml (Sabalza et al., 2012). Our data suggest
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that the 2G12 yields in rice could also be improved beyond 42 μg/g dry seed weight by selective
breeding.
The localization of 2G12 in the transgenic endosperm was investigated by
immunohistochemistry and TEM, revealing that most of the antibody accumulated in PB-II
compartments and to a lesser extent in PB-I compartments. The subcellular location of a
recombinant protein can influence its yield, structure and functionality, but it is difficult to
predict the localization of recombinant proteins in the endosperm of cereal seeds because protein
trafficking appears to be influenced not only by the species and tissue but also by intrinsic
properties of the expressed protein (Drakakaki et al., 2006). When a 2G12 antibody carrying a C-
terminal KDEL tag was expressed in maize endosperm, it accumulated within ER-derived zein
bodies but no significant labeling was observed in storage vacuoles or any other cell
compartment (Rademacher et al., 2008). In contrast, an untagged version of 2G12 accumulated
in the storage vacuoles and, to a much lesser extent, also in zein bodies (Ramessar et al., 2008b).
The expression of recombinant fungal phytase in rice resulted in the accumulation of phytase in
both types of protein bodies (PB-I and PB-II) but no additional labeling was observed in the
apoplast or other cell compartments (Drakakaki et al., 2006).
Our rice plants were transformed with the untagged version of 2G12 and the results were similar
to those reported in maize (Ramessar et al., 2008b). Immunohistochemistry showed that the
signal for 2G12 overlapped with that for glutelin, indicating that most of the antibody co-
accumulated with this storage protein in PB-II compartments, also known as glutelin bodies.
More detailed analysis by TEM confirmed that most of the 2G12 was localized in PB-II
compartments and a smaller amount in PB-I compartments, but we also observed novel protein
bodies that were not present in untransformed seeds, suggesting the compartments were formed
de novo as a consequence of high-level antibody expression even though they did not contain
significant amounts of the antibody. The novel protein bodies were unusual in architecture,
featuring prominent studs in the membrane caused by the presence of ribosomes. The induction
of novel protein bodies in transgenic rice cells has been reported before (Torres et al., 2001,
1999; Yang et al., 2012). In our transgenic lines, the antibody was able to induce novel protein
bodies without the benefit of a KDEL tag, suggesting that the protein was abundant enough in
the rough ER to induce the budding of protein bodies even without a dedicated retention
sequence. Green fluorescent protein fused to rice prolamin has also been shown to induce the
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formation of protein body-like structures in transgenic rice endosperm, although the protein
ultimately accumulated in PB-I compartments (Saito et al., 2009).
Further information about the intracellular trafficking of recombinant proteins can be gathered by
analyzing the glycan profile if the protein contains canonical N-glycan acceptor sites. The heavy
chain of IgG antibodies carries an acceptor site at residue N297 of the Fc domain, and the
structure of the glycan affects antibody-dependent cell-mediated cytotoxicity (ADCC) and
complement-dependent cytotoxicity (CDC), which can thus be modulated by choosing an
appropriate production platform (Jung et al., 2011). Antibodies expressed in plants typically
comprise a mixture of glycoforms, ranging from the absence of any glycans (aglycosylated
heavy chain) to high-mannose and complex-type glycans, and antibodies with single
oligosaccharides resulting from extensive glycan trimming (Baez et al., 2000; De Wilde et al.,
1998; Hristodorov et al., 2013; Khoudi et al., 1999; Ma et al., 1994). The aglycosylated fraction
is usually a minor component. For example, 13.3% of 2G12 was aglycosylated when the KDEL-
tagged version was expressed in standard maize and only 10.6% in a sweetcorn variety
(Rademacher et al., 2008), whereas in the absence of KDEL tag the aglycosylated fraction was
11.5% (Ramessar et al., 2008b). Surprisingly, we found that the aglycosylated fraction of 2G12
in transgenic rice endosperm represented 50% of the total, the remainder comprising vacuolar-
type complex N-glycans (19% MUXF and 14% MMXF), 13% individual N-acetylglucosamine
(GlcNAc) residues confirming the presence of ENGase activity, and only 4% oligomannose
glycans (Man7) as expected for ER-resident proteins, suggesting that the recombinant protein
was directed through distinct trafficking pathways characterized by different glycan signatures.
In most previous investigations, the predominant glycoforms were the complex type (if the
protein passed through the secretory pathway to the apoplast or the storage vacuole) or the
oligomannose type (if the protein was retrieved to the ER lumen). Only one previous study
reported a prevalent aglycosylated fraction and that involved the expression of an scFv-Fc
antibody in Arabidopsis seeds, where most of the antibodies carried oligomannose glycans but
35–40% were aglycosylated (Van Droogenbroeck et al., 2007). The authors proposed that the
glycosylation machinery may have been saturated at the high expression levels they achieved,
but we observed no change in the steady-state mRNA levels of BiP and PDI, two proteins that
are usually upregulated when the secretory pathway is under heavy load. Indeed we even noted a
slight decline in the level of PDI mRNA in the some transgenic lines. These results suggest that a
78
large proportion of the heavy chain is co-translationally imported into a region of the ER that
lacks glycosyltransferases and accumulates in protein bodies without further modification. The
remaining proportion appears to follow the canonical pathway, undergoing initial glycosylation
in the ER lumen followed by either complex modifications in the Golgi body and/or trimming
back to a single GlcNAc residue. The glycosylation of 2G12 is not only important from a protein
trafficking and accumulation perspective but also because it affects the functionality of the
protein once it has been purified from the rice grains. We tested the antigen-binding efficiency of
the purified OS2G12, the crude extracts of different lines expressing 2G12 and the ZM2G12 with
plant glycans produced in maize. We found that OS2G12 binds to HIV gp120 with a similar
efficiency to ZM2G12, but the OS2G12 was more potent in HIV neutralization assays, suggesting
that the absence of glycans is advantageous for the intended function of the protein. Functional
aglycosylated antibodies are advantageous because potentially they can be expressed in any
platform, including bacteria (which do not add glycans to recombinant proteins). Fc
glycosylation is necessary only for IgG effector functions. Aglycosylated antibodies can be used
when these functions are unnecessary or undesirable, such as for neutralizing, agonistic or
antagonistic antibodies and the treatment of chronic inflammatory diseases (Hristodorov et al.,
2013). Therefore, the glycosylation of the 2G12 Fc domain should not be necessary for its HIV-
neutralizing activity but this is the first evidence that the absence of glycans may actually be
better than the presence of plant-specific glycans.
The IC50 of 2G12 with mammalian glycans (i.e. 2G12 produced in CHO cells) is lower than that
of aglycosylated 2G12 purified from rice endosperm, which is in turn lower than that of the
glycosylated 2G12 variants produced in other plants. Although the glycans do not appear to be
required to establish the domain-exchange structure that binds the mannose cluster on gp210 or
for any other aspect of antigen binding (Calarese et al., 2003) there is increasing evidence that
aglycosylated antibodies are at least equivalent but in some cases even better in terms of
neutralizing activity than their glycosylated counterparts. For example, a plant-derived
aglycosylated antibody against Bacillus anthracis PA (pp-mAbPANG) was able to neutralize the
anthrax LeTx more efficiently in vitro and in non-human primates than the glycosylated
equivalent (Mett et al., 2011). Several studies have shown the equivalence or near-equivalence of
aglycosylated and glycosylated variants of the same antibody produced in CHO cells
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(Hristodorov et al., 2013), maize (Baez et al., 2000) and soybean compared with mouse cells
(Zeitlin et al., 1998).
We also tested the distribution of peptides and proteins in the rice database and seed proteome by
NanoUPLC-MSE. The 2G12 peptide and protein sequences were found as anticipated because
the sequences of both chains were added manually to the database. We identified the major
proteins in the seed proteome of transgenic rice line 15 and these were clustered into different
functional groups including storage proteins, type I hypersensitivity proteins, starch biosynthesis
proteins and other functions. The most abundant proteins were the seed allergen protein, the α
1,4 glycan-branching enzyme, glutelin type A1 and 19 kDa globulin.
We also investigated the wider effects of high-level antibody production by carrying out a
proteomic analysis of four transgenic lines compared to wild-type endosperm tissue followed by
the analysis of transcripts corresponding to the four differentially-expressed proteins we
identified. We sampled 24 seeds from line 10, 36 seeds from lines 7, 12 and 14, and 48 wild-type
seeds. The two downregulated proteins were both related to starch biosynthesis, i.e. ADP-
glucose pyrophosphorylase (GLGS) and starch-branching enzyme (GLGB). GLGS controls a
rate-limiting step in starch biosynthesis involving carbon partitioning between starch and sucrose
in photosynthetic tissues (Heldt et al., 1977; Preiss et al., 1991). It also regulates starch
biosynthesis in non-photosynthetic sink organs such as seeds, and in cereals the major form of
this enzyme is located in the cytoplasm (Denyer et al., 1996; Sikka et al., 2001; Thorbjornsen et
al., 1996). GLGB is the only enzyme that can introduce α-1,6-glucosidic linkages into α-glucans
and it is required for amylopectin biosynthesis. Plants express two classes of this enzyme (BEI
and BEII) with different functions (Nakamura et al., 2003). Rice and maize have two isoforms of
the BEII enzyme (BEIIa and BEIIb), the latter expressed only in the endosperm (Abe et al.,
2014). The downregulation of GLGS and GLGB in the transgenic plants was confirmed at both
the mRNA and protein levels suggesting that the accumulation of 2G12 has a significant impact
on starch metabolism and results in the accumulation of less starch in the seeds. Accordingly, we
found that the weight of the transgenic seeds was ~22% lower than the wild-type seeds,
potentially indicating that the expression of recombinant proteins in the rice endosperm can
disrupt the balance between protein and carbohydrate storage.
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This hypothesis was supported by the greater abundance of PRO7, a seed storage protein, and
GRXC8 (glutaredoxin-C8), an enzyme that scavenges reactive oxygen species (Lin et al., 2014).
In rice, prolamins accumulate in the PB-I compartments which bud directly from the ER. The
greater abundance of prolamin in the transgenic endosperm may be related to the downregulation
of carbohydrate metabolism discussed above and/or may reflect the disruption of protein
trafficking in the cell due to the accumulation of 2G12 in the ER, resulting in a compensatory
mechanism as the cell attempts to sort several abundant proteins into different compartments.
The concentration of 2G12 in PB-II compartments and the genesis of novel ER-derived protein
bodies may generate feedback at the level of storage protein deposition that results in the
upregulation of particular prolamin genes. The surge of proteins through the endomembrane
system is likely to cause local stress that induces the production of reactive oxygen species,
resulting in the production of glutaredoxin-C8 as a stress response. These data suggest that yields
of proteins could be improved in rice seeds by regulating protein/carbohydrate metabolism and
protecting the endosperm from abiotic stress.
1.6 CONCLUSIONS
Our data show that a recombinant HIV-neutralizing antibody can be produced in transgenic rice
endosperm with yields similar to those achieved in transgenic maize. Unusually, the most
prevalent form was the aglycosylated version of the antibody, representing 50% of the total, with
the remainder featuring complex vacuolar-type and oligomannose-type glycans as well as single
GlcNAc residues, suggesting that the antibody was not trafficked through any specific pathway
but was distributed via several different routes featuring different glycan signatures. This was
supported by the accumulation of the antibody primarily in PB-II compartments but also in PB-I.
In addition novel protein bodies was observed that were not present in wild-type endosperm. The
aglycosylated version of the antibody proved to have a greater HIV-neutralizing activity than the
glycosylated version produced in tobacco seeds, although neither were as potent as the original
form of 2G12 produced in CHO cells. Proteomic analysis allowed us to identify the 2G12 heavy
and light chains at the protein and peptide levels and we also identified the major seed proteins in
transgenic rice line 15 and clustered them into different functional groups. Proteomics analysis
revealed that starch metabolism was suppressed in the transgenic seeds and a prolamin gene was
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upregulated, indicating that transgene expression caused some disruption in the balance between
carbohydrate and protein storage in the seed. The metabolic disruption and unusual subcellular
architecture of the cell appears to cause stress within the protein trafficking networks, perhaps
due to the unusually high level of traffic that needs to be processed, resulting in the further
induction of genes encoding the radical scavenger glutaredoxin-C8. These data suggest that
yields of proteins could be improved in rice seeds by regulating protein/carbohydrate metabolism
and protecting the endosperm from abiotic stress.
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CHAPTER 2
Production of the anti-HIV protein griffithsin (GRFT) in rice
endosperm
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2.1 INTRODUCTION
Lectins are proteins that bind carbohydrates without causing enzymatic chemical modifications
(Weis and Drickamer, 1996). Lectins are found in most organisms, including viruses and
bacteria, sea corals, algae, fungi, plants and animals (De Mejía and Prisecaru, 2005; Gabius,
1997; Lis and Sharon, 1998). The carbohydrate-binding domains have been studied mainly in the
plant kingdom (Sharon, 2007; Vandenborre et al., 2011). Lectins have diverse structures (De
Hoff et al., 2009) and are therefore defined functionally, often in terms of the biological
processes they mediate, e.g. host–pathogen interactions, cell signaling, induction of apoptosis,
cancer metastasis and differentiation (Ziółkowska et al., 2006).
The function of many lectins in plants remains unclear (Etzler, 1986; Goldstein and Poretz, 1986;
Kijne et al., 1986; Kumar et al., 2012; Pusztai, 1991). Lectins bind reversibly to soluble
carbohydrates and glycan chains on glycoproteins or glycolipids. They bind to the N-linked
glycans of glycoproteins predominantly via mannose, glucose, fucose, N-acetylglucosamine,
galactose, N-acetylgalactosamine and/or sialic acid residues (Goldstein and Poretz, 1986).
Lectins can be used as antiviral agents because the surfaces of many retroviruses including HIV
contain glycans (François and Balzarini, 2012). Lectins that bind virus glycans can disrupt
interactions between proteins on the viral envelope and their cellular receptors (Balzarini, 2006;
Botos and Wlodawer, 2005; Sacchettini et al., 2001; Shenoy et al., 2002).
The most widely studied prokaryotic antiviral lectins are griffithsin (GRFT) and cyanovirin-N
(CV-N). Both are entry inhibitor molecules that bind to mannose residues in N-linked glycans
displayed on the surface of Human immunodeficiency virus (HIV) envelope glycoproteins.
GRFT is a potent anti-HIV lectin isolated from the red alga Griffithsia spp. (Mori et al., 2005)
and it selectively targets mannose-rich glycan arrays on HIV-1 (Balzarini, 2005). As shown in
Table 2.1, it has a higher potency (EC50 ~43 pM) against HIV-1 than other lectins, such as
jacalin, concanavalin A and scytovirin (Charan et al., 2000; Ziółkowska and Wlodawer, 2006).
This makes it an attractive candidate for microbicide development (Alexandre et al., 2010; Mori
et al., 2005). In addition, GRFT shows little or no toxicity towards human cells and does not
activate T cells (Emau et al., 2007; Kouokam et al., 2011). It acts synergistically with HIV-
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neutralizing antibodies such as 2G12, and other lectins such as scytovirin (Férir et al., 2012).
Only CV-N has been shown to interfere significantly with GRFT binding (Mori et al., 2005).
GRFT has broad-spectrum antiviral activity, inhibiting not only HIV-1 (Mori et al., 2005), but
also severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and other
coronaviruses (O’Keefe et al., 2010; Ziółkowska et al., 2006), Hepatitis C virus (Meuleman et
al., 2011), Japanese encephalitis virus (Ishag et al., 2013) and Herpes simplex virus (Nixon et
al., 2013). The antiviral activity of GRFT reflects its ability to bind high-mannose
oligosaccharides on viral envelope glycoproteins, specifically terminal mannose residues on
Man5–9-GlcNAc2 (Moulaei et al., 2010; Ziółkowska et al., 2007). The inactivation of HIV-1 by
GRFT occurs almost immediately after contact with the virus (Emau et al., 2007). Although
GRFT has no sequence homology to other lectins and shows protective effects against HIV at
lower concentrations than other lectins, the basis of these unique differences remains unknown
and needs further investigation (Giomarelli et al., 2006; Mori et al., 2005; O’Keefe, 2001).
GRFT has no mitogenic effect on peripheral blood mononuclear cells (PBMCs), but shows full
activity in the presence of macaque vaginal secretions (Emau et al., 2007) and has a good safety
profile in the rabbit vaginal irritation model (O’Keefe et al., 2009). The treatment of human
cervical explants with GRFT induced minimal alterations in the expression profile of a panel of
pro-inflammatory chemokines and cytokines (Kouokam et al., 2011). GRFT strongly inhibited
the infection of human cervical explants by HIV-1, and the dissemination of the virus by resident
cells to T cells (O’Keefe et al., 2009). GRFT can also inhibit HIV-1 binding to the dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and prevent
DC-SIGN-mediated transfer of the virus to target cells (Alexandre et al., 2010).
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Table 2.1: The anti-HIV activity of several lectins (Ziółkowska et al., 2006). The half maximal effective
concentration (EC50) is the lectin concentration that induces a response half way between the baseline and maximumafter a specified exposure time. The EC50 of a graded dose response curve therefore represents the concentration atwhich 50% of the maximal effect is observed. The half maximal inhibitory concentration (IC50) measures the abilityof a compound to inhibit a biological or biochemical function. This quantitative measure indicates how much of a
particular lectin is needed to inhibit a given biological process by 50%.
GRFT has a molecular weight of 12.7 kDa and is 121 amino acids in length, with three strictly
conserved repeats of the sequence GGSGG (Figure 2.1) (Mori et al., 2005; Ziółkowska et al.,
2006). The residue at position 31 does not appear to correspond to any standard amino acid and
its identity and functional role are still unknown (Mori et al., 2005). This residue was replaced by
an alanine in both Escherichia coli (Giomarelli et al., 2006) and Nicotiana benthamiana
(Ziółkowska et al., 2006) expression constructs without affecting the ability of GRFT to bind
carbohydrates. GRFT exists exclusively as a 25 kDa dimer and has been crystallized as a
domain-swapped dimer, yielding several high-resolution structures (Moulaei et al., 2010;
Ziółkowska et al., 2006). The GRFT fold is a β-prism-I motif as found in a variety of lectins,
vitelline membrane outer layer protein 1 (VMO-1) and δ-endotoxin (Shimizu and Morikawa,
Lectins EC 50  (nM)
Jacalin > 227
Myrianthus holstii lectin 150
Urtica diocia agglutinin 105
Concanavalin A 98
Narcissus pseudonarcissus lectin 96
 Psophocarpus tetragonolobus lectin 52
Microcystis viridis lectin (MVL)* 30
Scytovirin (SVN) 0.3
Cyanovirin-N (CV-N) 0.1
Griffithsin (GRFT) 0.04
*IC 50  rather than EC50 reported
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1996). The motif consists of three repeats of an anti-parallel four-stranded β-sheet that form a
triangular prism (Figure 2.2).
Figure 2.1: Structure-based sequence alignment of the three β sheets (blades) in GRFT. Conserved residues that
interact directly with the bound carbohydrates are highlighted in red, whereas conserved residues that do not make
such contacts are shown in magenta (Ziółkowska et al., 2006).
Figure 2.2: The tertiary structure of GRFT. The motif of monomer GRFT consists of three repeats of an anti-
parallel four-stranded β-sheet that form a triangular prism (Ziółkowska and Wlodawer, 2006).
Unlike other proteins in the same fold family, a single molecule of GRFT contains three almost
identical carbohydrate-binding sites, each capable of binding a monosaccharide through multiple
epitopes. Therefore, GRFT presents six binding sites for mannose per dimer, and hence shows a
significant ability to bind the high-mannose glycans on gp120 (Figure 2.3) (Ziółkowska and
Wlodawer, 2006). This is why the reported biological activity of GRFT against HIV is much
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more potent than the activities of the monosaccharide-specific lectins listed in Table 2.1 (Charan
et al., 2000; Ziółkowska et al., 2006).
Figure 2.3: Left: The structure of the GRFT dimer in a complex with mannose (Ziółkowska et al., 2006) based on
the Chimera package (Pettersen et al., 2004) using PDB structure 2gud. The arrows show the three mannose binding
sites on one monomer. Right: The structure of Man-9 (Shenoy et al., 2002), an oligosaccharide on the surface of
gp120 that is probably bound by GRFT.
Only small quantities of anti-HIV lectins can be isolated from nature (plants, algae,
cyanobacteria and fungi) so the development of lectin-based microbicides requires the
expression of recombinant lectins in larger amounts. The production of recombinant lectins in
plants was considered challenging because lectins have the potential to interfere with
endogenous biological processes (Lotter-Stark et al., 2012). Plants often produce large
quantitates of lectins in their seeds but smaller amounts in vegetative tissues, where they may
accumulate in the cytoplasm or nucleus (Peumans and Van Damme, 1995; Lannoo and Van
Damme, 2010). The production of recombinant lectins could therefore interfere with signaling
processes and plant development (Lotter-Stark et al., 2012).
GRFT has been expressed as a recombinant protein in E. coli (Giomarelli et al., 2006) and
N. benthamiana (O’Keefe et al., 2009). The yield of recombinant GRFT in E. coli was 819 mg/l
but the protein accumulated mostly as inclusion bodies where up to one third was mis-folded and
nonfunctional, so it was not possible to produce soluble and biologically active protein
(Giomarelli et al., 2006). In contrast, the production of GRFT in N. benthamiana was
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inexpensive and large quantities of the protein (up to 1 g per kg of fresh leaf weight) were
produced using a vector based on Tobacco mosaic virus (O’Keefe et al., 2009).
2.2 AIMS OF THE STUDY
The aims of the work described in this chapter were to determine whether rice endosperm can be
used as a production platform for recombinant GRFT and to test whether the rice-derived GRFT
retains its potent HIV-neutralizing activity.
2.3 MATERIALS AND METHODS
2.3.1 Cloning and construct design
The gene encoding GRFT in vector pET-28a (+) was kindly provided by Dr. Barry O’Keefe
(National Cancer Institute, Frederick, MD, USA). Cloning was carried out by Dr M. Sabalza.
The GRFT gene was amplified by PCR using primers designed to add restriction sites (Table 2.2)
that facilitated subcloning. The reagents are listed in Table 2.3 and the thermal cycling
conditions in Table 2.4. The PCR products were inserted into the shuttle vector pGEM-T easy
(Promega, Madison, Wisconsin, USA), introduced into competent E. coli cells and incubated
overnight at 37°C under ampicillin selection. The integrity of the plasmid DNA was confirmed
by sequencing (Universidad Autónoma de Barcelona, Spain) before digestion with SphI and SacI
to release the expression cassette, which was then inserted into vector pgZ63 containing the
endosperm-specific maize zein promoter (Naqvi et al., 2009) and the rice α-amylase 3A signal
peptide sequence (Figure 2.4).
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Figure 2.4: Transformation construct pgZ63-GRFT for stable expression in rice endosperm. The expression cassette
comprised the endosperm-specific maize zein promoter, the rice α-amylase 3A signal peptide sequence, the coding
region, a His6 tag and the nos terminator.
Table 2.2: Primers used to amplify the GRFT gene and add restriction sites for subcloning.
GENE PRIMER RESTRICTION SITE PRIMER SEQUENCE
BamHI restriction site
SacI restriction site
5'-TGC ATG CAT GGG CAG CAG CCA TCA T-3'
5'-GGG GAG CTC TTA GTA CTG TTC ATA GTA G-3'
Griffithsin (GRFT)
5'…GGATCC…3'
3'…CCTAGG…5'
5'…GAGCTC…3'
3'…CTCGAG…5'
Reverse
Forward
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Table 2.3: PCR reagents used to amplify the GRFT gene.
Table 2.4: PCR thermal cycling conditions.
2.3.2 Transformation and regeneration of transgenic rice plants
This procedure is described in detail in Chapter 1, section 1.1.2.
2.3.3 Confirmation of protein expression
Protein expression was confirmed using an enzyme-linked immunosorbent assay (ELISA).
Mature rice seeds were ground in three volumes of phosphate buffered saline (PBS) and
centrifuged twice at 13,000 x g for 10 min at 4°C to remove debris. GRFT expression was
confirmed by coating the wells of ELISA plates with 100 ng recombinant gp120 from HIV strain
Component GRFT (in μl)
10x Buffer (GoTaq, Promega, Madison, WI,USA) 10
10 mM dNTP 1
Forward primer (20 μM) 2.5
Reverse primer (20 μM) 2.5
Taq polymerase (Promega, Madison, WI, USA) 0.25
dH20 41.25
Plasmid containing the gene of interest (250 ng) 2.5
Total PCR volume per reaction 50
Step Temperature (°C) Time (min)
Initial denaturation 94 3
Denaturation 94 45
Annealing 60 45 35 Cycles
Elongation 72 3
Final elongation 72 10
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IIIB, provided by the MRC Centralized Facility for AIDS Reagents, Potters Bar, UK. After
washing and blocking with 5% nonfat milk, serial dilutions of each seed extract were added.
Protein assembly was confirmed using a primary rabbit anti-GRFT polyclonal antiserum and a
secondary horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antiserum (The Binding
Site, Birmingham, UK) diluted 1:1000. After washing, HRP was detected using the substrate
3,3',5,5'-tetramethylbenzidine (TMB) (Sigma, St. Louis, MO, USA) and reading the absorbance
at 450 nm.
2.3.4 His6-tag affinity purification
Rice seeds were crushed to a fine powder and extracted overnight at 4°C in five volumes of lysis
buffer (50 mM NaH2PO4, ≥ 300 mM NaCl, 5 mM imidazole, pH 8). Insoluble material was
removed by centrifuging twice at 8000 × g for 30 min at 4°C. The sample was loaded onto a
profinity IMAC-resin column at a flow rate of 2 ml/min. The column was washed twice with
wash buffer (50 mM NaH2PO4, ≥ 300 mM NaCl, 10 mM imidazole, pH 8) and the protein was
eluted four times with elution buffer (50 mM NaH2PO4, ≥ 300 mM NaCl, 250 mM imidazole,
pH 8). Protein-containing fractions were identified by the droplet Bradford method, and GRFT
concentrations were determined by ELISA. Fractions containing >50 μg/ml were pooled and
concentrated by ultrafiltration using spin-columns with a 3-kDa molecular mass cut-off.
2.3.5 SDS-PAGE analysis and immunoblotting
The efficiency of protein purification was tested by sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) in 4–12% pre-cast Bis-Tris Nu-PAGE gels (Invitrogen, Carlsbad,
CA, USA) using Precision Plus protein standards (BioRad, Hercules, USA). Each sample
comprised 5 µl of rice seed extract and 5 µl SDS loading buffer (0.3 M Tris-HCl pH 6.8, 10%
(w/v) SDS, 50% (v/v) glycerol, 0.125% (w/v) bromophenol blue). For immunoblotting, samples
were transferred to nitrocellulose membranes using the Hoefer TE70 semidry transfer system
(Amersham Biosciences, Piscataway, NJ) and blocked with 5% nonfat dried milk in Tris-
buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.6). After three washes with TBS
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containing 0.1% Tween-20 (TBST), protein expression was confirmed using a primary rabbit
anti-GRFT polyclonal antiserum and a secondary HRP-conjugated anti-rabbit IgG antiserum
diluted 1:1000. After further washes, the signal was detected using the ECL Plus Western
Blotting Detection System (GE Healthcare, Amersham, Little Chalfont, UK).
2.3.6 In vitro binding of GRFT to gp120
The specific antigen-binding activity of GRFT was determined by coating the wells of ELISA
plates with 100 ng recombinant gp120 from HIV strain IIIB, provided by the MRC Centralized
Facility for AIDS reagents, Potters Bar, UK. After washing with PBST and blocking with 5%
nonfat milk, serial dilutions of the GRFT protein were added and the amount of bound protein
determined using a secondary HRP-conjugated anti-rabbit IgG antiserum diluted 1:1000. After
washing, the signal was developed with TMB substrate and the absorbance was read at 450 nm.
2.3.7 Whole-cell anti-HIV bioassays
Whole-cell anti-HIV bioassays were carried out by Dr K. Ramessar at the NIH National Cancer
Institute, Rockville, Maryland, USA, using the 2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxanilide inner salt (XTT) tetrazolium system. The HIV-neutralizing activity
of GRFT produced in E. coli was compared to OSGRFT in HIV-1RF-challenged T-lymphoblastic
CEM-SS cells (Gulakowski et al., 1991). XTT was provided by the Drug Synthesis and
Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and
Diagnosis, National Cancer Institute. CEM-SS cells were maintained in RPMI 1640 medium
without phenol red and supplemented with 5% fetal bovine serum, 2 mM L-glutamine and 50
µg/ml gentamicin (all from BioWhittaker). Exponentially growing cells were washed and
resuspended in the complete medium, and a 50-µl aliquot containing 5 x 103 cells was added to
individual wells of a 96-well round-bottomed microtiter plates containing serial dilutions of
GRFT produced in E. coli or OSGRFT, in 100 µl of medium. Stock supernatants of HIV-1RF were
diluted in complete medium to yield sufficient cytopathicity (80–90% cell death in 6 days), and a
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50-µl aliquot was added to the appropriate wells. Plates were incubated for 6 days at 37°C and
then stained with XTT to detect viable cells. All experiments were carried out in triplicate.
2.4 RESULTS
2.4.1 Production of GRFT transgenic rice plants
Rice (Oryza sativa cv. Nipponbarre) mature seed-derived embryos were transformed by particle
bombardment with a construct containing the GRFT coding sequence under the control of the
maize zein promoter, and a second construct containing the selectable marker hpt. Embryo-
derived callus was selected on hygromycin-supplemented medium and 13 independent
transformants were regenerated and transferred to the greenhouse. Endosperm tissue was
analyzed by ELISA to confirm transgene expression.
2.4.2 Protein accumulation and assembly in rice endosperm
The presence of correctly-assembled GRFT in the T1 endosperm was confirmed using an
immunoglobulin-speciﬁc sandwich ELISA. The protein content of the endosperm was
determined by calculating the concentrations of different lines expressing GRFT from titration
curves based on positive controls spiked with known concentrations of the same protein
produced in E. coli (Figure 2.5). We used non-transformed rice endosperm as a negative control
to rule out cross reaction with endogenous plant proteins. From the 13 independent events, one
line (line 6) accumulating GRFT at the highest levels (0.38 μg/ml) was selected for more detailed
studies.
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Figure 2.5: GRFT accumulation in mature rice endosperm. An immunoglobulin-speciﬁc sandwich ELISA was used
to screen all independent events. The ELISA plate was coated with gp120 and GRFT protein assembly was
confirmed using a primary rabbit anti-GRFT polyclonal antiserum and a secondary HRP-conjugated anti-rabbit IgG
antiserum. Four dilutions per sample are shown. WT = wild-type plants; C– = PBS buffer used as a negative control;
C+ = GRFT purified from E. coli (concentration 500 ng/ml) used as a positive control. OD = optical density at 450
nm.
2.4.3 Purification of GRFT from rice endosperm
GRFT was purified from the endosperm extract of line 6 by IMAC targeting the His6 tag. Neither
the flow-through nor wash fractions contained measurable amounts of GRFT (data not shown)
indicating that the protein was folded correctly in planta and retained efficiently on the nickel
resin. The final concentration of GRFT from the T1 endosperm was ~223 μg/g dry seed weight
with a purity of almost 80%. The purified protein was separated by SDS-PAGE under reducing
conditions, with 5 μl loaded per lane corresponding to 3.5 and 3.8 μg of protein (Figure 2.6,
lanes A and B). A 14.6-kDa band was observed, corresponding to the expected size of GRFT
produced in E. coli, as well as some degradation products probably caused by the imidazole
present in the lysis, wash and elution buffers (Figure 2.6).
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Figure 2.6: Separation of the purified GRFT fraction by SDS-PAGE under reducing conditions. The presence of the
GRFT protein was confirmed (arrow) as well as degradation products. L = Precision Plus Protein™ All Blue
Standards (Biorad), lane A = 3.5 µg GRFT, and lane B = 3.8µg of GRFT protein.
2.4.4 Immunoblotting analysis of GRFT
The purified GRFT fraction was separated by SDS-PAGE under reducing conditions followed by
immunoblotting and detection using a primary rabbit anti-GRFT polyclonal antiserum and a
secondary HRP-conjugated anti-rabbit IgG. This revealed the anticipated 14.6-kDa band plus an
additional band of the same intensity with a size of 16–17 kDa. The larger band could potentially
represent a post-translational modification that alters the charge of the protein as well as its
molecular mass, but the twin bands could also represent versions of the protein with and without
the rice α-amylase (RAmy3D) signal sequence, which is 25 residues in length and has a
predicted molecular mass of ~2.6 kDa (Figure 2.7).
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Figure 2.7: Analysis of rice-derived GRFT by SDS-PAGE under reducing conditions and immunoblotting using a
primary rabbit anti-GRFT polyclonal antiserum and a secondary HRP-conjugated anti-rabbit IgG. C+ = positive
control (50 ng GRFT produced in E.coli), L = protein size marker Precision Plus Protein™ All Blue Standards
(Biorad). Lanes A and B represent 1μl of the purified simple of 3.5 µg GRFT and 3.8µg of GRFT protein
accordingly. The arrow represents the anticipated size of the GRFT-His6 protein.
2.4.5 HIV envelope glycoprotein binding by GRFT crude extracts produced in
rice endosperm
The ability of the endosperm-derived GRFT to bind gp120 was tested in vitro using an antigen-
speciﬁc ELISA. The capture reagent was gp120IIIB and the bound GRFT was detected using
primary rabbit anti-GRFT polyclonal antiserum and a secondary HRP-conjugated anti-rabbit
IgG. The wild-type extract showed no binding to gp120IIIB, confirming that there was no cross
reaction with the endogenous plant proteins. Lines 2, 6 and 10 showed the same gp120IIIB-
binding efficiency as the positive control. Line 1 showed no binding confirming the lack of
GRFT expression. These results indicate that the assembled GRFT protein produced in rice was
functional and comparable to the GRFT produced in E. coli (Figure 2.8).
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Figure 2.8: Antigen-binding activity of crude rice endosperm extracts containing GRFT and the purified GRFT
produced in E. coli by ELISA. Ordinate: Optical density at 450 nm. Abscissa: Serial dilutions. Values are the
average of two experiments. Plates coated with the HIV gp120 were tested with different concentrations of crude
extracts or fixed concentrations of purified GRFT and binding activity was measured using a primary rabbit anti-
GRFT polyclonal antiserum and a secondary HRP-conjugated anti-rabbit IgG. The binding kinetics showed a
concentration-dependent relationship, declining as the dilution factor increased. All the crude extracts showed higher
binding kinetics than wild-type extracts and similar kinetics to the purified GRFT. WT = wild type plants, C+ =
GRFT produced in E. coli (concentration 500 ng/ml) as a positive control. 2, 6, 10 = independent events expressing
GRFT protein. 1= independent event that does not express GRFT protein, OD = optical density at 450 nm.
2.4.6 Whole-cell anti HIV bioassays
Rice-derived GRFT (crude extract) and GRFT produced in E. coli were tested for their ability to
inhibit the cytopathic effects of HIV-1RF against T-lymphoblastic CEM-SS cells. Wild-type rice
was used as a negative control to exclude cross-reaction with endogenous plant proteins.
Previously, native GRFT and GRFT produced in N. benthamiana showed remarkably potent
activity against HIV-1, with EC50 values of 0.054 and 0.156 nM, respectively (O’Keefe et al.,
2009). In our experiments, GRFT at a concentration of 100 μg/ml showed potent activity against
HIV-1, with an EC50 value of 0.29 nM, comparable to the 0.28 nM of the positive control. No
IC50 value was measured, confirming that no toxic constituents had co-purified with the protein.
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Wild-type crude extract showed no activity confirming that endogenous plant lectins had no
effect on the virus (Figure 2.9).
Figure 2.9: Concentration-dependent effects of GRFT on cellular viability. The in vitro anti-HIV activity of a) rice-
derived GRFT, b) GRFT produced in E. coli and c) wild-type rice extracts against CEM-SS cells infected with HIV-
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1RF is presented as cell viability relative to uninfected and untreated controls. Cell viability was assessed using the
XTT assay. All points are averages (± SD) of triplicate measurements.
2.5 DISCUSSION
Griffithsin (GRFT) is a lectin isolated from the red alga Griffithsia spp. and it binds to mannose
residues in the N-linked glycans displayed on the surface of many different viruses (Xue et al.,
2013), including HIV (Ziółkowska et al., 2007). GRFT is active against HIV clades A, B and C,
which are predominant in sub-Saharan Africa, India and the West (Lotter-Stark et al., 2012) and
is equally active against T-tropic and M-tropic strains of HIV-1 (Mori et al., 2005). GRFT acts as
an HIV entry inhibitor, it blocks virus–cell fusion at sub-nanomolar concentrations and reduces
the cytopathic effect of laboratory strains and clinical primary isolates of HIV-1 at picomolar
concentrations (Mori et al., 2005). Native GRFT acts as a tight dimer (Xue et al., 2012) with a
swapped domain. Each subunit contains three similar mannose-binding sites (Ziółkowska et al.,
2006; Xue et al., 2013). Monomeric GRFT has no activity against HIV (Moulaei et al., 2010).
Native GRFT can be purified directly from its source (Mori et al., 2005) but the low yields mean
that the production of recombinant GRFT is necessary to meet the demand for this protein as a
microbicide component. GRFT was initially produced with a His-tag in E. coli (Giomarelli et al.,
2006) and the yield was 819 mg/l, of which 66% (542 mg) was in the soluble fraction and 33%
(277 mg) was in inclusion bodies. The authors attempted to isolate His-GRFT from the inclusion
bodies using different detergents but this did not release significant amounts of active protein.
O’Keefe et al. (2009) addressed this challenge by producing GRFT in tobacco leaves using a
TMV-based vector, achieving a yield of 1 g/kg leaf tissue.
We investigated the potential use of rice endosperm as an alternative production platform for
recombinant His-GRFT (OSHis-GRFT). We used particle bombardment to transform mature
seed-derived embryos with a construct containing the GRFT coding sequence under the control
of the maize zein promoter, plus a second construct containing the selectable marker hpt. We
regenerated 13 independent transgenic events under hygromycin selection and confirmed the
presence and strong expression of the transgene in three independent lines. This is the first time
that the His-GRFT protein has been produced in cereal endosperm. Ultimately we chose line 6
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for further investigation because this had the highest OSHis-GRFT yield of 223 μg/g dry seed
weight, which compares well with yields previously achieved for the HIV-neutralizing antibody
2G12 in maize (30–75 μg/g; Rademacher et al., 2008; Ramessar et al., 2008) and rice (42 μg/g;
see Chapter 1) and the HIV-neutralizing antibody 2F5 in maize (0.80 μg/g; Sabalza et al., 2012).
GRFT has been produced at higher levels in N. benthamiana by transient expression (1 mg/g
after 12 days) but after purification this was reduced to 300 mg/g which is only slightly higher
than the yields we achieved in rice (Zeitlin et al., 2009). Furthermore, we extracted OSHis-GRFT
from T1 generation seeds, which were not homozygous. It is therefore likely that the yield can be
improved by breeding to homozygosity and selection in each generation, as previously described
for the expression of enzymes in maize by Hood et al. (2012).
In order to determine whether any production system is economically viable there are three
major factors: the amount of product that accumulates per unit biomass (productivity, specific
yield), the amount of biomass that can be produced per hectare per year, and the quality of the
final product in terms of homogeneity and functionality (Sabalza et al., 2013). The production
system should also be facile, i.e. plants should be easy to transform and regenerate. The most
suitable production system for a particular protein should therefore be determined on a case-by-
case basis because no system is perfect for all proteins (Schillberg et al., 2005).
Although tobacco combines most of the above requirements, it also produces toxic compounds
such as nicotine that must be removed during downstream processing, thus increasing the final
cost of the product (Obembe et al., 2011). Furthermore, recombinant proteins expressed in
tobacco leaves and other leafy crops are often unstable (so that harvested material must be frozen
if not processed immediately) and can affect plant growth and development (Fischer et al.,
2004). Importantly, the yield from N. benthamiana was in fresh leaf weight meaning that the
infrastructure must be present to maintain the plants and carry out downstream purification
rapidly and at the optimum pH to achieve the maximum yield (O’Keefe et al., 2009).
Unlike tobacco, rice does not produce toxic compounds (hence its GRAS status) and
recombinant proteins are expressed in the seeds, so they are stable and even toxic proteins do not
affect vegetative growth and development. The absence of phenolic compounds and alkaloids in
the seeds means that chromatography media do not suffer from fouling and thus retain their
capacity for longer (Moloney et al., 1999). Like tobacco, the in vitro cultivation and
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transformation of rice are straightforward and production can be scaled up rapidly. Field plants
can be scaled up between 100-fold and 1000-fold in a single season depending on the species
(Schillberg et al., 2002). These advantages are shared by other cereals, but rice (unlike maize and
barley) is a self-pollinating crop, so there is a much lower risk of gene flow from pharmaceutical
to non-pharmaceutical crops and wild relatives (Sabalza et al., 2013). Rice endosperm also has
an interesting and apparently unique property in the diversity of its storage compartments. The
endosperm cells of most cereals contain specialized storage compartments known as protein
bodies, which have evolved for protein storage and bud from the endoplasmic reticulum when
sufficient protein has accumulated (Takaiwa et al., 2009). These compartments can also be used
to accumulate recombinant proteins using the appropriate promoters and targeting sequences,
increasing protein yields by providing an ideal stable environment (Muntz, 1998; Yamagata and
Tanaka, 1986). In practical terms, this means that cereal seeds containing pharmaceutical
proteins can be stored and distributed in countries lacking a reliable cold chain. Most cereals
form a single type of protein body, whereas rice endosperm forms two distinct types of
compartment, known as PB-I and PB-II (Takaiwa et al., 2009). Protein bodies are insoluble in
low-salt aqueous buffers, so they can be purified by centrifugation. Therefore the presence of
two different protein bodies in rice potentially allows different proteins to be expressed and
targeted to different compartments simultaneously, and then recovered by first separating the
compartments by density centrifugation (Sabalza et al., 2013).
The yields of recombinant proteins produced in rice and other cereals can often be improved by
breeding and selection (Hood et al., 2012), which suggests that our GRFT yields could be
improved in the same manner. For example, human transferrin was produced with a yield of 8.8
mg/g (0.88%) in first-generation rice plants, but this increased to 10 mg/g (1%) in the second
generation (100-fold more than the commercial threshold) and remained stable at that level in
subsequent generations (Zhang et al., 2010). As discussed above, the yield of GRFT in tobacco
was 0.3 mg/g or 0.03% TSP and our initial yields were similar at 0.223 mg/g or 0.0223% TSP.
The number and nature of purification steps and the overall cost of processing are key issues that
determine the commercial viability of a production platform. Mori et al. (2005) purified the
native GRFT from Griffithsia spp. by ammonium sulfate precipitation, hydrophobic interaction
chromatography, anion exchange chromatography, reversed-phase chromatography and size
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exclusion chromatography to yield a homogeneous, highly pure and biologically active protein.
We found that ammonium sulfate precipitation did not work, not even when combined with
ethanol precipitation. However, protein extraction using phosphate buffer combined with IMAC
resin purification gave us satisfactory results and >80% protein purity. Several purification
methods have been used with the E. coli production platform. For example, Giomarelli et al.
(2006) purified soluble His-GRFT from E. coli using Ni-NTA resin and the dialyzed protein was
then applied to a TALON resin before stepwise elution using two different buffers containing
different amounts of imidazole (50 mM and 250 mM, respectively). Ishag et al. (2013) used
IMAC followed by elution in a buffer containing 250 mM imidazole before further purification
by size exclusion chromatography using a SuperdexTM 75 column (GE Healthcare). The resulting
purified protein contained both the monomeric and dimeric forms of GRFT. Finally, Xue et al.
(2013) used a nickel-chelating column (Qiagen) and eluted the His-GRFT protein with 500 mM
imidazole, refolding the protein by drop-wise addition to a low-salt refolding buffer before final
purification using a C4 reversed-phase chromatography column (Vydac, Hesperia, CA). When
GRFT was produced in tobacco using viral vectors, the first purification step involved the
removal of the virus coat protein by filtration through a ceramic membrane, followed by ion
exchange chromatography over SP-Sepharose resin, ultrafiltration/diafiltration (UF/DF) to
concentrate the protein and elution with 100 mM NaCl, achieving >99.8% purity (O’Keefe et al.,
2009). In our case, we used non-reducing conditions to prepare the protein extract thus keeping
GRFT in its native confirmation to avoid the need for a refolding step. The protein was captured
on a Profinity IMAC column and eluted with 250 mM imidazole. There are many commercial
kits and protocols for the purification of His­tagged proteins but we used the simplest, one-step
method to see if purification costs could be reduced without sacrificing the purity and bioactivity
of the protein. Accordingly, we achieved a purity of ~80% and the protein remained active.
Multiple bands were observed when the purified sample was separated by SDS-PAGE and the
gel was stained with Coomassie Brilliant Blue. A western blot using a primary rabbit anti-GRFT
polyclonal antiserum and a secondary horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
antiserum revealed an intense band at 14.6 kDa (the anticipated molecular mass of GRFT) and
another at 16–17 kDa. The gel was run under denaturing conditions so the additional band is
unlikely to represent a conformational isomer or a non-covalent interaction. It is possible that
GRFT undergoes partial post-translational modification and is therefore present in two forms,
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but the sequence does not contain a glycan acceptor site and no other modifications would
explain the difference in mobility (2–3 kDa) unless the modification also caused a significant
change to the charge of the protein (e.g. phosphorylation). A more likely explanation is the
incomplete removal of the rice α-amylase (RAmy3D) signal peptide, which is 25 residues in
length and has a predicted molecular mass of 2.6 kDa.
GRFT can interfere with the interaction between HIV and CD4 cells by binding to several
mannose-rich viral glycoproteins, namely gp120, gp41 and gp160 (Mori et al., 2005). GRFT
interacts with a number of viruses, but has particular potency against HIV because it can bind to
multiple sites on gp120 (Giomarelli et al., 2006). We therefore compared the biological activity
of OSHis­GRFT and GRFT produced in E. coli by testing their ability to bind gp120 in a
plate­based binding assay, initially comparing the purified E. coli GRFT to crude rice extracts
from different lines. We found that OSHis­GRFT bound to gp120 in a manner similar to E. coli
GRFT and that the binding activity was concentration dependent. Line 6 showed slightly greater
affinity for gp120 than E. coli GRFT, indicating that the OSHis­GRFT possessed essentially the
same oligosaccharide-dependent binding properties as the bacterial recombinant protein. These
results agree with O’Keefe et al. (2009), who showed that tobacco GRFT had a comparable or
even higher affinity for gp120IIIB than E. coli GRFT. Giomarelli et al. (2002) also demonstrated
that the His-GRFT produced in E. coli retained the biological activity and gp120-binding activity
of its native counterpart, and endogenous plant lectins did not interfere with binding.
We also tested OSHis­GRFT and E. coli GRFT side-by-side in a whole-cell anti-HIV assay in
order to define their anti-HIV activity. Giomarelli et al. (2006) showed that the recombinant His-
GRFT inhibited HIV-induced cytopathicity with an EC50 value of 0.089 nM, similar to the EC50
value of native GRFT (0.163 nM) and they concluded that both forms of GRFT were
functionally equivalent. However, these data were different from those reported by O’Keefe et
al. (2009), who recorded an EC50 value of 0.054 nM for native GRFT and 0.156 nM for tobacco
GRFT. This discrepancy may have reflected differences in the assay set up or the nature of the
samples. As expected from the gp120 binding assay, our comparison of OSHis­GRFT and E. coli
GRFT confirmed that both displayed nanomolar activity against HIV. The OSHis­GRFT has an
EC50 value of 0.29 nM compared to E. coli GRFT with an EC50 value of 0.28 nM, well within the
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range previously reported by Mori et al. (2005). The wild-type crude extract showed no activity
against HIV, confirming there was no cross reaction with endogenous plant lectins.
2.6 CONCLUSIONS
Our data show that OSHis­GRFT can be expressed in rice endosperm with yields comparable to
or even higher than GRFT produced transiently in tobacco. One-step His-tag purification
resulted in the isolation of GRFT with almost 80% purity. Furthermore, we obtained moderate
yields of OSHis­GRFT even in first-generation plants suggesting that rice seeds could be used as
a production platform for GRFT after future optimization. The ability of OSHis­GRFT to bind
and inhibit HIV was tested by ELISA against gp120 and a whole-cell anti-HIV assay. In both
cases, OSHis­GRFT showed similar behavior to the control GRFT produced in E. coli. This is the
first time that GRFT has been produced in cereals and this allows the comparison of different
plant-based production platforms to see whether they affect the anti-HIV activity of GRFT. We
therefore demonstrated that rice endosperm can be used as an economical production platform
for GRFT.
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CHAPTER 3
Preliminary investigations for the production of the anti-HIV
protein Cyanovirin-N (CV-N) in rice endosperm
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3.1 INTRODUCTION
Cyanovirin-N (CV-N) is an 11-kDa monomeric non-glycosylated protein originally isolated from
an aqueous extract of the cyanobacterium Nostoc ellipsosporum while screening for anti-HIV
activity carried out at the US NCI Natural Products Repository in the late 1990s (Boyd et al.,
1997). CV-N inhibits all HIV clades in vitro by blocking multiple stages of membrane fusion and
virus entry (Dey et al., 2000). CV-N binds to the HIV surface envelope glycoprotein gp120
(Boyd et al., 1997; Mori et al., 1997), specifically interacting with N-linked high-mannose
residues (Bolmstedt et al., 2001; Botos et al., 2002) blocking the attachment and fusion of the
virus particle to target cells, and thereby preventing infection. CV-N also blocks vaginal HIV
transmission in non-human primates but relatively high concentrations are needed to demonstrate
this positive effect because of the protein has a short half-life and undergoes rapid clearance
(Taha et al., 1998). In addition, in vivo studies showed that CV-N formulated as a gel had
promising efficacy as a microbicide candidate, whereas ex vivo studies demonstrated that CV-N
has stronger antiviral effect than the nonspecific polyanion microbicide PRO 20O (Fischetti et
al., 2009; Huskens et al., 2009). CV-N also inhibits HIV-1 binding to the DC-SIGN receptor and
DC-SIGN mediated transfer of the virus to target cells (Alexandre et al., 2012). This is important
because in addition to the infection of CD4+ T lymphocytes and macrophages by cell-free virions
and donor-infected cells, the DC-SIGN-directed capture of HIV-1 and transmission to CD4+ T
lymphocytes is considered an avenue of primary infection in women exposed to HIV-1 through
sexual intercourse (Hladik and Hope, 2009).
Conventional biochemical techniques were used to determine the primary structure of CV-N and
the pattern of disulfide bridges (Boyd et al., 1997; Gustafson et al., 1997). CV-N has a unique
sequence of 101 amino acids (Boyd et al., 1997) comprising two internal repeats of 50 and 51
amino acids, respectively (Figure 3.1) (Bewley et al., 1998; Ziółkowska and Wlodawer, 2006).
The 1-50 and 51-101 repeats have 70% similarity. Structural alignment of the repeats showed
that 16 residues were identical and 19 were conservative replacements (Figure 3.1) (Bewley et
al., 1998).
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Figure 3.1: Structure alignment of the first and second sequence repeats of the algal lectin CV-N. Conserved
residues are highlighted in yellow, whereas identical residues are highlighted in red. Black and red lines demarcate
domains A and B, respectively (Bewley et al., 1998).
CV-N contains four cysteine residues that form two intramolecular disulfide bonds. Disruption
of these disulfide bonds causes the loss of anti-HIV activity (Bewley et al., 1998; Yang et al.,
1999). In addition to HIV, CV-N is also active against rhinoviruses, Herpes simplex virus (HSV-
1), Hepatitis C virus (HCV), Ebola virus, Human herpes virus 6 (HHV-6), measles virus,
influenza viruses A and B (Balzarini, 2007; Barrientos et al., 2002; Buffa et al., 2009; Helle et
al., 2006; O’Keefe et al., 2003; Smee et al., 2007; Xiong et al., 2010), murine leukemia virus and
vesicular stomatitis virus (Shahzad-ul-Hussan et al., 2011).
The Protein Data Bank contains 24 entries for Nostoc ellipsosporum CV-N based on x-ray
crystallography (17) and nuclear magnetic resonance (NMR) spectroscopy (7) data. The
predominant form of CV-N in solution is the monomeric form, but because it contains two
carbohydrate recognition sites on symmetrically-opposed domains, it can cross-link branched
oligomannosides to form higher-order structures (Bewley and Otero-Quintero, 2001; Bewley,
2001; Bewley et al., 1998; Liu et al., 2009). CV-N specifically recognizes Manα(1–2)Man linked
mannose substructures in the D1 and D3 arms of Man9 (Figure 3.2) (Bewley, 2001; Botos et al.,
2002). Although the two halves in the monomeric CV-N share a high degree of sequence
similarity, there are never more than eight contiguous amino acids or 20% of the total sequence
that are related to any other known protein (Yang et al., 1999).
127
Figure 3.2: Different structures reported for CV-N. Domain A of each monomer is shown in cyan and domain B in
green. A) Compact monomer observed by NMR; B) Extended monomer that is found in all crystal structures and
some NMR structures as part of a dimer – it does not exist in isolation; C) Domain-swapped dimer comprising two
monomers as shown in panel B; D) A complex of CV-N with Man9 (Ziółkowska and Wlodawer, 2006).
A 5-mg dose of CV-N was effective as a microbicide candidate in macaques, but this equates to
a demand of 5000 kg per year to supply twice-weekly doses for 10 million women (Shattock and
Moore, 2003). This scale of production requires an expression system that could produce
recombinant CV-N efficiently at a low cost. CV-N has been expressed in Escherichia coli, but
the yields were low at 10 mg/l (Boyd et al., 1997). The yield was increased to ~40 mg/l in
shaking-flask cultures by targeting CV-N for accumulation in cytosolic inclusion bodies, and this
increased again to 140 mg/l in high-density fed-batch cultures, but the final product was
heterogeneous (Colleluori et al., 2005). CV-N has also been expressed using a chaperone fusion
system in E. coli, in which the protein was double-tagged with hexa-histidine and a small
ubiquitin-related modifier (SUMO). This achieved CV-N yields of >30% total soluble protein
(TSP) (Gao et al., 2010). CV-N was also expressed in commensal Streptococcus gordonii either
as a secreted protein or attached to the bacterial cell surface. The secreted CV-N was able to bind
HIV-1 and the surface-attached version was able to capture HIV-1 (Giomarelli et al., 2002).
Lactobacillus jensenii has also been shown to secrete recombinant CV-N with potent antiviral
activity against laboratory and primary HIV-1 isolates (Liu et al., 2006). This recombinant
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bacterium has been shown to deliver CV-N directly to the mucosal surface in macaques,
reducing the transmission of a the chimeric virus SHIV by 63% after repeated vaginal challenges
(Lagenaur et al., 2011). Finally, CV-N has also been produced in the yeast Pichia pastoris,
which is widely used for the production of recombinant proteins because it is adapted for highly
efficient secretion. However, the recombinant CV-N produced in yeast was inactive due to the
high mannose N-glycosylation at position N30 and P51-mediated dimerization of the final
product in the hinge region, both of which result in a loss of activity (Mori et al., 2002). The
overall yield was less than 10 mg/l.
Transgenic plants provide an alternative and more scalable platform for CV-N expression and
tobacco plants (Nicotiana tabacum) have been used to produce recombinant CV-N at yields of
~130 μg per gram of fresh leaf tissue, or 0.635 ± 0.298 mg/l in a 24-day rhizosecretion system,
with most of the recombinant protein present in the monomeric form demonstrating high stability
(Sexton et al., 2006). Under optimized conditions, the yield of the rhizosecretion system was
increased to 3.2 mg/l, or 766 μg/g root dry weight per 24 h. This is the highest reported yield for
the rhizosecretion of a heterologous protein although further optimization would be required to
achieve commercial viability (Colgan et al., 2010; Drake et al., 2009). CV-N has also been
produced in the marshmallow plant (Althaea officinalis L.) using Agrobacterium rhizogenes with
yields of 2.4 μg/g fresh weight (Drake et al., 2013).
3.2 AIMS OF THE STUDY
The aims of the experiments described in this chapter were to explore rice endosperm as a
production platform for the production of CV-N and to evaluate the efficiency of rice-derived
CV-N for the neutralization of HIV.
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3.3 MATERIALS AND METHODS
3.3.1 Cloning and construct design
The gene encoding CV-N (N30Q/P51G) in plasmid pET30b, recombinant purified CV-N
produced in E. coli, and anti-CV-N polyclonal antisera, were all kindly provided by Prof. Julian
Ma, St George’s Hospital Medical School, University of London, UK, under a material transfer
agreement with Dr. Barry R. O’Keefe, National Cancer Institute, Frederick, MD, USA. Cloning
was carried out by Dr M. Sabalza. The CV-N gene was amplified by PCR using primers designed
to append specific restriction sites (Table 3.1) facilitating the construction of transformation
vectors using the reagents listed in Table 3.2 and thermal cycling conditions as shown in Table
3.3.
The PCR products were ligated into the shuttle vector pGEM-T Easy (Promega, Madison,
Wisconsin, USA) and introduced into competent E. coli cells, which were incubated overnight at
37°C under ampicillin selection. Plasmid DNA from positive samples was verified by
sequencing (Universidad Autónoma de Barcelona, Spain). Plasmid DNA was digested with
restriction enzymes SphI and SacI and the CV-N gene was transferred to the pRP5 vector
containing the endosperm-specific rice prolamin promoter (Naqvi et al. 2009a) and the rice
α-amylase 3A signal peptide sequence (Figure 3.3).
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Table 3.1: PCR primers for the CV-N gene and appended restriction sites
Table 3.2: Reagents used to amplify the CV-N gene.
Table 3.3: PCR thermal cycling conditions.
GENE PRIMER RESTRICTION SITE PRIMER SEQUENCE
BamHI restriction site
EcoRI restriction siteCyanovirin-N (CV-N)
Forward 5'-GGG ATC CAT GCT TGG TAA ATT CTC CCA G-3'5'…GGATCC…3'
3'…CCTAGG…5'
Reverse 5'-CCG AAT TCT TAT TCG TAT TTC AGG GTA CCG-3'5'…GAATTC…3'
3'…CTTAAG…5'
Component CV-N (in μl)
10x Buffer (GoTaq, Promega, Madison, WI,USA) 10
10 mM dNTP 1
Forward primer (20 μM) 2.5
Reverse primer (20 μM) 2.5
Taq polymerase (Promega, Madison, WI, USA) 0.25
dH20 41.75
Plasmid containing the gene of interest (250 ng) 2
Total PCR volume per reaction 50
Step Temperature (°C) Time (min)
Initial denaturation 94 3
Denaturation 94 45
Annealing 60 45 35 Cycles
Elongation 72 3
Final elongation 72 10
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Figure 3.3: Transformation construct pRP5-CV-N for stable expression in rice seeds. The expression cassette
comprised the endosperm-specific rice prolamin promoter, the rice α-amylase 3A signal peptide sequence, the
coding region, and the nos terminator.
3.3.2 Transformation and regeneration of transgenic plants
This method is described in detail in Chapter 1, section 1.3.2.
3.3.3 Crude extract of CV-N from rice endosperm
We crushed 5 g of mature rice seeds into a fine powder using a glass mortar. The total soluble
protein (TSP) was extracted in three volumes (v/w) of PBS by vortexing overnight at 4°C. The
samples were then centrifuged twice (13,000 x g, 15 min, 4°C) and the supernatant was filtered
and transferred into a 50-ml falcon tube.
3.3.4 SDS-PAGE and immunoblotting
Proteins were separated under non-reducing conditions on 4–12 % gradient pre-cast Bis-Tris
Nu-PAGE gels (Invitrogen, Carlsbad, CA, USA) using Precision Plus protein standards (BioRad,
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Hercules, USA). Each sample comprised 5 µl of rice seed extract plus 5 µl SDS loading buffer
(0.3 M Tris HCl pH 6.8, 10 % (w/v) SDS, 50 % (v/v) glycerol, 0.125 % (w/v) bromophenol
blue). For immunoblotting, samples were transferred to nitrocellulose membranes using the
Hoefer TE70 semidry transfer system (Amersham Biosciences, Piscataway, NJ) and blocked
with 5% nonfat dried milk in Tris-buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.6).
After three washes with TBS plus 0.1 % Tween-20 (TBST), protein expression was detected
using a primary rabbit anti-CV-N polyclonal antiserum and a secondary horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG antiserum (The Binding Site, Birmingham, UK; 1:1000
dilution). After three further washes, the signal was detected using the ECL Plus Western
Blotting Detection System (GE Healthcare, Amersham, Little Chalfont, UK).
3.3.5 Confirmation of protein expression (ELISA)
Mature rice seeds were ground in three volumes of PBS and centrifuged twice (13,000 x g, 10
min, 4°C) to remove seed debris, and serial dilutions of the extract were added to ELISA wells
previously coated with 100 ng recombinant gp120 from HIV strain IIIB (MRC Centralized
Facility for AIDS Reagents, Potters Bar, UK), washed and blocked with 5% nonfat milk. Protein
assembly was confirmed using a primary rabbit anti-CV-N polyclonal antiserum and a secondary
HRP-conjugated anti-rabbit IgG antiserum (1:1000 dilution). After washing, HRP was detected
by adding 3,3',5,5' tetramethylbenzidine (TMB) substrate (Sigma, St. Louis, MO, USA) and
reading the absorbance at 450 nm.
3.3.6 In vitro binding of cyanovirin-N to gp120 (ELISA)
The specific antigen-binding activity of CV-N was detected by coating ELISA wells with 100 ng
recombinant gp120 from HIV strain IIIB. After washing with PBST and blocking with 5%
nonfat milk, serial dilutions of CV-N were added and the amount of bound protein determined
using a secondary HRP-conjugated anti-rabbit IgG antiserum (1:1000 dilution) detected as
described above.
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3.3.7 Whole-cell anti-HIV bioassays
Whole-cell anti-HIV bioassays were carried out by Dr K. Ramessar at the NIH/NCI, Frederic,
Maryland, USA. A 2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide
inner salt (XTT)-tetrazolium-based assay was used to determine the anti-HIV activity of rice-
derived CV-N against HIV-1RF challenged T-lymphoblastic CEM-SS cells, as described
previously (Gulakowski et al., 1991). XTT was supplied by the Drug Synthesis and Chemistry
Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis,
National Cancer Institute. CEM-SS cells were maintained in RPMI 1640 medium without phenol
red and supplemented with 5% fetal bovine serum, 2 mM l-glutamine and 50 µg/ml gentamicin
(all BioWhittaker). Exponentially-growing cells were washed and resuspended in this complete
medium, and a 50-µl aliquot containing 5 x 103 cells was added to the individual wells of a 96-
well round-bottomed microtiter plate containing serial dilutions of rice-derived CV-N in 100 µl
of medium. Stock supernatants of HIV-1RF were diluted in complete medium to yield sufficient
cytopathicity (80–90% cells killed in 6 days), and a 50-µl aliquot was added to the appropriate
wells. Plates were incubated for 6 days at 37 °C and then stained for cellular viability using XTT.
All experiments were carried out in triplicate.
3.4 RESULTS
3.4.1 Production of CV-N in rice endosperm
Rice (Oryza sativa cv. Nipponbarre) mature seed-derived embryos were transformed by particle
bombardment with a construct containing the CV-N coding sequence, under the control of the
rice prolamin promoter, plus a second construct containing the selectable marker hpt. Embryo-
derived callus was selected on hygromycin-supplemented medium and 10 independent
transformants were regenerated and transferred to the greenhouse. Endosperm tissue was
analyzed by ELISA to confirm transgene expression.
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3.4.2 Confirmation of protein expression and assembly in rice endosperm
The presence of correctly-assembled CV-N in the T1 endosperm was confirmed using an
immunoglobulin-speciﬁc sandwich ELISA. The protein content of the endosperm was
determined by calculating the concentrations of different lines expressing CV-N from titration
curves based on positive controls spiked with known concentrations of the same protein
produced in E. coli (Figure 3.4). We used non-transformed rice endosperm as a negative control
to rule out cross-reaction with endogenous plant proteins. Among 10 independent events, two
lines were found to express CV-N (lines 2 and 6, with yields of 6 and 0.5 μg/ml, respectively)
although it is necessary to take into consideration that a 1/25 dilution was necessary for
detection. We selected line 2, with the highest yields of assembled CV-N, for more detailed
investigation.
Figure 3.4: CV-N accumulation in mature rice endosperm. An immunoglobulin-speciﬁc sandwich ELISA
procedure was used to screen all the independent events for CV-N production. The ELISA plate was coated with
gp120 IIIB and the bound CV-N was detected using primary rabbit anti-CV-N polyclonal antiserum and a secondary
HRP-conjugated anti-rabbit IgG antiserum (1:1000 dilution). Four dilutions per sample are shown; WT = wild type
plants and C– = PBS buffer used as negative control. C+ = CV-N produced in E. coli (concentration of 500 ng/ml) as
a positive control.
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3.4.3 Binding activity of the CV-N crude extract from rice endosperm
The ability of the endosperm-derived CV-N to bind gp120 was tested in vitro using an antigen-
speciﬁc ELISA. The capture reagent was gp120 IIIB and the bound CV-N was detected using
primary rabbit anti-CV-N polyclonal antiserum and a secondary HRP-conjugated anti-rabbit
IgG. The wild-type extract showed no binding to gp120, confirming that there was no cross
reaction with the endogenous plant proteins. The positive control showed higher gp120-binding
activity than any of the independent events and remained at the same level throughout the range
of serial dilutions. Line 2 showed promising gp120-binding activity and both lines 4 and 6 were
also positive for gp120 binding but only at the highest concentration (or lowest dilution). These
results indicate that the recombinant CV-N protein produced in the transgenic endosperm was
functional (Figure 3.5).
Figure 3.5: Antigen-binding activity of the crude rice endosperm extracts containing CV-N measured by ELISA
compared to the purified CV-N produced in E. coli. Ordinate: Optical density at 450 nm. Abscissa: Serial dilutions.
Values are the average of two experiments. Binding activity was measured with a primary rabbit anti-CV-N
polyclonal antiserum and a secondary HRP-conjugated anti-rabbit IgG. The binding kinetics showed a
concentration-dependent relationship, declining as the dilution factor increased in all the samples except the positive
control. All the crude extracts showed higher binding kinetics than wild-type extracts but lower binding kinetics than
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the purified CV-N. WT = wild type plants. C– = PBS buffer used as negative control. C+ = CV-N produced in E. coli
(concentration of 500 ng/ml) as a positive control. Lines 2, 4 and 6 are independent events expressing CV-N.
3.4.4 Higher yields of CV-N in rice endosperm over successive generations
Three lines (1, 2 and 4) were self-pollinated over three generations to produce T4 seeds. The
yields of CV-N were compared in the T1 and T4 seeds, revealing a substantial increase in lines 2
and 6 (Figure 3.6). In the T1 generation, the expression of CV-N was lower than the ELISA
detection limit and therefore indistinguishable from the wild-type extracts, but a significant
upward trend was apparent during through to the T4 generation (Figure 3.6).
Figure 3.6: Comparison of CV-N yields in generations T1 and T4. Four dilutions per sample are shown; WT =
wild-type plants. C+ = CV-N purified from E.coli (concentration 500ng/ml) as a positive control.
3.4.5 HIV-neutralization activity of rice-derived CV-N in whole-cell bioassays
Rice-derived CV-N (crude extract) was tested for its ability to inhibit the cytopathic effects of
HIV-1RF against T-lymphoblastic CEM-SS cells. Wild-type rice was used as a negative control
to exclude any potential cytotoxicity or antiviral activity caused by endogenous plant proteins.
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Rice-derived CV-N at a concentration of 100 μg/ml showed low activity against HIV-1, with an
EC50 value of 28 μg/ml, much higher than that reported previously (O’Keefe, 2001). This
probably was due to the fact that even though a specific concentration of extract was used, the
concentration of CV-N inside the final extract was low (Figure 3.7 a). It was not possible to
determine an IC50 value, confirming that no toxic constituents had co-purified with the protein.
Wild-type crude extract showed no activity confirming that there was no toxicity or antiviral
activity caused by endogenous plant lectins or other components (Figure 3.7 b).
Figure 3.7: In vitro anti-HIV activity of rice-derived CV-N. The anti-HIV activity of a) CV-N and b) wild-type rice
in CEM-SS cells infected with HIV-1RF revealing concentration-dependent effects of CV-N on cellular viability
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relative to the uninfected and untreated controls. Cell viability was assessed using the XTT assay. All points are
averages (± SD) of experiments carried out in triplicate.
3.5 DISCUSSION
CV-N is an entry inhibitor originally isolated form the cyanobacterium Nostoc elipsosporum
which shows promising in vivo efficacy against HIV (Boyd et al., 1997; Buffa et al., 2009).
CV-N binds to N-linked high-mannose glycans on the surface of HIV envelope glycoproteins,
such as gp120 and gp41, inhibiting viral attachment to its target cells (Dey et al., 2000; Shenoy et
al., 2001). Furthermore, CV-N is resistant to chemical and thermal denaturation and degradation.
It is stable in a low-pH environment and survives multiple freeze-thaw cycles (Boyd et al.,
1997). Native CV-N can be purified directly from its source but only low yields can be achieved
(Gustafson et al., 1997). Other platforms are therefore required for the large-scale expression of
this protein, and recombinant CV-N has accordingly been produced in E. coli (Boyd et al., 1997)
and other bacteria such as Streptococcus gordonii and Lactobacillus jensenii (Giomarelli et al.,
2002; Liu et al., 2006), the yeast Pichia pastoris (Mori et al., 2002) and the plants Nicotiana
tabacum and Althaea officinalis (Drake et al., 2013; Sexton et al., 2006).
We transformed mature seed derived rice embryos by particle bombardment using a construct
containing the coding sequence of CV-N under the control of the rice prolamin promoter, plus a
second construct containing the selectable marker hpt. We successfully expressed CV-N in rice
endosperm and tested its HIV-neutralization activity. We regenerated 10 independent events
under hygromycin selection and confirmed CV-N expression in three independent events,
ultimately choosing one event (line 2) with the highest yield of OSCV-N (6 mg/l) for more
detailed analysis. This yield was comparable to the 10–40 mg/l achieved in E. coli (Boyd et al.,
1997; Mori et al., 2002, 1998). Boyd et al. (1997) expressed a FLAG-CV-N fusion protein
targeted to the periplasmic space, resulting in a yield of less than 10 mg/l. The FLAG tag
inhibited the activity of CV-N, and the recombinant protein was a mixture of intact and truncated
forms of CV-N. Mori et al. (1998) produced full-length soluble CV-N by directing the protein to
the periplasmic space using the pelB leader sequence, again achieving a yield of ~10 mg/l. They
attempted to improve the yield by adding a C-terminal His5 tag and expressing Asn30 and/or
Pro51 substitution mutants but the maximum yield remained at ~10 mg/l. We did not use any
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fusion tags to express recombinant CV-N in rice, although we did use the rice α-amylase 3A
signal peptide sequence to direct the protein to the secretory pathway.
Because periplasmic expression in E. coli resulted in low yields, others have attempted to
express the protein in the cytosol (Colleluori et al., 2005; Gao et al., 2010). Colleluori et al.
(2005) expressed CV-N within cytosolic inclusion bodies, increasing the yield to 40 mg/l in
shaking flasks and 140 mg/l in high-density fed-batch cultures, which is the highest yield
achieved thus far. However, the final product was a mixture of monomeric and dimeric forms
including variants with N-terminal deletions. For this reason, Gao et al (2010) used a chaperone-
fusion system to express soluble in the E. coli cytosol, yielding 3–4 mg CV-N per gram wet cell
yielding equivalent to 30% TSP. The purification process was simplified and the product was
intact and homogeneous. CV-N production in the yeast Pichia pastoris was less successful. A
secreted version of the protein with a C-terminal His5 tag was expressed with a maximum yield
of 10 mg/l and N-glycosylation resulted in the formation of a heterogeneous and largely inactive
product; however, a P51G mutant showed comparable activity and stability to the wild-type
enzyme (Mori et al., 2002). CV-N has also been expressed in tobacco and marshmallow (Sexton
et al., 2006; Drake et al., 2013). Sexton et al. (2006) expressed soluble CV-N in tobacco, with a
yield of 130 μg/g fresh leaf tissue or 0.85% TSP. The yield achieved by rhizosecretion after 24
days was 0.635 ± 0.298 mg/l and almost all of the CV-N protein was in the monomeric form. In
comparison, the yield in A. officinalis was 0.02 mg/l/day or 0.5 μg/g root fresh weight/day.
We observed an increase in OSCV-N yields over successive generations indicating that breeding
cycles could be used to improve the yields even further, as previously reported (Clough et al.,
2006; Hood et al., 2012; 2007; 2003; Streatfield et al., 2002) demonstrating that germplasms
manipulation could lead to increases in recombinant proteins. Clough et al. (2006) backcrossed
multiple independent transgenic maize lines with elite inbred lines for several generations
demonstrating that the high-level expression of manganese peroxidase (MnP) was maintained.
Hood et al. (2003) used a high-oil germplasm to increase germination efficiency and promote the
expression of a fungal laccase gene by breeding and selection over several generations. Hood et
al. (2012) also used a breeding program to introgress the E1 and CBH I cellulases into elite,
high-oil germplasm to enhance protein accumulation in the grain. Streatfield et al. (2002)
produced the GM1 receptor binding B subunit of the heat-labile toxin from enterotoxigenic
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strains of E. coli in maize and increased the yields again by several generations of breeding and
selection. We did not need to carry out backcrossing or selective crossing with elite inbred lines
because rice is a self-pollinating crop. Ramessar et al. (2008) by subjecting immature zygotic
embryos from one 2G12 highly expressing line to dedifferentiation and subsequent regeneration
subjecting immature zygotic embryos from one 2G12 highly expressing line not only boosted
protein yields but also eliminated most of the seed-to-seed variation.
Native CV-N has a potent virucidal activity against multiple strains of HIV-1 and HIV-2, with
EC50 < 10 nM (Xiong et al., 2010). Only two studies have reported a precise anti-HIV activity
(EC50 or IC50) for CV-N (Gao et al., 2010; Mori et al., 2002). Mori et al. (2002) calculated an
EC50 value of 0.3 ± 0.09 nM for recombinant CV-N produced in P. pastoris and Gao et al.
(2010) calculated an IC50 value of 31.3 ± 2.15 nM for recombinant CV-N produced in E. coli.
Other studies have merely stated that the anti-HIV activity of CV-N is concentration dependent,
and have emphasized the need to use the correct concentration of recombinant CV-N in the virus
neutralization assay. We found that OSCV-N had a low potency against HIV-1, with an EC50
value of 28 μg/ml. Furthermore, OSCV-N showed little evidence of cytotoxicity. This may reflect
the low concentration of OSCV-N in the crude endosperm extracts.
In addition to these results, three of the above studies showed that gp120 binding was
concentration dependent, and only one demonstrated that the affinity of the recombinant CV-N
was lower than the native CV-N (Giomarelli et al., 2002). We observed a concentration
dependent relationship in gp120-binding efficiency for all the samples except the control, which
appeared to be stable through the entire range of serial dilutions. In addition, OSCV-N showed
relatively good binding efficiency compared to the control (CV-N produced in E.coli) at the
highest concentration (lowest dilution). This might explain the low anti-HIV activity,
emphasizing the importance of the correct dilution of the samples. It is therefore important to use
an optimized extraction protocol to obtain large quantities of recombinant CV-N in crude
extracts. We also tried to purify OSCV-N using ethanol and ammonium sulfate precipitation but
only minimal amounts of the protein were recovered, resulting in no anti-HIV activity in the
whole-cell assays. A high-yield crude extraction protocol to separate CV-N from starch and other
proteins is therefore necessary.
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3.6 CONCLUSIONS
Our data show that CV-N can be produced in rice endosperm albeit at lower yields than has
previously been achieved in E. coli and P. pastoris but at higher yields than previously reported
in tobacco and marshmallow. This is the first time that CV-N has been stably expressed in rice
endosperm and we succeeded in increasing the expression levels by breeding the transgenic lines
over several generations. Crude extracts from the transgenic plants were not cytotoxic towards
CEM-SS cells indicating that the production of CV-N in rice seeds is safe. The low
neutralization activity and concentration-dependent gp120-binding efficiency probably reflect
the low CV-N concentration in the crude extracts. A simple crude extraction method for lectins is
therefore essential to increase the recovery and purity of recombinant CV-N.
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CHAPTER 4
Towards the production of microbicide cocktails in rice
endosperm
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4.1 INTRODUCTION
The number of people living with HIV increased from 29.4 million in 2001 to 35.3 million in
2012 (UNAIDS, 2013). Even though there is no cure for HIV, the disease can be managed with
antiretroviral drugs that reduce the rate of viral replication and hence the mortality and morbidity
associated with acquired immunodeficiency syndrome (AIDS). However, long-term side effects
and particularly the emergence of resistant strains under drug selection pressure is a growing
problem that reduces the impact of therapy (Balzarini, 2007; MTN, 2014). For this reason, new
strategies are required to prevent the spread of HIV.
HIV is a retrovirus with a high mutation rate, resulting in numerous subtypes and clades
(Vigerust and Shepherd, 2007). The glycans on the viral envelope are essential for transmission
(Balzarini, 2007). HIV infection is a multi-stage process involving: (i) binding of the viral
envelope glycoprotein gp120 to the cellular receptor CD4, (ii) interaction between gp120 and the
viral chemokine co-receptor CXCR4 or CCR5, (iii) conversion of gp41 into a fusogenic
conformational state, and (iv) transfer of the fusion peptide into the target cell (Figure 4.1)
(Permanyer et al., 2010).
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Figure 4.1: The multistep process of HIV infection. The well-defined HIV infection process leading to the delivery
of the viral core into the cytoplasm begins when the viral envelope glycoprotein gp120 binds to the cellular receptor
CD4 (binding site shown in green). After gp120–CD4 engagement, conformational changes in gp120 trigger its
interaction with the viral chemokine co-receptor CXCR4 or CCR5. Thereafter, gp41 is converted into a fusogenic
conformational state that triggers the transfer of the fusion peptide into the target cell. Finally, the formation of a six-
helix bundle brings the membranes close together and enables fusion (Permanyer et al., 2010).
Carbohydrate-binding agents (CBAs) obstruct viral entry into target cells by interacting with the
glycans on the HIV envelope (Huskens and Schols, 2012). The CBAs include proteins that
recognize carbohydrate structures (lectins) and non-peptide small agents with affinity for
monosaccharides and/or oligosaccharide structures (Balzarini, 2007). HIV gp120 is heavily
glycosylated and is presented on the virion surface as trimers of gp120/gp41complexes (Kwong
et al., 1998; Leonard et al., 1990; Wyatt et al., 1998). These glycans affect Env conformations
and oligomerization, viral entry, infectivity and antibody recognition (Huang et al., 2012; Kumar
et al., 2011; McLellan et al., 2011; Scanlan et al., 2002). Specifically, gp120 comprises 30–40%
high-mannose glycans (Figure 4.2 a) which are preferably deleted under CBA selection pressure
(Figure 4.2 b) (Balzarini, 2007). Thus there is a clear relationship between the number of glycan
deletions and resistance to CBAs (Balzarini et al., 2005b). Although HIV mutates almost every
time a new copy is made, not every mutation causes resistance. For example, the deletion of
individual N-linked glycans would not be sufficient for the virus to escape the antiviral action of
lectins, and indeed multiple oligosaccharide deletions are necessary for the virus to evolve
resistance (Balzarini et al., 2005a).
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Figure 4.2: The HIV envelope glycoprotein gp120. Ribbon diagrams showing the 24 putative N-glycosylation sites
(colored circles) in the HIV-1(IIIB) envelope glycoprotein gp120 according to Kwong et al. (1998) and Leonard et
al. (1990) a. High-mannose (green) and complex/hybrid-type (yellow) glycans. b. The red circles indicate the
deleted N-glycosylation sites that appear under pressure from carbohydrate-binding agents (CBAs) in more than 30
different mutant virus isolates. The green circles represent glycosylation sites that, as yet, have not been deleted
under CBA pressure (Balzarini, 2007; Kwong et al., 1998).
One major challenge for the treatment of HIV infections is that the incoming virus may already
contain mutations rendering it resistant to antiretroviral drugs. In vitro studies have identified
HIV-1 escape mutants resistant to polyanionic compounds, which are some of the most
promising microbicide candidates (Bobardt et al., 2004; Este et al., 1997). In order to prevent the
emergence of resistant HIV-1 isolates, combinations of two or more compounds that target
separate viral structures or functions are used in microbicide formulations. Therefore, the
development of effective microbicides will likely require a combination of several compounds to
prevent the rapid evolution of HIV resistance and to provide sufficient cross-clade protection
(Sexton et al., 2009).
Highly active antiretroviral therapy (HAART) involves the administration of combinations of
antiviral drugs and is already well-established as a treatment for HIV (Portsmouth and Scott,
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2007) because it is much more effective than a monotherapy (Palella et al., 1998). Likewise,
combination microbicides are likely to demonstrate greater efficacy than microbicides with only
one active component (Garg et al., 2009). The theory behind the combinatorial microbicides is
based on three principles. The first is that they increase the range of activity, reducing the
likelihood that infections could be initiated by existing resistant viruses or new escape mutants.
Secondly, combination microbicides can reduce the amount of each drug needed to achieve the
same efficacy if there is synergy between them drugs. Finally, combination microbicides can
target not only in the infection process but also in the viral life cycle, expanding the mechanisms
of protection. This hypothesis is demonstrated by the prevention of mother-to-child transmission
using antiretroviral therapy (Sturt et al., 2010).
There are numerous examples of combination microbicides. Truvada (Gilead Sciences, Inc.,
Foster City, CA) is a combination of two antiretroviral drugs (the NRTI emtricitabine plus
tenofovir disoproxil fumarate) and was approved in 2012 for HIV pre-exposure prophylaxis and
is taken daily to reduce the risk of infection (see General Introduction). In addition, the b12-
CV-N fusion product combined two HIV-neutralizing components in one protein and
accordingly showed a much greater neutralizing efﬁcacy than either protein acting alone (Sexton
et al., 2009). The synergistic inhibition of HIV-1 infection by combinations of potential
microbicide components has also been demonstrated, e.g. the two leading polyanionic
microbicides, dextran sulfate and PRO 2000 (Gantlett et al., 2007). They have been combined
with the neutralizing antibody b12 and the cyanobacterial protein CV-N and demonstrated
synergistic activity, although the degree of synergy depended on the inhibitor concentration and
combination (Pirrone et al., 2011; Ramessar et al., 2010). These examples also include successful
combinations of NNRTIs such as efavirenz and nevirapine, which are also used in combination
antiretroviral therapy, or the lipophilic molecules UC781 and TMC120, which are being
developed as vaginal gels for phase III trials (Herrera et al., 2009). Phase I trial MTN-
013/IPM026 is the first clinical trial of a vaginal ring consisting of two antiretroviral drugs:
dapivirine and maraviroc (AVAC, 2014).
Vaccine candidates have already been developed in which malaria antigens from different stages
of the life cycle of the parasite have been combined into a single fusion protein (Patarroyo et al.,
2012) or combined with the cholera toxin B chain as an adjuvant. Indeed, apical membrane
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antigen 1 (AMA1) and merozoite surface protein 1 (MSP1) have been expressed as fusions with
the cholera toxin B chain in tobacco and lettuce chloroplasts exhibiting dual immunity against
cholera and malaria either by oral or injectable delivery (Davoodi-Semiromi et al., 2010).
Finally, MAPP66 is a cocktail of several antibodies targeting HIV and Herpes simplex virus
(HSV), and was produced using the MagnICON (magnifection) system in N. benthamiana
(Gleba et al., 2005). HIV microbicides work in the first line of defense on the exposed surfaces
by blocking the earliest steps of the infection cycle. By using the HIV microbicides, the
concentration of the active substance is high but the long-term toxicity in healthy but at-risk
individuals is reduced (Nuttall, 2014; Shattock and Rosenberg, 2012).
CBAs such as the lectins CV-N and GRFT, and human HIV-neutralizing monoclonal antibodies
such as 2G12, can acts as entry/fusion inhibitors to inhibit the first steps of HIV infection by
binding directly to glycans on the envelope proteins or indirectly promoting glycan deletion
(Balzarini, 2007). The interactions between several CBAs and gp120 have been investigated, e.g.
the prokaryotic lectins CV-N and actinohivin, the plant lectins HHA and UDA, and the
monoclonal antibody 2G12. These studies have shown that binding does not prevent the initial
contact between HIV and the cell, but blocks the subsequent binding to co-receptors (Balzarini et
al., 2007, 1991; Bewley, 2001; Huskens et al., 2007). Although the precise molecular mechanism
is unknown, it may reflect the inhibition of gp120 conformational changes that normally occur
once the virus has made contact with CD4 on the cell surface (Balzarini et al., 1991).
Several important characteristics need to take into consideration for the development of a
combinatorial microbicide. These include: safety, efﬁcacy, cost, acceptability, appropriate drug
delivery, long-term effect, potential for resistance and impact on therapy, and prioritization of
best-in-class products for clinical trials. For example, phase III clinical trials are not only
expensive and time-consuming, but also a large number of participants is necessary in order to
demonstrate efficacy (Shattock and Rosenberg, 2012). A production platform combining all the
above characteristics with the lowest cost would be highly appropriate for the production of HIV
microbicides.
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4.2 AIMS OF THE STUDY
The main aim of the work described in this chapter was to produce combination microbicides in
rice endosperm tissue by co-expressing the monoclonal antibody 2G12 together with two
antiviral lectins (CV-N and GRFT) and testing the cytotoxicity and anti-HIV activity of crude
extracts containing these components.
4.3 MATERIALS AND METHODS
4.3.1 Cloning and construct design
Constructs for the expression of 2G12, GRFT and CV-N are described in detail in Chapter 1
section 1.3.1, Chapter 2 section 2.3.1, and Chapter 3 section 3.3.1, respectively.
4.3.2 Transformation and regeneration of transgenic plants
This procedure is described in detail in Chapter 1, section 1.3.2.
4.3.3 Crude extracts from rice endosperm
We crushed 5 g of mature rice seeds into a fine powder using a glass mortar. The total soluble
protein (TSP) was extracted in three volumes (v/w) of PBS by vortexing overnight at 4°C. The
samples were then centrifuged twice (13,000 x g, 15 min, 4°C) and the supernatant was filtered
before transfer to a 50-ml Falcon tube.
4.3.4 Confirmation of protein expression (ELISA)
A pool of mature rice seeds was ground in three volumes of PBS and centrifuged twice (13,000 x
g, 10 min, 4°C) to remove seed debris. The expression of 2G12, CV-N and GRFT was confirmed
using three separate enzyme-linked immunosorbent assays (ELISAs). Antibody 2G12 was
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detected by coating ELISA wells with goat anti-human kappa light chain (Sigma K3502) or goat
anti-human IgG Fc chain (Sigma K2136) as capture antibodies. After washing and blocking with
5% nonfat milk, serial dilutions of each seed extract were added and bound 2G12 was detected
using a horseradish peroxidase (HRP)-conjugated sheep anti-human kappa-chain antiserum (The
Binding Site, Birmingham, UK, 1:1000 dilution). For GRFT and CV-N, the ELISA plates were
coated with 100 ng recombinant gp120 from HIV strain IIIB (MRC Centralized Facility for
AIDS Reagents, Potters Bar, UK). After washing and blocking with 5% nonfat milk, serial
dilutions of each seed extract were added and the lectins were detected primary rabbit anti-GRFT
anti-CV-N or polyclonal antisera, followed by the HRP-conjugated anti-rabbit IgG as above.
HRP was detected by using 3,3',5,5' tetramethylbenzidine (TMB) as the substrate (Sigma, St.
Louis, MO, USA) and reading the absorbance at 450 nm.
4.3.5 In vitro binding of crude extracts containing multiple combinations to
gp120 (ELISA)
The specific antigen binding activity of 2G12, GRFT and CV-N was confirmed by coating
ELISA wells with 100 ng recombinant gp120 from HIV strain IIIB. After washing with PBST
and blocking with 5% nonfat milk, serial dilutions of the crude extracts were added and the
amount of bound antibody or protein determined using HRP-conjugated sheep anti-human
kappa-chain antiserum for 2G12 or HRP-conjugated anti-rabbit IgG (1:1000 dilution) for GRFT
and CV-N. The signal was detected using TMB substrate as described above.
4.3.6 Whole-cell anti-HIV bioassays
This procedure is described in detail in Chapter 3, section 3.3.7
4.3.7 Cytotoxicity and antiviral assay
Cytotoxicity and antiviral assays were carried out by Dr. A. Evans at St. Mary’s Campus
Imperial College, Department of Medicine, London. The cytotoxicity of all samples was
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assessed using the MTT colorimetric assay as previously described (Mesquita et al., 2008).
Crude extracts of OS2G12, OSGRFT, OSCV-N and combinations of these were titrated in triplicate
onto TZM-bl cells (105/well), a cervical epithelial cell line expressing CD4, CCR5 and
luciferase. Twofold serial dilutions of the extracts were prepared for testing and Nonoxynol-9
was used as a positive control. Results were expressed as the percentage of cellular viability
compared to the negative (medium-only) control, plus or minus the standard deviation (SD).
To determine antiviral potency, the same crude extracts were titrated onto TZM-bl cells
(104/well) in triplicate and cultured for 72 h with HIV-1 BaL using a concentration optimized for
infectivity. Twofold serial dilutions of the extracts were prepared for testing. The extent of viral
replication was determined by measuring luciferase activity in the cell lysates (Promega,
Madison, WI, USA). Results were expressed as the percentage of infection attained relative to
the virus-only control, plus or minus the standard error (SE).
4.4 RESULTS
4.4.1 Production of 2G12 + GRFT + CV-N in rice endosperm
Rice (Oryza sativa cv. Nipponbarre) mature seed-derived embryos were transformed by particle
bombardment with a construct containing the coding sequences of the 2G12 heavy and light
chains, under the control of the rice glutelin-1 promoter (Ramessar et al., 2008), the GRFT
coding sequence under the control of the maize zein promoter, the CV-N coding sequence, under
the control of the rice prolamin promoter, plus a fifth construct containing the selectable marker
hpt. Embryo-derived callus was selected on hygromycin-supplemented medium and multiple
independent transformants were regenerated and transferred to the greenhouse. Endosperm tissue
was analyzed by ELISA to confirm transgenes expression.
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4.4.2 Confirmation of combinatorial expression and assembly in rice
endosperm
The presence of correctly-assembled 2G12, GRFT and CV-N in the T1 endosperm was
confirmed using an immunoglobulin-speciﬁc sandwich ELISA. The concentration of each
protein in the endosperm was determined by calculating the concentrations of different lines
expressing 2G12, GRFT and CV-N from titration curves based on positive controls spiked with
known concentrations of the same proteins produced in rice endosperm or E. coli (Figure 4.3).
We used non-transformed rice endosperm as a negative control to rule out cross reaction with
endogenous plant proteins. Among the nine independent events, lines 1', 2', 3' and 4' were found
to co-express CV-N and GRFT. Line 1' expressed CV-N (0.15 μg/ml) at higher levels than
GRFT (0.09 μg/ml) and line 2' expressed GRFT (8.73 μg/ml) at higher levels than CV-N (0.14
μg/ml). Lines 5', 6' and 7' co-expressed 2G12 and CV-N, whereas line 8' co-expressed 2G12
(1.43 μg/ml) and GRFT (0.12 μg/ml). Finally, line 9' co-expressed all three proteins: 2G12 (0.61
μg/ml), GRFT (2.28 μg/ml) and CV-N (0.04 μg/ml). These lines were selected for more detailed
studies.
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Figure 4.3: The accumulation of 2G12, GRFT and CV-N in mature rice endosperm. An immunoglobulin-speciﬁc
sandwich ELISA was used to screen all independent events. The ELISA plate was coated with gp120, and 2G12
antibody assembly was confirmed using a primary goat anti-human kappa light chain or goat anti-human IgG Fc
chain and a secondary HRP-conjugated sheep anti-human kappa-chain antiserum. CV-N and GRFT protein
assembly was confirmed using a primary rabbit anti-CV-N and anti-GRFT polyclonal antiserum and a secondary
HRP-conjugated anti-rabbit IgG for both. Four dilutions per sample are shown. Non-expressed transgenes are not
shown. WT = wild-type plants; C– = PBS negative control; C+ = 2G12 (pink) purified from rice (500 ng/ml), GRFT
(blue) and CV-N (yellow) purified from E. coli (concentration 500 ng/ml) as positive controls.
4.4.3 HIV-binding activity of the crude extracts
The ability of the endosperm-derived 2G12, GRFT and CV-N in to bind gp120 in combination
was tested in vitro using an antigen-speciﬁc ELISA. The capture reagent was gp120 IIIB and the
bound proteins were detected using primary goat anti-human kappa light chain or goat anti-
human IgG Fc chain for 2G12, and a primary rabbit anti-GRFT or anti-CV-N polyclonal
antiserum for the lectins. A secondary HRP-conjugated sheep anti-human kappa-chain antiserum
was used to detect 2G12 and a secondary HRP-conjugated anti-rabbit IgG antiserum was used to
detect GRFT and CV-N. In all the combinations, the wild-type extract showed no binding to
gp120, confirming the absence of a cross reaction with endogenous plant proteins. We obtained
three groups of extracts expressing different combinations of 2G12, GRFT and CV-N.
 Fist group: Lectin combination
The first group comprised four different events expressing GRFT and CV-N at different relevant
levels. Line 1' showed moderate binding kinetics for GRFT (midway between the positive and
negative controls) but the highest binding kinetics for CV-N. Lines 2' and 4' showed similar
GRFT binding kinetics as the positive control but low binding activity for CV-N (Figure 4.4).
Line 3' showed moderate binding kinetics for CV-N but the lowest binding kinetics for GRFT.
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Figure 4.4: Antigen-binding activity (ELISA) of crude rice endosperm extracts containing GRFT and CV-N and the
purified GRFT and CV-N produced in E. coli. Ordinate: Optical density at 450 nm. Abscissa: Serial dilutions.
Values are the average of two experiments. ELISA plates were coated with the gp120 and were tested with different
concentrations of crude extracts or fixed concentration of purified GRFT and CV-N. Binding activity was measured
with primary rabbit anti-GRFT and anti-CV-N polyclonal antisera and a secondary HRP-conjugated anti-rabbit IgG.
The binding kinetics showed a concentration-dependent relationship, declining as the dilution factor increased in all
the samples except the positive control for CV-N. WT = wild type plants. C+ = GRFT and CV-N produced in E. coli
(concentration 500 ng/ml) as positive controls. Lines 1', 2', 3' and 4' are independent events expressing GRFT and
CV-N.
 Second group: Antibody/lectin combinations (2G12 + CV-N or 2G12 + GRFT)
The second group consisted of two subgroups, combining (i) 2G12 and CV-N, or (ii) 2G12 and
GRFT. The first subgroup comprised three independent events. Lines 5 and 7 showed the best
binding kinetics in both ELISAs, with higher binding kinetics for 2G12 than the positive control
and the highest binding kinetics for CV-N, although still at half the value of the positive control
at the highest concentration (Figure 4.5). The second subgroup comprised one independent event
(line 8) coexpressing 2G12 and GRFT, with higher binding kinetics than the 2G12 positive
control but lower binding kinetics than the GRFT positive control (Figure 4.6).
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Figure 4.5: Antigen-binding activity (ELISA) of crude rice endosperm extracts containing 2G12 and CV-N and the
purified 2G12 produced in maize and CV-N produced in E.coli. Ordinate: Optical density at 450 nm. Abscissa:
Serial dilutions. Values are the average of two experiments. ELISA plates were coated with the gp120 and were
tested with different concentrations of crude extracts or fixed concentration of purified 2G12 and CV-N. Binding
activity was measured with a primary goat anti-human kappa light chain or goat anti-human IgG Fc chain for 2G12
and a primary rabbit anti-CV-N polyclonal antiserum for CV-N, followed by a secondary HRP-conjugated sheep
anti-human kappa-chain antiserum for 2G12 or a secondary HRP-conjugated anti-rabbit IgG for CV-N. The binding
kinetics showed a concentration-dependent relationship, declining as the dilution factor increased. WT = wild type
plants. C+ = 2G12 produced in maize and CV-N produced in E. coli (concentration of 500 ng/ml) as positive
controls. Lines 5', 6' and 7 ' are independent events expressing 2G12 and CV-N.
Figure 4.6: Antigen-binding activity (ELISA) of crude rice endosperm extracts containing 2G12 and GRFT and the
purified 2G12 produced in maize and GRFT produced in E. coli. Ordinate: Optical density at 450 nm. Abscissa:
Serial dilutions. Values are the average of two experiments. ELISA plates were coated with the gp120 and were
tested with different concentrations of crude extracts or fixed concentration of purified 2G12 and GRFT. Binding
activity was measured with a primary goat anti-human kappa light chain or goat anti-human IgG Fc chain for 2G12
and a primary rabbit anti-GRFT polyclonal antiserum for GRFT, followed by a secondary HRP-conjugated sheep
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anti-human kappa-chain antiserum for 2G12 or a secondary HRP-conjugated anti-rabbit IgG for GRFT. The binding
kinetics showed a concentration-dependent relationship, declining as the dilution factor increased. WT = wild type
plants. C+ = 2G12 produced in maize and GRFT produced in E. coli (concentration of 500 ng/ml) as positive
controls. Line 8' is an independent event expressing 2G12 and GRFT.
 Third group: 2G12+GRFT+CV-N combination
The third group comprised one event (line 9') expressing all three recombinant proteins. This
showed higher binding kinetics than the 2G12 and GRFT positive controls and relatively low
binding kinetics compared to the CV-N positive control (Figure 4.7).
Figure 4.7: Antigen-binding activity (ELISA) of crude rice endosperm extracts containing 2G12, CV-N and GRFT
and the purified 2G12 produced in maize and GRFT and CV-N produced in E. coli. Ordinate: Optical density at 450
nm. Abscissa: Serial dilutions. Values are the average of two experiments. ELISA plates were coated with the gp120
and were tested with different concentrations of crude extracts or fixed concentration of purified 2G12, CV-N and
GRFT. Binding activity was measured with a primary goat anti-human kappa light chain or goat anti-human IgG Fc
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chain for 2G12 and primary rabbit anti-GRFT and anti-CV-N polyclonal antisera for GRFT and CV-N, followed by
a secondary HRP-conjugated sheep anti-human kappa-chain antiserum for 2G12 or a secondary HRP-conjugated
anti-rabbit IgG for GRFT and CV-N. The binding kinetics showed a concentration-dependent relationship, declining
as the dilution factor increased. WT = wild type plants. C+ = 2G12 produced in maize and GRFT/CV-N produced in
E. coli (concentration of 500 ng/ml) as positive controls. Line 9' is an independent event expressing 2G12, CV-N
and GRFT.
4.4.4 Anti-HIV activity bioassays
The crude extract from line 2' expressing CV-N and GRFT was tested for its ability to inhibit the
cytopathic effects of HIV-1RF against T-lymphoblastic CEM-SS cells. Wild-type rice was used as
a negative control to exclude antiviral effects caused by endogenous plant proteins. Previously,
native GRFT and GRFT produced in N. benthamiana showed remarkably potent activity against
HIV-1, with EC50 values of 0.054 and 0.156 nM, respectively (O’Keefe et al., 2009). In addition,
CV-N displays potent virucidal activity against diverse primary isolates and laboratory strains of
HIV-1 and HIV-2, with EC50 values generally in the 1–10 nM range (Boyd et al., 1997). In our
experiments, the crude extract at a concentration 50 μg/ml showed potent activity against HIV-1,
with an EC50 value of 3.15 μg/ml. It was not possible to determine an IC50 value, confirming that
no toxic constituents had co-purified with the protein. Wild-type crude extract showed no
activity confirming that endogenous plant lectins had no effect on the virus (Figure 4.8).
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Figure 4.8: In vitro anti-HIV activity of crude rice extracts. The anti-HIV activity of (a) line 2' and (b) wild-type
rice in CEM-SS cells infected with HIV-1RF. Concentration-dependent effects of CV-N on cellular viability were
observed. Cellular viability data are shown relative to uninfected, untreated controls. Cell viability was assessed
using the XTT assay. All points are averages (± SD) of experiments carried out in triplicate.
4.4.5 Cytotoxicity and antiviral assay
An MTT assay (Mesquita et al., 2008) was used to determine the potential cytotoxicity of crude
extracts from wild-type rice endosperm and lines expressing 2G12, GRFT, CV-N, 2G12 +
GRFT, 2G12 + CV-N, and two lines (1' and 2') expressing CV-N + GRFT against TZM-bl cells,
which were used to study the effects of these crude extracts on HIV-1 infection. As shown in
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Figure 4.9, all the crude extracts at dilutions 1/4 and higher exhibited no significant cytotoxicity
against the cell line. The same samples were used for an infectivity assay.
Figure 4.9: Effect of different concentrations of numerous crude extracts on cell viability. Cytotoxicity was
determined using an MTT assay and was expressed as the percentage of dead cells (mean ± SD, n = 3). Ordinate: %
of relative viability. Abscissa: Serial dilutions. Nonoxynol-9 was used as a cytotoxic positive control.
The same crude extracts were tested for their effect on HIV infectivity. To avoid the cytotoxicity
of crude extracts, the neat extract and the half-strength dilution were not tested. Figure 4.10
shows the proportion of infection achieved relative to the virus-only control (no extract). A value
of 0% indicates that the extracts have completely inhibited viral replication and 100% means that
the extracts have no antiviral effect. We observed potent antiviral activity in the extracts
containing GRFT and to a lesser extent CV-N. The extracts containing 2G12 showed a generally
low antiviral activity that was only observed at the highest concentration (lowest dilution). The
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wild-type extract showed a low level of viral inhibition, maybe by preventing the virus from
contacting the cells. The extract containing 2G12+CV-N showed some antiviral activity at the
1/8 and 1/16 dilution (0.0625 and 0.03125). However the 1/4 and 1/32 dilutions showed no
antiviral activity. All the extracts containing GRFT alone or in a combination with CV-N or
2G12 showed high antiviral activity, probably reflecting the presence of GRFT (Figure 4.10).
Figure 4.10: HIV-1 infectivity assay. TZM-bl cells were incubated with serial dilutions (in triplicate) and cultured
for 72 h with HIV-1BaL using a concentration optimized for infectivity. The extent of viral replication was
determined by measuring the luciferase activity of cell lysates. Ordinate: percentage of relative infection. Abscissa:
Serial dilutions. Results are shown as the percentage of infection relative to the virus-only control, plus or minus the
standard error (SE).
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4.5 DISCUSSION
Topical microbicides are considered to be one of the most promising approaches for the
prevention of HIV. An effective microbicide should have multiple advantages, such as a potent
and preferentially broad-spectrum microbicidal activity, limited to no toxicity on the vaginal or
rectal epithelial cell layer, and a beneficial pharmacokinetic/dynamic profile (Doncel and Clark,
2010). For this reason, the development of effective microbicides will likely require a
combination of several compounds to prevent the rapid evolution of HIV resistance and to
provide sufficient cross-clade protection (Sexton et al., 2009). Therefore the feasibility of
production is a significant concern. Because the HIV envelope protein gp120 is highly
glycosylated and N-linked glycans account for ∼50% of its molecular mass, carbohydrate-
binging agents such as human monoclonal antibody 2G12, and the lectins CV-N and GRFT
could be used as potent HIV microbicidal agents with a high genetic barrier to resistance (Férir et
al., 2012).
The design of a suitable combinatorial microbicide must take into account any potential
competition for binding sites on the HIV envelope. Although GRFT and CV-N do not compete
for these sites, they both compete with 2G12 (Mori et al., 2005) such that lectin-resistant HIV
strains are often susceptible to the antibody. We have previously expressed 2G12, CV-N and
GRFT independently in rice endosperm (Chapters 1, 2, and 3) and in this chapter we combined
them to identify lead events expressing different combinations of 2G12, GRFT and CV-N,
allowing us to compare their HIV-neutralizing activities.
No combination microbicides have yet been produced in plants, but several CV-N fusion
proteins have been investigated (McFadden et al., 2007; Sexton et al., 2009). In one case, the
antibody b12 was fused with the lectin CV-N, and the fusion protein was more potent than its
components (Sexton et al., 2009). In another case, CV-N was fused with the linear peptide 12pi
and this also showed enhanced anti-HIV activity (McFadden et al., 2007). We used a mixture of
plasmids containing the coding sequences for each protein so that each could be stably expressed
in rice endosperm. Both the gp120 binding efficiency and anti-HIV whole-cell assays
demonstrated that crude endosperm extracts producing combinations of anti-HIV proteins were
promising as combinatorial microbicides. The candidate microbicides need to be tested for
efficacy and safety in order to be accepted and finally enter the market, using in vitro cellular
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models, ex vivo mucosal tissue explants, small animal models and non-human primates. There
are several cell lines that are widely used for efficacy tests, including PM-1 CDA+T cells (Lusso
et al., 1995) and the TZM-bl luciferase reporter cell line (Wei et al., 2002). TZM-bl cells provide
a single viral cycle assay model that requires 2 days of culture, comparted to at least 7 days for
PM-1 cells, before infectivity is evaluated by the measurement of luciferase activity driven by
the expression of the viral trans-activator of transcription (Tat) (Nuttall, 2014). In terms of
safety, cellular models are used to measure the potential cytotoxicity of microbicides, often by
measuring the cleavage of a tetrazolium salt (MTT) into a blue-colored product (formazan) in
viable cells (Slater et al., 1963).
We found that crude rice endosperm extracts at dilutions of 1/4 and higher exhibited no
significant cytotoxicity to the cell line, suggesting that the enhanced HIV-1 infection did not
result from the cytotoxicity of the rice crude extracts at the concentrations we tested. Thus the
lower viability that was measured in this assay in the more concentrated dilutions is possible to
be due to the fact that the contents of the extracts are covering the cells so thoroughly that they
cannot access the nutrients in the culture media and are not growing properly.
The infectivity assay confirmed the potent activity of the combination of CV-N + GRFT against
HIV-1, particularly line 2', where GRFT is more abundant than CV-N. The crude extract
containing 2G12 showed satisfactory antiviral activity but only at the highest concentration. The
combination of 2G12 + CV-N in the extract from line 7' at 1/4 dilution showed antiviral activity
similar to the wild-type extract, but in both consecutive dilutions the activity was more potent.
The CV-N crude extract was active against HIV-1 throughout the dilution series. This result
combined with the anti-HIV assay described in chapter 3 confirms that CV-N has antiviral
activity when expressed in rice. Finally, in the combination of 2G12 + GRFT (line 8'), the
antiviral activity was most probably due to the GRFT and not 2G12, even though the
concentration of 2G12 was higher. It is possible that these components demonstrate synergy, but
the exact concentration of each protein in the crude extracts is unknown so we would need to
perform a much wider titration to establish a dose response curve and calculate the IC50 values in
order to compare the combination extracts with the extract components individually. Even then it
would be difficult to say whether we have synergy or additive effects. Nevertheless, we can
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conclude that we have achieved our goals and demonstrated that combinatorial microbicides can
be produced in rice endosperm.
4.6 CONCLUSIONS
The data from our experiments show that multiple anti-HIV microbicides can be successfully
produced in rice endosperm with potent anti-HIV activity. These results open the way for the
production of more combinatorial microbicides in rice endosperm, which is a suitable low-cost
production platform for molecular pharming applications.
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GENERAL CONCLUSIONS
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1. A recombinant HIV-neutralizing antibody (2G12) was produced in transgenic rice
endosperm with a maximum yield of 42 μg/g, which is similar to the yields previously
achieved in transgenic maize. The most prevalent form of the antibody was aglycosylated
with the remainder featuring complex vacuolar-type and oligomannose-type glycans as
well as single GlcNAc residues, suggesting that the protein was translated in a region of
the ER where the addition of the N-glycan does not occur.
2. The aglycosylated antibody exhibited a greater HIV-neutralizing activity than the
glycosylated version produced in tobacco seeds, although neither were as potent as 2G12
produced in CHO cells.
3. Proteomics analysis revealed that starch metabolism was suppressed in the transgenic
seeds and a prolamin gene (PRO7) was upregulated, indicating that transgene expression
caused some disruption in the balance between carbohydrate and protein storage in the
seed. The metabolic disruption and unusual subcellular architecture of the cell appears to
cause stress within the protein trafficking networks, perhaps due to the unusually high
level of traffic that needs to be processed, resulting in the further induction of genes
encoding the radical scavenger glutaredoxin-C8. These data suggest that yields of
proteins could be improved in rice seeds by regulating protein/carbohydrate metabolism
and protecting the endosperm from stress.
4. GRFT was expressed in rice endosperm with yields comparable to or even higher than
GRFT produced transiently in tobacco and other recombinant proteins produced in rice.
Our yield of GRFT (223 μg/g) was the highest among the three recombinant proteins
under investigation. A one-step purification protocol using the His6 tag achieved ~80%
purity. Recombinant GRFT produced in rice showed potent anti-HIV activity in a cell-
based neutralization assay.
5. CV-N was produced in rice endosperm at lower yields than previously reported in E. coli
and P. pastoris but with higher yields than tobacco and marshmallow. Our yield of CV-N
(6 μg/g) was the lowest among the three recombinant proteins under investigation.
Recombinant CV-N showed moderate anti-HIV activity in a cell-based neutralization
assay.
6. The binding activity of each protein (2G12, GRFT and CV-N) was concentration
dependent.
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7. Whole-cell neutralization assays confirmed that the combination of CV-N and GRFT
produced in the same plant showed potent anti-HIV activity and may therefore constitute
a promising combination microbicide cocktail.
8. Overall, rice endosperm was shown to be an effective production platform for
combination microbicides.
179
ANNEX
